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Abstract 
Pluripotency inducing transcription factors (TFs) Oct4, Sox2 and Nanog under the 
influence of epigenetic modifications (especially, DNA methylation and histone H3 
modifications) and signaling pathways work stringently to guard stem cell pluripotency 
and smoothly manoeuvre transition between differential gene expression states during 
both normal and pathological conditions. The present work is undertaken to investigate 
the influence of epigenetic regulators and signaling pathways on pluripotency inducing 
TFs during tumorigenesis. The expression profile of Oct4, Sox2 and Nanog in breast and 
prostate cancer along with epigenetic regulatory enzymes (DNA methyltransferases 
(DNMTs), histone methyltransferases (HMTs) and histone deacetylases (HDACs) 
predominantly active in controlling the expression of these TFs are studied. Furthermore, 
hedgehog (HH) signaling pathway mediated regulation of Oct4, Sox2 and Nanog is also 
examined. Oct4, Sox2 and Nanog are over-expressed both at transcript (mRNA) and 
protein level in a stage-specific manner in both cancers. The over-expression of Oct4, 
Sox2 and Nanog is associated with enhanced tumorigenic potential as is evident from 
reduction in cell proliferation, decrease in cell migration and invasive potential, cell cycle 
arrest at G1 phase and increase in apoptotic population upon silencing of these factors via 
si-RNA. Upon investigating the epigenetic regulatory mechanism controlling their over-
expression, it was found that active histone modifications H3K4me3 and H3K9AcS10p in 
promoters of Oct4 and Sox2 predominantly up-regulate expression of these genes in both 
cancers whereas promoter DNA methylation is not effective. Alongside these marks, it is 
also seen that HH-Sox2 axis is active in prostate cancer and mediates androgen 
independent prostate cancer. As researchers and oncologists are struggling to find a 
successful treatment approach for metastatically aggressive malignancies, unravelling the 
epigenetic machinery and allied signaling pathways controlling transcriptional network of 
a cancer cell will be one step forward in this endeavour.  
Keywords: Pluripotency; Epigenetics; Transcription Factors; Breast Cancer; Prostate 
Cancer; Signaling Pathway 
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Chapter 1 
Introduction 
The overall phenotypic and functional identity of a cell is determined by coordinated 
crosstalk between transcriptional regulatory networks, epigenetic modifiers and cellular 
signaling pathways (Patra et al., 2011; Apostolou and Hochedlinger, 2013) (Fig. 1.1). In 
response to critical developmental signals, genes critical for maintaining pluripotency are 
switched “on” by core pluripotency inducing transcription factors (TFs) and sustained by 
permissive chromatin remodelling whereas genes necessary for differentiation are 
transiently repressed by histone modifications. However, during linage-speciation and 
commitment, genes crucial for pluripotency are more permanently silenced by DNA 
methylation whereas differentiation-specific gene expression is activated by lineage-
determining factors (Lunyak and Rosenfeld, 2008; Christophersen and Helin, 2010; 
Watanabe et al., 2013). Thus, integration of extrinsic signaling cues with intrinsic 
epigenetic factors and allied transcriptional response ensures homeostatic balance 
between determination, maintenance and expression of pluripotency (Reik, 2007; Pei, 
2009).  
On the other hand, disruption of this ordered developmental scheme is responsible 
for genomic instability that drives progenitor cells towards improper malignant phenotype 
(Easwaran et al., 2014; Feinberg et al., 2016). Constitutively active oncogenic signaling 
pathways trigger changes in chromatin structure and dynamics in precursor cells and 
predispose them towards aberrant differentiation by endowing strategic advantageous 
properties of survival and proliferation (Sever and Brugge, 2015). Secondly, altered 
epigenetic events result in silencing of prominent tumor suppressor, DNA repair and cell 
cycle regulatory genes, and even facilitate the emergence of cancer stem cells (CSC) 
(Scaffidi and Misteli, 2010; Baylin, 2012). Finally, unscheduled expression of 
pluripotency inducing TFs like octamer binding transcription factor 4 (Oct4), SRY (sex 
determining region Y) box 2 (Sox2) and Nanog hinders normal maturation programs and 
removes barriers against dedifferentiation of cancer cells into CSC phenotype (Klimczak, 
2015; Muller et al., 2016). Hence, understanding the intricate relationship between these 
three crucial determinants is necessary to apprehend the molecular floor plan that 
underlies cellular development as well as fuels oncogenic transformation. 
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Figure 1.1: The three corner stones of pluripotency and differentiation in mammalian 
developmental saga. The transition from totipotency in zygote, through pluripotency in 
blastocyst and multipotency in embryo to unipotency in adults is facilitated by co-ordination 
between signaling pathways, epigenetic modifications and transcription factors. 
1.1 Epigenetic modifications play crucial role in 
determining  transcriptional fate: 
The functional template of all eukaryotic genetic information and the associated protein 
components are subjected to a diverse array of pre- and post-transcriptional and 
translational modifications. These distinct set of biochemical tags in both DNA 
(methylation) and histones (methylation, acetylation, phosphorylation etc.) can generate 
synergistic or antagonistic interaction affinities with chromatin domain binding proteins 
and dictate dynamic transitions between transcriptionally active or silent states (Jaenisch 
and Bird, 2003; Meissner, 2010). A harmonious and homeostatic balance between various 
epigenetic modifications essentially preserves the integrity of the genetic message across 
several generations. On the molecular level, these signatures include DNA methylation 
and demethylation of cytosine (5meC)
5
, covalent post-translational reversible 
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modifications (PTMs) of all histone proteins, incorporation of specific histone variants as 
well as RNA mediated interference and gene silencing (Jurkowska et al., 2011; Li et al., 
2012). In general, epigenetic manipulation of chromatin landscape impacts almost all 
transcriptional outcomes and decides cell-specific phenotypic archetype and functional 
destiny during both normal and pathological development (Hajkova, 2011; Kar et al., 
2012).  
1.1.1 DNA methylation mediated epigenetic modulation in transcription: 
DNA methylation is a principal epigenetic enforcer that facilitates functional re-
orientation of genomic data and effectively modulates gene expression profile via cell-
specific regulation of transcriptional activity. Methylated cytosine in the genome was first 
discovered in calf thymus DNA by Hotchkiss in 1948 (Hermann et al., 2004a). 
Methylation of DNA is a post-synthetic biochemical process, facilitated by a family of 
DNA methyltransferases (DNMTs) which methylate C5 cytosine residue specifically at 
CpG rich promoter sequences in the presence of cofactor S-adenosyl methionine (SAM) 
(Patra et al., 2003; Lan et al., 2010; Patra et al., 2011). The methylation signature is 
generated during early embryonic development and maintained faithfully in each 
successive cellular division by synchronized interaction between the DNMTs. Addition of 
new methyl marks to previously unmethylated cytosines is supervised by de novo 
methyltransferases DNMT3A and DNMT3B in the nucleolus, whereas DNMT1, the 
maintenance methyltransferase ensure that hemi-methylated daughter strands in somatic 
differentiated cells faithfully maintain and propagate the proper DNA methylation 
patterns across successive cell generations (Jeltsch, 2008; Jones and Liang, 2009; Denis et 
al., 2011). DNA methylation obstructs transcriptional activity via two ways; firstly 
methylated cytosine bases sterically hinder the interaction of transcriptional factors and 
RNA polymerase II with their cognate DNA recognition sequences (Bogdanovic and 
Veenstra, 2009). Secondly, methyl-CpG-binding proteins such as methyl-CpG-binding 
domain (MBD) proteins associate with methylated DNA and result in heterochromatin 
formation by recruiting histone deacetylases (HDACs) (Klose and Bird, 2006; Clouaire 
and Stancheva, 2008; Kar et al., 2014). 
DNA methylation predominantly acts as a gene silencing mechanism, which 
assimilates the repression marks previously established via histone modifications, 
rearrangement of nucleosomes as well as higher-order chromatin restructuring to 
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permanently turn off unnecessary genes at crucial junctures during development and 
differentiation. In prokaryotes, DNA methylation takes places in both adenine and 
cytosine bases, and functions to distinguish between self and non-self DNA as a defense 
against bacteriophagial infection using the restriction/modification (RM) systems. It also 
helps in recognizing and repairing replication errors by differentiating unmethylated 
daughter strand from methylated parent template (Jeltsch, 2002). In eukaryotes, DNA 
methylation participates in a number of cellular processes to set-up the appropriate 
framework of transcriptional activity in varied biological settings. It plays an important 
role in regulation of parental imprinting and stabilization of X-chromosome inactivation 
(Suzuki and Bird, 2008). It guarantees maintenance of the genome integrity by silencing 
of repetitive sequences, endogenous retroviruses and selfish genetic elements like 
transposons (Hermann et al., 2004; Dean et al., 2005). It is also implicated in the 
development of the immune system, in brain function and behavior as well as in cellular 
reprogramming and induction of stem cell differentiation (Weber and Schubeler, 2007; 
Lees-Murdock, and Walsh, 2008). 
1.1.2 Histone modifications extend the potential, specificity and diversity 
of downstream chromosomal processes: 
Histone proteins are subjected to an assorted array of covalent modifications such as 
methylation, acetylation, phosphorylation, ubiquitination, ADP-ribosylation and 
glycosylation (Sims et al., 2003; Kouzarides, 2007). These post-translational alterations 
occur typically on highly accessible N-terminal histone tails which changes the structural 
dynamics of the nucleosome core and affects accessibility of the underlying DNA to 
transcription factors and other nucleosomes. Histone modifications can act individually to 
directly alter chromatin architecture and assembly as well as in combination to reinforce 
or reverse existing DNA and other histone modifications (Bannister and Kouzarides, 
2011). They may also provide a scaffold for binding of chromatin-associated factors or 
act as signals for nucleosomal repositioning and rearrangement. The reversible histone 
modifications are fundamentally responsible for regulation of a diverse set of biological 
processes such as DNA replication, repair and recombination, chromosome condensation 
(mitosis) and spermatogenesis (meiosis) (Bhaumik et al., 2007; Suganuma and Workman, 
2011). Together with DNA methylation, covalent histone modifications carry out the bulk 
of epigenetic maintenance and control of genetic transcriptional status. 
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Histone Acetylation and Deacetylation: 
Histone acetylation occurs by the enzymatic addition of an acetyl group (-COCH3) to the 
ε-amino group of lysine side chains from acetyl coenzyme A. Histone acetyltransferases 
(HAT) and deacetylases (HDACs) are the enzymes responsible for writing and erasing the 
acetylation of histone tails (Eberharter and Becker, 2002). Lysine residues within histone 
H3 (H3K9, H3K14, H3K18) and H4 (H4K5, H4K8, H4K12) are preferential targets for 
acetylation. Addition of an acetyl group reduces electrostatic attraction between histones 
and negatively charged DNA backbone, thus opening up access to DNA loosening and 
generating accessible chromatin for transcription factors and polymerases (Wang et al., 
2008). The process of histone acetylation is tightly involved in the regulation of many 
cellular processes including chromatin dynamics and transcription, gene silencing, cell 
cycle progression, apoptosis, differentiation, DNA replication, DNA repair, nuclear 
import, and neuronal repression (Verdone et al., 2005; Tamburini and Tyler, 2005). 
H3K9ac and H3K27ac are normally associated with enhancers and promoters of active 
genes. H3K56ac stabilizes the genome at replication forks to prevent fork collapse at 
DNA damage checkpoints after DNA repair is complete, allowing cells to re-enter the cell 
cycle. H4K16ac mediates chromatin decondensation during G2/M transition (Shogren-
Knaak et al., 2006; Vaquero et al., 2006; Wurtele et al., 2012).  
Histone Phosphorylation and Dephosphorylation: 
Phosphorylation of histones is highly dynamic and takes place on serine, threonine and 
tyrosine residues (Oki et al., 2007; Banerjee and Chakravarti, 2011; Rossetto et al., 2012). 
Phosphorylation of H2A, especially in serine 139 of the H2AX variant histone, commonly 
referred to as γH2AX is the most noted histone phosphorylation mark. It occurs in all 
phases of cell cycle during DNA damage responses (DDR) and hence is considered to be 
an indispensable tag for DNA repair (Pinto and Flaus, 2010). At the site of double strand 
DNA break, γH2AX results in accumulation and retention of DNA damage response 
proteins such as mediator of DNA damage checkpoint protein 1 (MDC1) and p53-binding 
protein 1 (53BP1), thus preventing cell progression through G1/S phase and cell cycle 
arrest (Celeste et al., 2003; Fernandez-Capetillo et al., 2004). This modification is also 
linked to induction of apoptosis by death receptor activation as well as reduced epithelial 
growth factor receptor (EGFR)-mediated cellular growth and differentiation. Similarly, 
H2B phosphorylation in serine residues (Ser14 and Ser36) mediates a number of 
physiological functions such as (1) chromatin condensation and DNA fragmentation 
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leading to cell death and apoptosis (Fernandez-Capetillo et al., 2004; Solier and Pommier, 
2008) (2) cellular response to stress (by facilitating transcriptional elongation of stress-
activated genes such as peroxisome proliferator-activated receptor gamma coactivator 1-
alpha (PGC-1α) and target of rapamycin complex 2 (TORC2) to support cell survival, and 
(3) sustaining adenosine monophosphate-activated protein kinase (AMPK-FOXO3) 
hormone signaling and circadian function so as to connect cellular energy status to 
genomic responses (Bungard et al., 2010).  H3 phosphorylation marks H3S10p and 
H3S28p are both indicators of cell cycle progression. H3S10p mediates dissociation of 
heterochromatin protein 1 (HP1) facilitating chromosome decondensation at metaphase 
and subsequent segregation during telophase. H3S10 phosphorylation is also present at 
pericentric heterochromatin of cells during G2 (Nowak and Corces, 2004; Lau et al., 
2011). H4S1 phosphorylation is also linked to DNA repair via joining of non-homologous 
ends in double stranded breaks and stabilizing new nucleosomes by preventing their 
acetylation (Bird et al., 2002). 
Histone Methylation and Demethylation: 
Histone methylation is considered to be the most complex of all histone modifications, 
since its functional output is dependent upon the precise methylation site and degree of 
modification (Sims et al., 2003). Histone methylation occurs on positively charged amino 
acid residues such as lysine and arginine. Lysine can undergo monomethylation, 
dimethylation or trimethylation on its ε-amine group whereas arginine can be 
monomethylated, symmetrically demethylated or asymmetrically dimethylated on its 
guanidinyl group. The most extensively studied histone methylation marks among these 
include histone H3 lysine (K) (H3K4, H3K9, H3K27, H3K36, H3K79 and H4K20. 
Important residues where arginine (R) is mostly methylated includes H3R2, H3R8, 
H3R17, H3R26 and H4R3 (Bedford and Clarke, 2009). Three families of enzymes are 
known to catalyze the addition of methyl groups donated by S-adenosylmethionine 
(SAM) to histones. While SET-domain containing proteins and disruptor of telomeric 
silencing 1 (DOT1)-like proteins methylate lysine residues, members of the protein 
arginine N-methyltransferase (PRMT) family are known to methylate arginines (Lachner 
and Jenuwein, 2002; Le and Fujimori, 2012).  
Transcriptional regulation mediated by histone methylation is carried out in two 
different contexts; firstly gene-specific expression and secondly at the bulk chromosomal 
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level. The methylation of histone lysine residues in the promoter regions of individual 
genes constitutes “gene level” regulation. Similarly, regulation at ‘chromosome level’ 
includes formation of heterochromatin and euchromatin via methylation of various large 
chromatin domains (Zhang and Reinberg, 2001; Black et al., 2012). Histone methylation 
is a multi-factorial tag with contrasting effects in different settings; while lysine 
methylation of H3 and H4 is implicated in both transcriptional activation and repression 
depending on the methylation site, while arginine methylation promotes transcriptional 
activation. At the chromosomal level, large-scale permissive and transcriptionally 
competent euchromatin is established by H3K4 methylation (H3K4me2 and H3K4me3) 
which disrupt large-scale silencing by H3K9 methylation and by H3K79 methylation 
which prevent spreading of heterochromatin. After large-scale permissive chromatin is 
established, gene-specific transcriptional activation and elongation is assisted by H3K4 
and H3K36 methylation at mRNA coding regions (H3K4me at enhancers and H3K4me3 
at gene promoters) and gene bodies respectively (Greer and Shi, 2012; Deb et al., 2014). 
On the other hand, histone lysine methylation-mediated chromosome level repression is 
mainly targeted to H3K9, H3K27, H4K20 residues. Highly condensed constitutive 
heterochromatic regions of chromosomes correspond to H3K9 and H3K27 tri-
methylation. H3K9me3 is generally enriched in gene poor regions such as satellite 
repeats, telomeres and pericentromeres and retrotransposons whereas H3K27me3 is found 
primarily at promoters in gene-rich regions, closely associated with developmental 
regulators. Inactive X-chromosome (Xi) is also marked by H3K9me3 and H3K27me3 
marks that help in establishment and maintenance of this modification might participate in 
the initiation of X-chromosome inactivation (Justin et al., 2010). Protein arginine 
methylation mediates a number of biological processes including nuclear/cytoplasmic 
shuttling, mRNA splicing, DNA Repair, signal transduction as well as affects 
transcriptional status by acting as transcriptional co-activator or co-repressor (Lanouette 
et al., 2014).  
In theory, methyl turnover is always believed to be slower than other PTMs, and 
histone methylation was originally thought to be irreversible. However, the discovery of 
histone demethylase enzyme capable of demethylating methylated lysines known as 
lysine-specific demethylase (LSD1A; also KDM1A) established that  histone methylation 
is, in fact, alterable (Bannister and Kouzarides, 2005). Currently, two families of 
demethylases have been recognized such as amine oxidases and jumonji C (JmjC)-
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domain containing, iron-dependent dioxygenases. The first group of histone demethylases 
consists of amine oxidase-domain containing enzymes represented by LSD1 (also known 
as AOF2) and LSD2 (also known as AOF1) which specifically remove H3K4me1/me2 
marks. The second group of histone demethylases consists of Jumonji domain-containing 
proteins (JmjC), the prominent members being Fe (II) and 2-oxoglutarate (2OG) 
dependent oxygenases capable of erasing all the three histone lysine tags (Hou and Yu, 
2010). The histone demethylase enzymes contribute significantly to specification of 
active and repressive chromatin as well as cellular reprogramming events. Stem cell 
differentiation is affected by histone demethylation where specific epigenetic states
 
during lineage commitment, reprogramming of germline and maintaining epigenetic 
stability are arbitrated by histone demethylases. Histone demethylation is also essential 
for cell cycle transitions by re-expressions of cell cycle regulators and segregation of 
chromosomes. Histone demethylation also protects the genome by specifying DNA 
damage response and sustaining genomic integrity (Cloos et al., 2008; Dimitrova et al., 
2015). 
Other Histone Modifications: 
In addition to the above major biochemical alterations of the histone proteins, 
large molecule covalent modifications such as ubiquitylation and sumoylation have also 
been reported in histones. Histone ubiquitylation occurs within H2A and H2B; H2AK119 
mono-ubiquitylation involved in gene silencing and H2BK123 mono-ubiquitylation plays 
an important role in transcriptional initiation and elongation, nucleosome stability and 
mediating trans-histone H3 methylation (Weake and Workman, 2008; Kim et al., 2009; 
Chandrasekharan et al., 2010). This covalent modification is reversed by de-ubiquitin 
enzyme which also affects gene activity and silencing. Histone sumoylation involves 
addition of small ubiquitin-like molecules to lysine residues in all four core histones. It 
acts antagonistically to acetylation and ubiquitylation and is largely responsible for gene 
silencing events (Shiio and Eisenman, 2003; Ouyang and Gill, 2009). Histones (H2A, 
H2B, H3 and H4) have also been shown to be modified by β-N-acetylglucosamine (O-
GlcNAc) on serine and threonine residues which regulates mitosis-specific 
phosphorylation and coordinate G2/M transition of the cell cycle (Zhang et al., 2011; 
Fong et al., 2012). All the above covalent histone modifications are highly dynamic and 
cross-talk with each other to constitute a “histone code” that shapes gene-expression 
patterns by modulating the transcriptional potential of genomic domains. 
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1.2 Epigenetic definition of oncogenesis: 
Cancer has been explained in many different ways. From Hippocrates’ depiction of neo-
angiogenesis in tumors as the claws of a crab to Laennec’s view of malignancy as an 
inappropriate developmental malady; cancer has always confounded the human mind 
regarding its amazingly unpredictable nature (Feinberg et al, 2006). The past century 
witnessed dominance of the genetic model of cancer which perceived cancer as a set of 
disorders caused by progressive genetic and chromosomal abnormalities including 
mutations in key tumor suppressor genes and oncogenes. Each activating or silencing 
mutation resulted in promoting continued growth of clonally selected tumor cells with 
increasing tumorigenic potential such as invasiveness, metastasis, drug resistance and 
recurrence (Hanahan and Weinberg, 2000; Baylin and Ohm, 2006; Zhao et al., 2008; 
Hanahan and Weinberg, 2011). However, in the last two decades, molecular 
heterogeneity in cancer cells have led to the idea that alongside genetic changes, extensive 
alterations of chromatin in neoplastic as well as adjacent non-malignant cells play a 
greater part in mediating malignant conversion and progression (Hassler and Egger, 
2012).  In recent years, cancer as a disease has acquired more of an epigenetic essence, 
with researchers acknowledging epigenetics as the more dominant protagonist in 
oncogenic transformation. In fact, epigenetic alterations are not only recognized as 
strategic features of cancer cells, but are also considered to herald the onset of 
carcinogenesis (Pogribny, 2010; Dhanasekaran et al., 2013).  
1.2.1 The theory of epigenetic progenitor origin of cancer: 
In an attempt to explain oncogenesis in epigenetic language, epigenetic progenitor model 
of cancer was envisioned. According to this model, early epigenetic alterations in 
progenitor cells trigger neoplastic changes which together with succeeding genetic lesions 
drive tumorigenic transformation (Feinberg et al., 2006; Feinberg et al., 2016). Besides 
initiating pre-neoplastic changes, these epigenetic modifications set the stage for tumor 
plasticity and genetic variations later during tumor progression. Moreover, by placing 
precursor/progenitor/stem cells at the epicenter of neoplastic reprogramming, epigenetic 
changes provide mechanistic evidence for similarities between embryonic differentiation 
and oncogenic conversion (Baylin, 2012; Sandoval and Esteller, 2012) (Fig. 1.2). Thus, 
epigenetic progenitor model more effectively explains issues such as tumor recurrence 
and resistance, acquisition of heterogeneity and aggressive tumor properties in later stages 
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as well as genetics of cancer risk by precluding epigenetic disruption of stem/progenitor 
cells as a key step before commonly recognized neoplastic changes.  
In the first step, progenitor/precursor/stem cell population in any given anatomical 
system is exposed to initial epigenetic stress which primes them to be neoplasia-ready. 
The polyclonal population of precursor cells continuously strives to maintain an 
extremely delicate balance between competing interests of proliferation and 
differentiation (Mathews et al., 2009). They are the primary targets of multitude of 
genetic, age-dependent damage or injury that largely account for their susceptibility to 
neoplastic distress. Hence, small but profound epigenetic changes which can be due to 
distubances within the stem cells themselves or environmental stress perturb the 
equilibrium between undifferentiated progenitor cells and differentiated committed cells 
(van Vlerken et al., 2012). These early epigenetic changes force the precursor cells to 
acquire the capacity of aberrant differentiation and progress towards tumorigenic 
phenotype (Suva et al., 2013).  
The second step involves onset of gatekeeper mutations (GKM) within the 
compartment of rapidly expanding, epigenetically altered progenitor cells that gives rise 
to earliest stages of neoplasm and subsequent benign lesions (Sawan et al., 2008). These 
initiating mutations are specific for different tumor types, for example, mutation in tumor 
suppressor genes that encode adenomatosis polyposis coli (APC) in solid tumors like 
colorectal cancer whereas for leukaemia and lymphoma, rearrangement of oncogene 
homologue Breakpoint Cluster Region–Abelson Murine Leukaemia (BCR–ABL) is more 
crucial. The gatekeeper mutations were initially recognized as the earliest steps in 
tumorigenesis, but now epigenetic events are perceived as surrogates for mutation-
induced oncogene activation or tumor suppressor-gene silencing (Dawson and 
Kouzarides, 2012). 
In the third and final phase, progressive genetic and epigenetic instabilities lead to 
stable evolution of primary cancer into advanced tumors with enhanced oncogenic 
properties such as invasion, metastasis and drug resistance. These phenotypic features are 
inherently present in the progenitor cells and do not require further mutations, however 
epigenetic influence stimulates their aberrant expression and function in the developing 
neoplasia (You and Jones, 2012; Hassler and Egger, 2012). Genetic plasticity can be 
explained in terms of telomere erosion and DNA palindromes formation, wherein 
chromosomal shortening by both the processes results in a bridge-break-fuse cycle greatly 
Chapter 1                                                                                                                                      Introduction 
 
 
11 
destabilizing the genome. Epigenetic plasticity on the other hand, results in 
heterochromatin decondensation and consequent chromosomal rearrangements as well as 
pleiotropic changes in transcriptional status of chromatin modifiers. For example, 
chromosomal rearrangements leading to increase or decrease of active or repressive 
histone modifying marks alter the gene expression status of many cancer causing genes 
ultimately leading to evolution of aggressive properties in malignant tumors. The ultimate 
outcome of repetitive epigenetic and genetic stochasticity is alteration of the epigenomic 
landscape in the tumor micro-environment which allows enhancing properties and 
aggressive behavior (Feinberg and Irizarry, 2010; Timp and Feinberg, 2013). Epigenetic 
progenitor model thus propagates epigenetic alterations as main culprit in oncogenic 
transformation. 
1.2.2 Epigenetic choreography of neoplastic transformation: 
During tumorigenic progress, the epigenome is subjected to wide-spread alterations that 
affect nuclear architecture and chromatin compaction. The effects of these altered 
epigenetic events influence the course of malignant development in more than one ways 
involving silencing of prominent tumor suppressor, DNA repair and cell cycle regulatory 
genes, activation of oncogenes, disruption of differentiation programs and even 
facilitating the emergence of CSCs (Jones and Baylin, 2002; Sadikovic et al., 2008; 
Iacobuzio-Donahue, 2009). Following Darwin’s theory of selective evolution, these 
heritable gene silencing processes team up with genetic alterations to confer selective 
growth and proliferative advantages to tumor cells and sustain neoplastic progress (Jones 
and Baylin, 2007; Pogribny, 2010). 
Epigenetic gene-silencing causes loss of function and pre-disposition to mutation: 
Gene silencing via promoter DNA hypermethylation is the most prevalent and 
documented epigenetic change occurring in almost all tumor types (Baylin, 2012). In fact, 
promoter CpG hypermethylation is so extensively operational in the neoplastic cells that 
methylation induced epigenetic silencing of tumor-suppressor genes is presently 
considered to be more effective than genetic mutations in inflicting tumorigenic growth 
(Bhattacharjee et al., 2016). The transcriptional inhibition as a consequence of promoter 
hypermethylation causes loss of function of genes involved in important cellular 
processes such as (i) DNA repair by O-6-methylguanine–DNA methyltransferase 
(MGMT), MutL homolog 1 (MLH1) and breast cancer 1 (BRCA1), (ii) cell cycle control 
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by cyclin-dependent kinase Inhibitor 2A (CDKN2A), retinoblastoma (Rb) (iii) apoptosis 
by target of methylation-induced silencing 1(TMS1), death associated protein kinase1 
(DAPK1), (iv) metastasis by cadherin 1 (CDH1), CDH13, (v) detoxification by 
glutathione S-transferase pi 1 (GSTP1) (Muntean and Hess, 2009; Sharma et al., 2010; 
Kanwal and Gupta, 2012; Shukla and Meeran, 2014). The lack of functional expression of 
these tumor-suppressor genes results in faulty mismatch repair and microsatellite 
instability, thus destabilizing the genome and making it susceptible to genetic mutations. 
Moreover, methylated cytosines are susceptible to spontaneous hydrolytic deamination 
which causes transitional mutations such as C to T and CC to TT.  Silencing of cell cycle 
regulatory genes like cyclin dependent kinase inhibitor 2B (CDKN2B) allows defective 
cells to proliferate abnormally and cause tumor growth. Thus, epigenetic gene silencing 
can be considered as the primary cause of tumor adaptability and evolution (Wilting and 
Dannenberg, 2012). 
 
Figure 1.2: The clonal genetic and epigenetic progenitor models of cancer initiation, 
maintenance and progression.  While the clonal genetic model predominantly supported genetic 
mutations in tumor suppressor genes (TSG) and oncogenes (ONC) as the propagators of 
neoplastic conversion, epigenetic model gave credit to epigenetic alterations in tumor progenitor 
genes (TPG), especially pluripotency factors as the main mediators of oncogenesis. 
Epigenetic derepressing mechanisms activate unwanted oncogenic activity: 
Global loss of methylation occurs mainly at non-coding intergenic and intronic regions 
like retrotransposons and pericentromeric repeats where it promotes chromosomal 
rearrangements and insertional mutagenesis to destabilize and predispose the epigenome 
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to cancer-initiating mutations (Patra et al., 2008; Ehrlich, 2009; De Smet and Loriot, 
2010). Additionally, DNA hypomethylation results in transcriptional derepression and 
over-expression of (i) proto-oncogenes such as c-Myc and related-RAS (R-Ras), (ii) 
genes associated with metastasis and invasion like mammary serine protease inhibitor  
(MASPIN), urokinase-type plasminogen activator (uPA) and S100 calcium-binding 
protein A4 (S100A4), (iii) cancer-testis (CT) antigens like melanoma-associated antigen 
(MAGE) and (iv) imprinted genes like insulin growth factor 2 (IGF2) that drives 
malignant cell proliferation, invasion and metastasis (Syzf et al., 2004; Wilson et al., 
2007; Wild and Flanagan, 2010). In fact, paradoxical genomic hypomethylation and gene-
specific hypermethylation are considered characteristic feature of neoplastic progression. 
Epigenetic “addiction” to oncogenic signaling pathways: 
Epigenetic gene silencing events in pre-malignant lesions result in over-activation of 
oncogenic signaling pathways and cell-signaling molecules. The addicted cells are 
susceptible to genetic mutations during early stages of tumor development that endows 
them with greater proliferative and survival abilities that ultimately drives neoplastic 
development (Baylin and Ohm, 2006; Baylin and Jones, 2011). For example, loss of 
secreted frizzled-related protein (SFRP) expression (due to its promoter 
hypermethylation) during early stages of colon cancer development results in abnormal 
activation of the Wnt signaling pathway. The colon epithelial progenitor cells become 
habituated to over-activity of the Wnt pathway and subsequently accumulate mutations in 
APC complex. This favors sustained survival and proliferation of early-stage colon 
lesions into aberrant crypt foci (ACF) (Suzuki et al., 2004; Schepers and Clevers, 2012).  
Epigenetic disruption of differentiation programs in cancer:  
Aberrant epigenetic silencing events can interfere with cellular differentiation programs in 
pre-malignant cells and result in continuous self-renewal and inherent tumorigenicity 
(Scaffidi and Misteli, 2010). One of the most notable oncogene c-Myc induces tumor cell 
to acquire stem cell properties and interferes with cellular differentiation by histone 
deacetylation and chromatin remodeling (Liu et al., 2007; Rapp et al., 2008; 
Varlakhanova and Knoepfler, 2009). In addition, epigenetic signatures found in 
embryonic stem cells (ESC) is mimicked in various cancers, indicating that epigenetic 
reprogramming may lead to loss of cellular identity, generation of tumor heterogeneity 
and finally facilitate the emergence of CSCs (Ben-Porath et al., 2008; Wong et al., 2008). 
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1.3 Pluripotency inducing nuclear transcription factors act 
as epigenetic mediators of malignant changes: 
Pluripotency is essentially defined by two distinct characteristics, firstly the ability to 
undergo continuous self-renewal indefinitely and secondly, the capacity to generate 
differentiated progeny of nearly all lineages in mature organisms. These molecular 
hallmarks of pluripotency can be explained through a distinct set of markers that outline a 
unique stemness profile for pluripotent cells (Gonzales and Ng, 2011; Adachi and 
Scholer, 2012). In concert with signaling axes, transcription factors decide between 
various states of pluripotency (Liu et al., 2013; Kar et al., 2013). Transcription factors 
maintain pluripotent ESCs in their undifferentiated state by activating genes necessary for 
stem cell survival and proliferation while simultaneously repressing genes responsible for 
lineage commitment and speciation. In contrast, by facilitating expression of cell type-
specific genes, transcription factors also participate in establishment of cellular identity 
(Romito and Cobellis, 2016). Remarkably, the ectopic over-expression of Oct4, Sox2 and 
Nanog triumvirate has also been shown to induce the reprogramming of differentiated 
somatic cells back to pluripotent state of ESC (Takahashi and Yamanaka, 2006;  Jaenisch 
and Young, 2008; Welstead et al., 2008; Heng et al., 2010). 
1.3.1 A veritable cocktail of transcription factors govern maintenance, 
expression and acquisition of pluripotency: 
The establishment of embryonic pluripotency is carried out by three crucial factors Oct4, 
Sox2 and Nanog that constitute the core pluripotency network (Silva and Smith, 2008; 
Smith et al., 2016). Oct4 was the first identified germline specific pluripotency 
determinant. Though Oct4 null embryos develop blastomeres, yet inner cell mass (ICM) 
in the blastomeres do not have the power to give rise to pluripotent ESCs and ultimately 
give rise to trophoectodermal cells. Similarly, Sox2, another HMG-box transcription 
factor is a close associate of Oct4 and together they decide stem cell pluripotent state. 
Knockout of Sox2 results in embryonic lethality. Nanog is more involved in preventing 
differentiation than in maintaining pluripotency (Orkin et al., 2008; Greenow and Clarke, 
2012). Embryos lacking Nanog die around implantation due to lack of epiblast and 
absence of Nanog in ICM results in differentiation into endoderm.  Not only are Oct4, 
Sox2 and Nanog necessary for establishing pluripotency, they also maintain the 
pluripotent state without allowing differentiation programs to start. Therefore, silencing or 
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over-expression of Oct4, Sox2, or Nanog initiates ESC differentiation. For example, 
increase in Oct4 expression induces endodermal and mesodermal lineages, whereas 
decrease in Oct4 level causes trophoectodermic differentiation (Barrand and Collas, 
2010). Oct4, Sox2 and Nanog form auto-regulatory positive feedback circuitry for 
pluripotency by not only binding to their own promoters, but also activating the 
transcription of other protein-coding genes and microRNAs (miRNA) involved in 
pluripotency maintenance. In addition to the core transcriptional circuitry, many auxiliary 
transcriptional factors, including transcription factor 3 (TCF3), SMAD Family Member 1 
(SMAD1), signal transducer and activator of transcription 3 (STAT3), spalt-like 
transcription factor 4 (SALL4), dosage sensitive sex-reversal (DSS), adrenal hypoplasia 
congenita (AHC) critical region on the X-chromosome, gene 1 (DAX1), estrogen related 
receptor beta (ESRRB), nuclear receptor subfamily 5 group a member 2 (NR5A2), T-box 
transcription factor 3 (TBX3), zinc finger X-chromosomal (ZFX), kruppel-like factor 4 
(KLF4), forkhead box protein D3 (FOXD3), forkhead box protein O1 (FOXO1), forkhead 
box protein P1 (FOXP1), PR domain zinc finger protein 14 (PRDM14) and zinc finger of 
the cerebellum 3 (Zic3) have been demonstrated to be involved with the complex 
machinery that directs pluripotency maintenance (Huang and Wang, 2014; Ohnishi et al., 
2014). These accessory factors help the core regulators by activating developmentally 
inclined signaling pathways or by stabilizing the core transcriptional circuitry (Fig. 1.3). 
1.3.2 Pluripotency inducing transcription factors as the mechanistic link 
between embryogenesis and carcinogenesis: 
As it became clear that ectopic introduction of core pluripotency factors can revert back 
cells into ESC like condition, focus of scientific community shifted towards exploring the 
role of these factors in malignant transformation (Yamada et al., 2014). Elevated 
expression of Nanog, Oct4 and Sox2 has been reported in several cancers where they are 
known to actively induce tumorigenesis, contribute towards cancer maintenance and 
encourage acquisition of more aggressive tumor properties such as metastasis and lymph 
node invasion (Kim and Orkin, 2011). Cancer cells share many properties in common 
with early ESCs, especially expression of Oct4, Sox2 and Nanog. Therefore, it is not 
surprising that over-expression of these factors is found in many somatic cancers 
including oral squamous cell carcinoma, prostate and breast cancer and their aberrant 
activity increases inherent tumorigenicity in human malignancies by boosting tumor 
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transformation, metastasis and post-therapeutic distant recurrence and remission. 
(Kashyap et al., 2009). 
 
Figure 1.3: Pluripotency inducing transcription factors control three different aspects of 
stem cell pluripotency via differentiation, redifferentiation and dedifferentiation. Oct4, Sox2 
and Nanog form the core pluripotency network that participate in maintenance via self-renewal, 
expression via differentiation into lineage-committed fates and acquisition via reprogramming 
into undifferentiated ground state.  
 The molecular basis of similarity between embryonic development and oncogenic 
transformation is exemplified by transcription factors as they either target or are targeted 
by signaling pathways that are active in both ESCs and cancer cells (Semi et al., 2013). 
Oct4, Sox2 and Nanog in their molecular capacity of pluripotency determinants are 
modulated by developmentally inclined pathways that help them to ensure self-renewal 
and maintain pluripotency (Hadjimichael et al., 2015). However, the same signaling 
pathways are aberrantly hijacked in cancer and drive transcription factors to activate 
inappropriate expression of genes involved in cell cycle, cell proliferation, apoptosis and 
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cell death. For example, Oct4 increases transcriptional activity of AKT pathway which 
encourages abnormal cell growth. Meanwhile, Sox2 participates in the stromal interaction 
molecule 1 (STIM1) pathway via Sox2/Orail nodule and enhances anti-apoptotic potential 
in prostate cancer. Nanog is a direct target of the leukemia inhibitory factor (LIF)-STAT3 
pathway and maintains self-renewal of CSCs by up-regulating CD133, ATP-binding 
cassette sub-family G member 2 (ABCG2), aldehyde dehydrogenase 1 family, member 
A1 (ALDH1A1) and CD44 (Kim and Zaret, 2015; Yilmazer et al., 2015). Pluripotency 
inducing TFs, otherwise called tumor progenitor genes (TPG) are now considered as the 
mechanistic link between embryogenesis and oncogenesis. 
1.4 Cellular signaling pathways as epigenetic modulators of 
oncogenic adaptation: 
In order to systematically maintain homeostatic balance between survival, proliferation, 
and differentiation into designated functional identity, cellular systems must respond to a 
wide variety of intrinsic and extrinsic developmental cues. Precisely timed and rigidly 
controlled intracellular signaling pathways are largely responsible for amalgamating and 
translating these developmental cues into cell-type specific transcriptional states and 
phenotypic status. However, signal transduction pathways utilized by normal cells to 
ensure equilibrium between cell growth and cell death are often inappropriately 
manipulated to participate in neoplastic transformation (Patra et al., 2011; Sever and 
Brugge, 2015). Constitutively active or aberrantly inhibited crucial signaling molecules or 
pathways encourage malignant conversion by endowing strategic advantageous properties 
of survival and proliferation on tumor cells. Some of these enabling characteristics 
include ability to proliferate without exogenous growth stimulation, insensitivity to anti-
proliferative signals, capacity to invade adjacent non-tumor niche and migrate to distant 
sites, evasion of apoptotic death and resistance to replicative senescence as well as to 
induce neo-angiogenesis (Hanahan and Weinberg, 2000; Martin, 2003; Dongguang and 
Shaoguang, 2007). Moreover, deregulation in the cellular signaling pathways that regulate 
self-renewal and differentiation might be a significant contributor to therapy resistance in 
CSCs (Dreesen and Brivanlou, 2007; Karamboulas and Ailles, 2013). Understanding the 
abnormal cell signaling events culminating in malignant transgression will provide useful 
insights to develop effective therapies for treatment of many aggressive and drug resistant 
cancers (Bianco et al., 2006; Levitzki and Klein, 2010). 
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1.4.1 Hedgehog signaling pathway in development and cancer:  
Hedgehog (HH) pathway is one of the most important developmental signaling pathways 
controlling many aspects of organogenic patterning and developmental transition from 
embryonic to adult tissues. Moreover, it also facilitates stem cell maintainenance, repair 
and regeneration in somatic compartments (Barakat et al., 2010; Teglund and Toftgard, 
2010; Kar et al., 2012). The mammalian HH family consists of three members such as 
sonic hedgehog (SHH), Indian hedgehog (IHH) and desert hedgehog (DHH) (Hatsell and 
Frost, 2007). The HH ligand reception system is constituted by a 12-span transmembrane 
protein called patched (PTCH); and a 7-span transmembrane G-coupled receptor protein 
smoothened (SMO) (Jiang and Hui, 2008). The five-zinc finger containing transcription 
factors GLI proteins including GLI1, GLI2 and GLI3 are the principal downstream 
effector molecules of HH signaling pathway (Jacob and Briscoe, 2003; Ingham et al., 
2011). In the absence of HH ligand, PTCH blocks SMO activity and retains the GLI 
proteins in the cytoplasm with other proteins such as kinesin-like COSTAL2, serine–
threonine kinase Fused and suppressor of Fused (SUFU). However, when HH ligand 
binds to PTCH, it enables translocation of SMO to the primary cilium where its 
associated G protein activity inhibits suppressive kinase action on GLI factors (Ruiz i 
Altaba et al., 2007). Accumulation of GLI activators in the nucleus results in increased 
expression of HH target genes such as PTCH, GLI, IGF-2, platelet derived growth factor 
receptor α (PDGFR-α), cyclin D1 (CCND1) and cyclin D2 (CCND2) for cell cycle 
acceleration, forkhead box A2 (FOXA2) and T-box transcription factor (TBX2) for cell 
fate determination, cancer proliferation and invasion-related genes such as CCND, N-
Myc, Myc, Snail and B-cell lymphoma-2 (BCL-2) etc. (Katoh and Katoh, 2008).  
Given its significant contribution in embryonic development, any aberration in 
HH pathway components or activities results in a number of pathophysiological disorders 
and ultimately favors carcinogenic development. In fact, HH pathway is considered to be 
an oncogenic signaling pathway found constitutively active in many different cancer 
types such as gastrointestinal cancer, medulloblastoma, breast, lung, skin, gastric, 
prostate, hepatic and pancreatic cancer. Aberrantly active HH signaling pathway is 
involved in initiation, proliferation and propagation of many different types of cancers. 
The constitutive activation of the pathway can be due to multiple genetic and epigenetic 
aberrations including loss-of-function mutations in PTCH, SUFU, gain-of-function 
mutations in SMO and missense mutations in GLI1 and GLI3 or manipulation of levels of 
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HH ligands (SHH, IHH or DHH) (Teglund and Toftgard, 2010; Kar et al., 2012). The 
dysregulated HH pathway affects tumorigenic properties such as increased metastatic 
behavior by up-regulation of Snail, enhanced survival capability by the up-regulation of 
anti-apoptotic mediators Bcl-2, increased proliferative capacity through modulation of the 
cell cycle machinery and promotion of tumor invasiveness by down-regulating E-  
cadherin, MMPs and other metalloproteases (Clement et al., 2007; Kasper et al., 2009). 
Moreover, HH communicates with other signaling pathways active in cancer like Wnt and 
Notch to co-operatively increase tumorigenicity and inherent malignancy (Cerdan and 
Bhatia, 2010) (Fig. 1.4). In recent years, studies have implicated HH pathway to 
synergistically interact with pluripotency factors in mediating tumorigenic progression. 
Thus, HH pathway can be considered to be a crucial accomplice of the core 
transcriptional machinery as they arbitrate malignant transformation. 
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Figure 1.4: HH signaling participates in tumorigenic transformation by controlling various 
hallmarks of cancer. Constitutively active HH pathway results in initiation, proliferation and 
sustenance of malignant transformation and tumorigenesis by interaction with different effector 
and downstream targets (Kar et al., 2012). 
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Chapter 2 
Review of Literature 
2.1 Oct4 as the “gatekeeper” safeguarding ground state 
embryonic pluripotency: 
The pit-oct-unc (POU) domain containing transcription factor Oct4 is a critical regulator 
of pluripotency in mammals. It is ubiquitously expressed in unfertilized oocytes, in the 
ICM of blastocyst and epiblasts in pre-implantation embryos as well as in the female 
germline (Livigni and Brickman, 2013; Jerabek et al., 2014; Wu and Schöler, 2014). One 
of the most important functions of Oct4 is to prevent early segregation of blastomeres into 
trophoectodermic lineage, thus it is called as the “gatekeeper” of pluripotent embryonic 
state (Zuccotti et al., 2011).  It is also one of the irreplaceable Yamanaka Factors, 
meaning that Oct4 is indispensable for somatic reprogramming and cannot be substituted 
by any other core or auxiliary transcription factor (Sterneckert et al., 2012; 
Radzisheuskaya and Silva, 2014). Therefore, Oct4 expression, stability and activity is 
closely monitored and regulated by transcriptional, translational and post-translational 
modifications (Parfitt and Shen, 2014; Zeineddine et al., 2014). Although Oct4 is not 
expressed in adult cells, it is re-expressed in different types of cancer where it enhances 
tumorigenic activity and promotes aggressive behavior of neoplastic cells. Therefore, 
molecular mechanisms of Oct4 regulation and function and its dynamic interaction with 
progenitor niche both in stem and tumor cells should be thoroughly investigated. 
2.1.1 Oct4 as the master embryonic fate determinant: 
Oct4 was discovered as a transcription factor specific to early embryogenesis: 
Oct4 was first identified in unfertilized oocytes, in the early embryo, in primordial germ 
cells (PGCs) and embryonic carcinoma cells (ECCs), but not found in somatic tissues 
(Schöler et al., 1989 (a)). The existence of Oct4 in almost all cell types having ESC 
properties identifies it as an ESC-specific transcription factor. Additionally, Oct4 is an 
indispensable marker for establishment of mammalian germline as its presence in PGCs 
ensures uninterrupted transfer of genetic information through succeeding generations. 
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Oct4 is a maternally expressed germline specific factor: 
Oct4 is expressed in both male and female PGCs; however it is not detected in sperm or 
testis implying that Oct4 is a maternally expressed protein essential for specification of 
female germline during germ cell differentiation. In fact, male and female gametes can be 
discerned by the presence of Oct4 (Schöler et al., 1989 (b); Schöler et al., 1990 (a)).  
Oct4 is essential for zygotic genome activation in pre-implantation embryo: 
Maternal Oct4 mRNA level is constantly maintained through unfertilized oocytes to 
zygotic pronucleus, but is subsequently diminished in the 2- and 4-cell stage of 
development. Up-regulation of Oct4 again occurs after zygotic genome activation in the 
blastocyst stage and high levels of Oct4 is found in all blastomeres. Thus, Oct4 is a 
crucial maternal-derived factor that guides early cell divisions during maternal-to-zygotic 
transition in early pre-implantation embryo (Schöler et al., 1990 (b); Rosner et al., 1990; 
Pesce and Schöler, 2000).  
Oct4 decides segregation of embryonic lineages in post-implantation blastocyst: 
Oct4 is differentially expressed during the first lineage differentiation events in the 
embryo; while trophoectodermic cells have lower levels of Oct4, while cells of ICM 
exhibit high protein expression (Palmieri et al., 1994; Nichols et al., 1998). Oct4 recruits 
SET domain bifurcated 1 (SETDB1) histone methyltransferase and blocks the expression 
of caudal-related homeobox 2 (CDX2) and other trophoblast associated genes in the 
blastocyst, thus commencing the first segregation event in embryonic development (Yuan 
et al., 2011; Blij et al., 2012). In the second part, Oct4 along with Sox2 and Nanog 
participates in the differentiation of ICM along primitive endoderm lineage by activating 
fibroblast growth Factor 4 (FGF4) and its downstream target GATA-binding factor 6 
(GATA6) which predisposes epiblast cells towards primitive endoderm (Yamanaka et al., 
2010). Moreover, Oct4 specifies meso-endodermal commitment with the help of bone 
morphogenetic protein 4 (BMP4) and suppresses neural ectodermal formation 
(Zeineddine et al., 2006; Downs, 2008; Thomson et al., 2011; Wang et al., 2012).  
Oct4 is restricted to germ cells after gastrulation: 
After gastrulation, Oct4 expression is restricted to the male and female germ cells. 
Although, maturing and ovulated oocytes exhibit Oct4 protein, resting oocytes and 
sperms are devoid of Oct4, implying that Oct4 is a female germline specific marker and 
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that Oct4 maintains “totipotency cycle” starting from fertilization to germ cell 
specification (Yeom et al., 1996).  
2.1.2 Multi-tiered regulation of Oct4 expression, stability and activity: 
Developmentally restricted auto-regulatory control of Oct4: 
The genomic locus of Oct4 in chromosome 6 features regulatory elements like proximal 
promoter (PP), cis-acting proximal enhancer (PE) and distal enhancer (DE) situated 2 kb 
upstream of transcription start site (TSS) (Niwa, 2007). The PP region is GC-rich, lacks 
TATA-box sequence but includes binding sites for specificity protein 1 (SP1), retinoic 
acid receptor (RAR) as well as for orphan nuclear receptors like germ cell nuclear factor 
(GCNF) and COUP transcription factor 2 (COUP-TFII/ARP-1) all of which contribute 
towards POU domain, class 5, transcription factor 1 (Pou5f1) silencing during 
differentiation (Ben-Shushan et al., 1995; Gu et al., 2005 (b)). The cis-acting enhancer 
elements are functionally restricted to specific developmental stages as PE and DE are 
differentially active in pluripotent and totipotent cells of embryo respectively. PE, 
referred to as epiblast enhancer, is stage-and tissue-specific as it controls Oct4 expression 
in epiblast and epiblast stem cells in the early post-implantation embryo. DE, otherwise 
called germline enhancer is lineage-specific and active in ICM of preimplantation embryo 
and embryonic germ cell lines where it specifically drives Oct4 expression in PGCs 
(Yeom et al., 1996). In addition, each enhancer is enriched with binding sites for 
numerous active/repressive epigenetic marks and transcription factors suggesting that 
chromatin remodeling and co-operative transcriptomic network also impact Oct4 
expression and function (Gao et al., 2013). 
Oct4 transcription is actively maintained in ESCs by Paf1: 
Oct4 transcription is actively maintained in ESCs by RNA polymerase II-associated 
factor 1C (Paf1C), a component of the Paf1 complex, which binds to PP in association 
with RNA polymerase II and retains active chromatin architecture (Ding et al., 2009). 
During differentiation, each of the subunits of Paf1 complex is downregulated, followed 
by decrease in Oct4 transcription. Similarly, Oct4 mRNA is rapidly translated by Lin28 
with the help of RNA helicase A in ESCs (Qiu et al., 2010). 
 
 
Chapter 2                                                                                                                        Review of Literature 
 
 
24 
DNA methylation and histone modifications silence Oct4 during differentiation: 
Epigenetic mechanisms play a very important role in suppressing Oct4 expression 
although Oct4 gene is not subjected to imprinting. In ESCs, Oct4 activation is necessary 
for maintaining pluripotency, therefore Oct4 gene locus is hypomethylated and enriched 
with active histone marks like H3 lysine9 acetylation (H3K9Ac), H3  lysine14 acetylation 
H3K14Ac and H3  lysine4 di-/tri-methylation (H3K4me2/me3) (Hattori et al., 2004). 
However, as differentiation sets in, sequential epigenetic changes gradually silences Oct4 
activity. Firstly, euchromatic histone-lysine N-methyltransferase 2 (EHMT2/G9A) binds 
and recruits histone deacetylases (HDACs) to the promoter of Oct4. Secondly, G9A 
catalyzes repressive histone H3 di-methylation on Lys 9 (H3K9me2) by its Su (var), E 
(z), Trithorax (SET) domain which results in binding of heterochromatin protein 1 (HP1) 
and formation of less accessible, highly condensed heterochromatin (Feldman et al., 
2006). Following transient repression by histone marks, Oct4 is permanently silenced in 
somatic cells by DNA methylation in the promoter and enhancer by de novo DNA 
methyltransferases 3A and 3B (DNMT3A, DNMT3B)  (Li et al., 2007; Athanasiadou et 
al., 2010). Additionally, cyclin-dependent kinase 2-associated protein 1 (CDK2AP1) 
interacts with methyl-binding domain 3 (MBD3) protein present in the methylated Oct4 
promoter in association with DNMT3A, DNMT3B and histone deacetylase/nucleosome 
remodeling (HDAC/NuRD) complex and augments down-regulation of Oct4 expression 
(Deshpande et al., 2009).  
Oct4 transcription is antagonistically modulated by orphan nuclear factors: 
Transcription of Oct4 is modulated both positively and negatively by a host of nuclear 
factors that bind to regulatory elements of Oct4 gene locus in a context-dependent manner 
(Mullen et al., 2007). For sustaining pluripotency in ESCs, Oct4 is up-regulated by 
steroidogenic factor1 (SF1) and ESRRB (Yang et al., 2007; Zhang et al., 2008). Similarly, 
liver receptor homolog 1 (LRH1) binds to PP and PE of Oct4 and sustain its expression in 
the epiblast (Gu et al., 2005(a)). On the other hand, GCNF up-regulated by retinoic acid 
during differentiation, binds to PP and by employing DNMT3A and DNMT3B 
permanently limits Oct4 expression in the germ cell lineage after gastrulation (Fuhrmann 
et al., 2001; Gu et al., 2005 (b); Sato et al., 2006). Also, COUP-TFII /ARP-1 and COUP 
transcription factor 1 (COUP-TFI /EAR-3) also bind to PP and repress Oct4 expression 
(Sylvester and Scholer, 1994; Ben-Shushan et al., 1995).  
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miRNA mediated post-transcriptional regulation of Oct4: 
Non-coding RNAs like microRNAs regulate post-transcriptional expression of Oct4. 
miR-145 directly binds to 3′ untranslated region of Oct4 mRNA and causes its decay 
during differentiation (Xu et al., 2009(a)). Similarly, miR-296, miR-134 and miR-470 
bind to the amino acid coding sequence of Oct4 to negatively regulate its expression (Tay 
et al., 2008). Moreover, ESC specific microRNAs miR-290, miR-291, miR-292, miR-
293, miR-294, miR-295 indirectly affect Oct4 by facilitating transcription of DNMT3A 
and DNMT3B (Sinkkonen et al., 2008). 
Alternate splicing generates post-transcriptional structural isoforms of Oct4: 
Alternate splicing of Oct4 generates three different mRNA transcripts referred to as 
Oct4A, Oct4B and Oct4B1 of which Oct4A is the only functional product which localizes 
to nucleus as Oct4 and helps in maintenance of pluripotency (Atlasi et al., 2008; Wang 
and Dai, 2010). The Oct4B transcript contains exon 2a in place of exon 1 sequence in the 
N-terminal and is alternately translated into Oct4B-265, Oct4B-190 and Oct4B-164 
proteins by internal ribosomal entry site (Wang et al., 2009). While Oct4B-265 is 
expressed during genotoxic stress induced by p53 mediated apoptosis; Oct4B-190 over-
expression protects cells against heat shock mediated apoptosis (Gao et al., 2012). 
Oct4B1 is functionally redundant with Oct4B producing the same gene products as Oct4B 
(Gao et al., 2010). 
Post-translation modifications affect functional capacity of Oct4 protein: 
Covalent PTMs of proteins such as methylation, acetylation, phosphorylation, 
sumoylation and ubiquitination influence their functional potential by affecting their 
activity, stability and interaction with other proteins (Cai et al., 2012; Kar et al., 2012). 
Oct4 is subjected to differential phosphorylation in POU domain (Thr235, Ser236, 
Ser288, and Ser289) as well as in the N- and C-terminal transactivation domains where 
they sterically hinder DNA-binding affinity, homodimer assembly and transactivation 
potential (Saxe et al., 2009; Brumbaugh et al., 2012). Moreover, phosphorylation of serine 
111 residue interferes in the nuclear trans-localization of Oct4 (Spelat et al., 2012). Oct4 
is also tagged with monosaccharide O-linked β-N-acetylglucosamine (O-GlcNAc) by the 
enzyme O-GlcNAc transferase (OGT), affecting the reprogramming capacity of Oct4 
(Jang et al., 2012). Sumoylation of K123 residue of Oct4 increases its stability, DNA-
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binding and transactivation potential during primitive endoderm differentiation (Wei et 
al., 2007; Zhang et al., 2007). Poly-ubiquitination of Oct4 by WW domain containing E3 
ubiquitin protein ligase 2 (WWP2) promotes proteosomic degradation of Oct4 drastically 
reduces its transcriptional activity during early stages of differentiation (Xu et al., 2009 
(b); Liao et al., 2013).    
2.1.3 Functional Interactomes and transcriptional targets of Oct4: 
 
Figure 2.1: Oct4 interacts with multiple partners and accomplices to either activate or 
repress context-dependent transcriptional program (Adapted from Shi and Jin, 2010).   
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Interaction with core pluripotency maintaining transcription factors to balance self-
renewal and differentiation of ESCs: 
The triumvirate of Oct4, Sox2 and Nanog constitute the core pluripotency transcriptional 
network and synergistically activate the expression of other axillary transcription factors 
such as ESRRB, SALL4, KLF4, ZFX, STAT3, rap1 interacting factor 1 (RIF1) and 
undifferentiated embryonic cell transcription factor 1 (UTF1) all of which play important 
roles in maintaining pluripotency (Matoba et al., 2006; Kim et al., 2008; Chambers and 
Tomlinson, 2009; Kashyap et al., 2009; Young, 2011). Concurrently, Oct4 directly 
inhibits serine/threonine kinase 40 (STK40) to prevent extra-embryonic endoderm 
differentiation (Li et al., 2010). Oct4 also hinders trophoectodermic differentiation by 
negatively regulating CDX2 and thwarts endoderm formation by repressing FOXD3 (Guo 
et al., 2002; Yuan et al., 2009) (Fig. 2.1). 
Interaction with epigenetic modifiers and chromatin remodelers: 
Oct4 is known to interact with many chromatin remodeling complexes such as NuRD/ 
HDAC complex, polycomb and trithorax group of proteins, SWItch/Sucrose Non-
Fermentable (SWI/SNF) and histone lysine specific demethylase 1 (LSD1) to either 
activate pluripotency genes or generate repressive/poised chromatin environment in ESC 
during development (Liang et al., 2012) (Fig. 2.1). In concert with stem cell-specific 
embryonic specific BRG1-or-HRBM-associated factors (esBAF), Oct4 establishes 
permissive transcriptional state where different other co-factors interact with basal 
transcriptional machinery to induce pluripotency gene expression. At the same time, Oct4 
instructs NuRD complex and polycomb proteins to add repressive H3 lysine27 tri-
methylation (H3K27me3) marks and silence developmentally committed genes (Ang et 
al., 2011; Mansour et al., 2012). These interactions present concrete evidences to support 
cooperativity between epigenetic modifiers and pluripotency inducing TFs in maintaining 
ESC-specific gene expression. In addition, during segregation of blastocyst, Oct4 partners 
with SETDB1 to restrict extraembryonic differentiation in trophoblast lineage (Yuan et 
al., 2009).  
Interaction with ESC exclusive developmental signaling pathways:  
In order to regulate stem cell pluripotency, Oct4 cooperates with components of many 
ESC exclusive developmental signaling pathways. For example, Oct4 associates with 
recombining binding protein suppressor of hairless (RBPJ), the transcriptional effector of 
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Notch signaling pathway (Pardo et al., 2010). Similarly, membrane-associated complex of 
Oct4 with β-catenin results in proteosomal degradation of β-catenin, demonstrating that 
Oct4 uses Wnt pathway to maintain ground state pluripotency in ESCs (Faunes et al., 
2013) (Fig. 2.1). 
Interaction with components of basal transcriptional machinery, cell cycle, DNA 
repair, replication and recombination pathways: 
Oct4 target gene ESRRB interacts with the mediator complex (transcription coactivator), 
RNA polymerase II subunits, TATA-box binding proteins and transcription factor II D 
(TFIID) in order to control the basal transcriptional machinery during maintenance of 
pluripotency or initiation of differentiation (Fig. 2.1). One of the direct partners of Oct4, 
transcription factor CP2-like 1 (TCFCP2L1) interacts with proteins involved in DNA 
replication and repair (van den Berg et al., 2010). Oct4 positively regulates miR-302a 
which maintains ESC-specific cell cycle profile by down-regulation of G1 regulator 
CCND1 (Card et al., 2008; Sheik Mohamed et al., 2010).  
2.2 Sox2 as the transcriptional alchemist conjuring 
differential stem cell destiny: 
Sox2 is one of the most important regulators of mouse and human embryonic stem cell 
destiny. It is considered as the transcriptional alchemist who arbitrates multiple lineage-
speciation and commitment events during embryonic development (Zhang and Cui, 
2014). It is also responsible for maintenance of adult stem cells in somatic tissues for 
homeostatic balance, tissue repair and regeneration and is one of the critical factors for 
generating induced pluripotent stem cells (iPSCs) (Takahashi and Yamanaka, 2006). 
Moreover, ectopic expression and gene amplification of Sox2 has been associated with 
occurrence and development of cancer in multiple tissues, such as lung and breast (Weina 
and Utikal, 2014). A dynamic surveillance system consisting of transcription factors, 
miRNAs, epigenetic regulators and signaling pathways and handled by transcriptional, 
translational and post-translational manipulations is therefore operational in order to 
control and regulate the diverse functional roles played by Sox2 (Liu et al., 2013; Sarkar 
and Hochedlinger, 2013; Feng and Wen, 2015). The intricate network of regulators and 
modulators controlling Sox2 expression, activity and stability is closely monitored and 
rigidly preserved so that Sox2 mediated differentiation and reprogramming efficiently 
maintains pluripotency and cell-specific destiny. 
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2.2.1 Versatility of Sox2 in regulating progenitor cell fate: 
Sox2 is a multi-tasking transcription factor associated with almost all stages of embryonic 
transition. It is necessary for the establishment of totipotent pre-implantation zygote, 
maintenance of pluripotent ESCs during blastocyst formation and differentiation of 
multipotent progenitor ectodermal, endodermal and mesodermal cells into lineage 
committed byproducts. Further down the lane, Sox2 also takes part in adult tissue 
homeostasis and regeneration displaying its indispensability during mammalian 
embryogenesis and organogenesis (Sarkar and Hochedlinger, 2013; Sarlak and Vincent, 
2016).  
Sox2 in pre-implantation zygotic development:  
Following fertilization, maternal Sox2 protein initiates maternal-to-zygotic transition by 
zygotic gene activation during morula to blastocyst transition resulting in totipotent 
blastomeres of the early preimplantation embryo (Pan and Schultz, 2011). Sox2 facilitates 
the first lineage speciation process involving segregation of blastocyst into ICM and 
trophoectoderm where it gets confined to the ICM and subsequently promotes 
maintenance of ESCs (Avilion et al., 2003; Keramari et al., 2010). In addition, deletion of 
Sox2 from ICM results in trophoblastic differentiation of ESCs demonstrating the 
significance of Sox2 in maintenance and stabilization of pluripotency (Masui et al., 2007) 
(Fig. 2.2). 
Sox2 in post-implantation lineage speciation and commitment: 
Post-gastrulation, Sox2 participates in lineage differentiation process in developing 
ectodermal, mesodermal and endodermal cell lineages (Fig. 2.2).. In ectodermal 
speciation, Sox2 adopts two contrasting methods; where firstly, it sustains proliferation of 
fetal progenitor cells into neuroectodermal fate and secondly induces terminal 
differentiation into central and peripheral nervous systems (CNS and PNS). Sox2 
contributes towards differentiation of ESCs into early neuroectodermal neural fate by 
suppressing meso-endodermal commitment via inhibition of brachyury (Thomson et al., 
2011; Wang et al., 2012). Sox2 decides the fate of early neural progenitor cells into either 
paraxial mesoderm in alliance with T-box 6 (Tbx6) or neural tubes in the absence of any 
other competing transcriptional regulator (Takemoto et al., 2011). Further, Sox2 mediates 
terminal differentiation of CNS and retinal progenitors into brain and eye respectively by 
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direct interaction with Notch1 (Taranova et al., 2006). Additionally, Sox2 is involved in 
proliferation of Schwann cell precursors and in maturation of neural crest progenitor cells 
into sensory ganglia (Le et al., 2005; Cimadamore et al., 2011). Sox2 expression  induced 
by fibroblast growth factor 8 (FGF8) in dental epithelial stem cells during early phases of 
tooth morphogenesis results in their segregation into enamel-producing ameloblasts and 
other differentiated cells of dental stem cell niche (Juuri et al., 2012). Moreover, Sox2 is 
necessary for the formation of cochlear prosensory domain within the inner ear (Dabdoub 
et al., 2008).  
 Similar to its role in ectoderm, Sox2 is also implicated in mesodermal lineage 
commitment during skin and bone development (Fig. 2.2). During skin development, 
Sox2 expression initiates formation of dermal sheath and dermal papilla (DP) from 
mesenchymal somatic dermal condensates. Continuous expression of Sox2 in DP niche 
induces differentiation of hair shaft progenitors by specifying hair follicle type and 
controlling BMP-mediated mesenchymal-epithelial crosstalk (Driskell et al., 2009; Clavel 
et al., 2012). Also, Sox2 is found to help in proliferation of osteoblast progenitors. 
Extending Sox2 function from ectodermal and mesodermal patterning into endodermal 
derivatives, it is seen that Sox2 helps in organogenic specification of foregut by giving 
esophagus and anterior stomach (Que et al., 2007). Sox2 also endorses morphogenic 
differentiation of embryonic tongue into taste bud sensory cells (Okubo et al., 2009) and 
lung and tracheal formation from respective embryonic counterparts (Gontan et al., 2008; 
Que et al., 2009). Thus, Sox2 is extensively associated with remodeling of ectodermal, 
mesodermal and endodermal progenitor populations into desired committed cells during 
lineage speciation events.  
Sox2 in sustaining adult tissue homeostasis and regeneration: 
Sox2 expression persists in the adult progenitor pool in those tissues and organs that are 
dependent upon Sox2 for development. For example, Sox2 maintains neural precursor 
cells (NPCs) in neurogenic regions of lateral ventricle and adult hippocampus where it 
mediates neurogenesis (Favaro et al., 2009).  Moreover, Sox2 also enables propagation of 
adult unipotent stems cells of retina, trachea, tongue epithelium and dermal papilla of the 
hair follicle (Taranova et al., 2006; Que et al., 2009; Okubo et al., 2009; Driskell et al., 
2009).  Also, adult testes, forestomach, glandular stomach, trachea, anus, cervix, 
esophagus, lens, and dental epithelium also depend upon Sox2 for constant tissue 
homeostasis (Arnold et al., 2011).  In addition, Sox2 is reactivated in case of tissue 
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damage and assist in the repair process by promoting dedifferentiation or expansion of 
resident adult progenitor cells. As in case of peripheral nerve damage, Sox2 is re-
expressed in mature adult Schwann cells by ephrin type-B receptor 2 (EphB2) signaling 
where it mediates demyelination and clustering of Schwann cells for regrowing axons 
across the site of injury (Parrinello et al., 2010)(Fig. 2.2). 
 
Figure 2.2: Versatile role of Sox2 in maintaining and expressing pluripotency states during 
development. Sox2 helps in determination and establishment of pluripotency and cell-fate in pre-
implantation zygotic, post-gastrulation embryonic and fetal as well adult progenitor and somatic 
stem cells (Adapted from Sarkar and Hochedlinger, 2013). 
2.3 Nanog as the transcriptional rheostat against 
differentiation and speciation: 
Nanog is a more recently identified transcription factor which participates in 
determination of cell fate in the pluripotent ICM, maintains stem cell phenotype in the 
epiblast, thwarting impromptu endoderm differentiation (Wang et al., 2013). Nanog 
expression is regulated by Oct4/Sox2 heterodimers which bind to its proximal promoter 
and regulate its transcriptional activity. In conjunction with Oct4 and Sox2, Nanog forms 
auto-regulatory feedback circuitry by binding to their own promoters and maintaining 
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pluripotency (Pan and Thomson, 2007; Saunders et al., 2013). Amazingly, Oct4, Sox2 
and Nanog simultaneously target many secondary transcription factors that stabilize the 
ESC state and subdue differentiation and lineage-specific genes. Most notably, Nanog 
also contributes towards malignant transformation in a variety of cancers and results in 
tumor growth and recurrence, increased drug-resistance, enhanced proliferation and up-
regulation of invasion and metastatic ability (Du et al., 2012). 
2.3.1 Regulatory networks controlling Nanog expression and function: 
Auto-regulatory positive and negative feedback control of Nanog: 
In order to compensate for the extensive fluctuations in its level in ESCs, Nanog can bind 
to its own promoter and positively or negatively impact its own mRNA and protein levels. 
Although, Nanog increases expression of its own protein generally in conjunction with 
Oct4 and Sox2, it can also interact with Zic3 at its promoter and drive its transcription 
even in the absence of Oct4 and Sox2 (Lim et al., 2010; Navarro et al., 2012). Similarly, 
auto-repression of endogenous Nanog production is achieved by interaction of Nanog 
with zinc finger protein 281 (Zfp281) associated with NuRD/HDAC repressor complex 
(Fidalgo et al., 2011; Fidalgo et al., 2012).  
Regulation of Nanog by key transcriptional factors of pluripotency network: 
Nanog is extensively regulated by a host of transcription factors, including Oct4 and Sox2 
in order to maintain balanced Nanog expression and functional capacity. Oct4, Sox2 and 
Nanog co-regulate each other through positive feedback loop by binding to enhancer 
elements in their respective promoters and modulate their expression (Rodda et al., 2005; 
Kuroda et al., 2005). The proximal promoter region of Nanog is mostly occupied by a 
battery of transcription factors that either activate or repress Nanog. For example, FoxD3 
binds to enhancer located 270 kb upstream to Nanog promoter and activates Nanog gene 
transcription. ESSRB, bound to nuclear receptor coactivator 3 (Ncoa3) is recruited to 
Nanog promoter by Oct4 where it associates with RNA polymerase II and activates the 
basal transcriptional machinery and Nanog expression (van den Berg et al., 2008; 
Festuccia et al., 2012). Another core transcriptional factor KLF4 also binds to the 
proximal promoter of Nanog to increase its expression (Chan et al., 2009). Negative 
regulators that reduce Nanog levels during differentiation include CDX2 and GCNR that 
bind to promoter of Nanog and down-regulate it in order to enable differentiation to start 
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(Chen et al., 2009). Further, TCF3 also suppresses Nanog levels by binding to its 
regulator region and allowing proper differentiation (Pereira et al., 2006). 
Regulation by epigenetic modifiers and chromatin remodeling complexes: 
Epigenetic modifications are already known to influence transcriptional activity of Oct4 
and Sox2, hence it is not surprising that expression and activity of Nanog is also affected 
by chromatin modifiers. For example, SIN3 homolog A/histone deacetylase 
(SIN3A/HDAC) co-repressor complex is recruited by p53 to the promoter of Nanog 
during differentiation to reduce acetylation and create a compacted chromatin structure so 
as to inhibit transcription of Nanog (Lin et al., 2005; Baltus et al., 2009). On the other 
hand, active gene expression of Nanog is supported by histone acetyltransferases and 
methyltransferases. The histone acetyltransferase, males absent on the first (MOF) 
directly binds to the promoter of Nanog and increases its mRNA and protein levels (Li et 
al., 2012). WD repeat-containing protein 5 (WDR5), a histone methyltransferase 
belonging to the mixed-lineage leukemia (MLL) complex is instructed by Oct4 to enrich 
H3K4 tri-methylation at Nanog promoter to stimulate its expression (Ang et al., 2011). 
Another histone methyltransferase enhancer of zeste homolog 2 (EZH2) is also known to 
influence expression of Nanog by H3K27me3 marks in the Nanog promoter and balances 
the equilibrium between self-renewal and differentiation in ESCs (Villasante et al., 2011; 
Herberg and Roeder, 2011). Higher order chromatin organizers like special adenine-
thymine (AT)-rich DNA-binding protein 1 (SATB1) and SATB2 are also respectively 
involved in positive and negative regulation of Nanog expression (Savarese et al., 2009). 
Post-translational modulation of the stability and function of Nanog: 
Post-translational phosphorylation of Nanog Serine/Threonine residues is known to 
increase Nanog stability by promoting its interaction with prolyl isomerase (Pin1) and 
preventing its proteosomal degradation (Moretto-Zita et al., 2010). Interestingly, 
phosphorylation of Nanog by focal adhesion kinase (FAK) and protein kinase Cε (PKCε) 
promotes nuclear translocation of Nanog where it activates oncomiR-21 and mediates 
tumor growth (Bourguignon et al., 2012). In addition, Nanog is ubiquitinated at Lys26 
and Lys48 residues which targets it for proteosomal degradation (Ramakrishna et al., 
2011).  
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Signaling pathways control Nanog expression and activity: 
Signal transduction pathways are crucial to maintaining homeostatic gene expression 
programs during self-renewal and pluripotency or differentiation and lineage-
commitment. Nanog expression is also modulated by several signaling cascades, notable 
among them being LIF pathway which works via two parallel effectors Janus 
kinase/signal transducers and activators of transcription 3 (JAK/STAT3) and 
phosphatidylinositol-4,5-bisphosphate 3-kinase/AKT (PI3K/AKT) (Niwa et al., 2009). 
LIF-STAT3 pathway also activates Nanog expression by interacting with Brachyury at 
STAT3 binding site in the enhancer region 5 kb upstream of the TSS in Nanog promoter. 
BMP pathway is also involved in the regulation of Nanog in association with 
transforming growth factor-β/SMAD1 (TGFβ /SMAD1) (Suzuki et al., 2006; Xu et al., 
2008). FGFR2 down-regulates Nanog gene transcription by activating MEK pathway and 
subsequently mediates differentiation into primitive endoderm (Santostefano et al., 2012). 
Similarly, glycogen synthase kinase 3 (GSK3) is also involved in regulation of Nanog in 
order to specify pluripotency (Luo et al., 2013).  
2.3.2 Role of Nanog in pro-tumorigenic reprogramming:  
Over-expression of Nanog is indicative of poor survival and prognosis: 
Expression of Nanog has been detected in germ cell tumors as well as other tumors, 
including breast, cervix, oral, kidney, prostate, lung, gastric, brain, and ovarian cancer. 
Strong expression of Nanog is shown as an indicator of a poor prognosis for ovarian 
serous carcinoma, colorectal, and breast cancer patients. In oral squamous cell and lung 
adenocarcinoma, higher expression of Nanog, along with Oct4, was associated with 
advanced cancer stage and shorter patient survival rate (Fig. 2.3). 
Nanog promotes increased cell proliferation and cell cycle in cancer:  
In cancers, over-expression of Nanog mediates increased tumor cell proliferation and 
growth (Fig. 2.3). Nanog interacts with members of cell cycle machinery such as CCND1, 
CCNE1, cyclin dependent kinase 1(CDK1), growth differentiation factor3 (GDF3) and 
transcriptionally activates them to accelerate proliferation of neoplastic cells by over-
riding cell cycle checkpoints.  While gain-of Nanog expression studies demonstrated 
increase in colony formation, loss-of-function of Nanog resulted in G1 arrest and lower 
proliferation and survival in lung, breast and ECC (Choi et al., 2012; Han et al., 2012; 
Park et al., 2012).  
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Figure 2.3: Role of Nanog in oncogenic reprogramming and malignant adaption. Nanog is 
regulated by several signaling pathways and in turn interacts with multiple protein partners to 
encourage tumorigenic properties and cause malignancy (Adapted from Wang et al., 2013). 
Nanog enhances tumor metastasis and invasive potential of tumor cells:  
Up-regulation of Nanog results in increase of transcript levels of epithelial to 
mesenchymal (EMT) specific genes such as E-cadherin, FOXO1, FOXO3A, forkhead 
box J1 (FOXJ1), forkhead box B1 (FOXB1) and SLUG, thus improving metastatic ability 
of tumor cells and encouraging EMT and invasiveness in higher grade, advanced stages of 
cancer (Chiou et al., 2010; Siu et al., 2013) (Fig. 2.3).  
Nanog provides resistance against apoptosis and chemotherapeutic drugs: 
Increase in stemness marker Nanog promotes resistance to chemotherapeutic drugs like 
cisplatin (Tsai et al., 2011). Nanog associates with STAT3 to increase the expression of 
multi-drug resistance transporter ATP-binding cassette sub-family B member 1 (ABCB1) 
which excludes drugs from tumor niche (Bourguignon et al., 2012). In addition, Nanog 
interacts with p53 and AKT pathways and makes tumor cells resilient to apoptotic death.  
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Nanog improves tolerance of tumor cells to immune attack and surveillance: 
In conjunction with hyperactive T-cell leukemia/lymphoma 1A/AKT (TCL1A/AKT) 
pathway, Nanog helps neoplastic cells to evade CD8+ cytotoxic T lymphocytes employed 
by host immune system. By increasing stem-cell like properties of cancer cells, Nanog 
empowers the tumor cells to avoid detection and elimination by immune system (Noh et 
al., 2012 (a); Noh et al., 2012(b)).  
Nanog interacts with oncogenic pathways to encourage malignant growth: 
Crosstalk between Nanog and oncogenic signaling pathways such as ESRRB, PI3K/AKT, 
HH, STAT3, p53 etc. boosts inherent tumorigenicity by enhancing CSC-like properties, 
cell survival and self-renewal and improving cross-communication between cancer 
associated stromal cells in the tumor niche (Zbinden et al., 2010; Lee et al., 2011; 
Hawkins et al., 2012; Yi et al., 2012) (Fig. 2.3). 
2.5 Objectives of the thesis: 
Crosstalk between pluripotency factors and epigenetic modifiers is one of the 
fundamental forces behind pluripotent state of stem cells and their gradual progression 
towards specialized cellular identity. The Holy Trinity of “Oct4, Sox2 and Nanog” are 
regarded as the connecting bridge between embryonic development and malignant 
evolution and are increasingly considered as novel targets for chemotherapeutic 
interventions in cancer. Hence, it is necessary to investigate the epigenetic regulatory 
network and signaling pathways controlling expression of pluripotency inducing TFs in 
cancer. Keeping the above views in mind, objectives of the thesis are as follows: 
1. To investigate the expression profile of pluripotency inducing TFs in breast and 
prostate cancer. 
2. To evaluate the role of pluripotency inducing TFs in promoting inherent 
tumorigenicity in breast and prostate cancer. 
3. To elucidate the epigenetic modification marks regulating pluripotency inducing TFs 
in breast and prostate cancer. 
4. To explore the connection between oncogenic Hedgehog signaling pathway and 
pluripotency inducing TFs in breast and prostate cancer. 
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Chapter 3 
To investigate the expression profile of 
pluripotency inducing TFs in  
breast and prostate cancer 
3.1 Introduction: 
Breast and prostate cancers are the most frequent cause of cancer-related deaths in 
females and males respectively. Both the solid tumors are heterogeneous diseases, with 
distinct morphologies, metastatic behaviour and therapeutic responses (Ferlay et al., 
2010). Despite advances in early detection, approximately 30% of patients with early 
stage breast and prostate cancer show recurrence (Gonzalez-Angulo et al., 2007). Initially, 
patients subjected to chemotheraphy or radiation treatment responded favourably to 
systemic therapy, but  post-therapeutic recurrence occurs in majority of cases leading to 
increased mortality rates (Ben-Porath et al., 2008). Cancer cells are one of the most 
adaptive entities which continuosly develop better alternatives to escape immune action 
and treament regimes; hence in order to improve the patient survival rate and develop 
better therapeutic strategies, understanding the diversity and versatility that underlie the 
molecular origin and maintenance of oncogeneis is a necessity.  
 As oncologists are struggling to unravel the molecular heterogenity that defines 
neoplastic progress, commonalities between embryonic differentiation and malignant 
transformation are considered to be of  prime importance. It is now assumed that factors 
mediating embryogenic pluripotency and differentiation are important contributors to 
malignant reprogramming where they facilitate the breaking of differentiation barriers and 
reset oncogenic potential. These factors are none other than pluripotency inducing TFs 
especially Oct4, Sox2 and Nanog who together function as the gatekeepers of 
pluripotency in ESCs. These TFs are now considered as the mechanistic link connecting 
embyrogenesis and oncogenesis by encouraging similar molecular re-configuration of the 
epigenomic landscape that supports neoplatic adaption (Klimczak, 2015). In many recent 
reports, Oct4, Sox2 and Nanog have found to be over-expressed in different types of 
cancers wherein by multiple mechanisms and interaction with numerous partners they 
arbitrate oncogenic progress (Ezeh et al., 2005). Considerable evidences have implicated
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Oct4 over-expression in neoplastic growth in breast, bladder, non-small cell lung, gastric, 
esophageal as well as germ cell tumors (Zhang et al., 2010; Rijlaarsdam et al., 2011; 
Huang et al., 2012; Zhao et al., 2012). Moreover, elevated Oct4 expression in these 
cancers has been associated with poor prognosis and shorter survival (Cheng et al., 2012; 
He et al., 2012). Similarly, Sox2 amplification has been reported in many human tumor 
types including glioblastoma, lung, colon, cervix, gastric, hepatic, breast and prostate 
cancer as well as in germ cell tumors (Weina and Utikal, 2014). Aberrant up-regulation of 
Nanog expression has been detected by several groups in germ cell tumors as well as 
other tumors, including breast, cervix, oral, kidney, prostate, lung, gastric, brain, and 
ovarian cancer (Choi et al., 2012; Han et al., 2012). The over-expression of Nanog is an 
indicator of a poor prognosis for ovarian serous carcinoma, colorectal, and breast cancer 
patients. Higher expression of Nanog is known to indicate advanced cancer stage and 
results in shorter patient survival rate in oral squamous cell and lung adenocarcinoma 
(Rodda et al., 2005; Wang et al., 2013). 
The present objective was designed to investigate and establish the expression 
profile of pluripotency inducing TFs- Oct4, Nanog and Sox2 in human breast and prostate 
cancer tissues and cancer cell lines. In this regard, two breast cancer cell lines, MCF7 and 
MDA-MB-231 and two androgen independent prostate cancer cell lines DU145 and PC3 
were selected as tumorigenic cell lines along with immortalized human keratinocytes 
HaCaT cell line chosen as the normal counterpart. In silico analysis using publicly 
available databases and experimental validation of transcript and protein level expression 
of Oct4, Nanog and Sox2 was done in order to elucidate the diverse expressions of these 
TFs in breast and prostate cancer. A clear and transparent picture regarding the status of 
Oct4, Nanog and Sox2 in breast and prostate cancer will be helpful in constructing the 
molecular roadmap by which these TFs mediate and support carcinogenic phenotype. 
Establishing the expression pattern and functional activity of pluripotency inducing 
transcription factors Oct4, Sox2 and Nanog in breast and prostate cancer will help in 
generating new prognostic and diagnostic biomarkers for early detection and 
identification of aberrant stem-cell signatures in neoplastic samples and provide 
opportunities for better treatment procedures. 
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3.2 Materials and Methods: 
3.2.1 In silico analyses from publicly available databases: 
Pre-experimental in silico analyses of expression of Oct4, Sox2 and Nanog was done 
prior to wet lab experiments by employing publicly available online bioinformatics tools 
cBioPortal having links to TGCA database (Cerami et al., 2012; Gao et al., 2013). From 
this database, copy number alteration (CNA – amplification, deletion, mutation) and 
genomic profile (mRNA up-regulation and down-regulation) of Oct4, Sox2 and Nanog 
from patient samples present in TGCA were evaluated for breast and prostate 
adenocarcinoma cancer. Further, mutually exclusive relationship between Oct4, Sox2 and 
Nanog in breast and prostate cancer was also computed. 
3.2.2 Immunohistochemistry of breast and prostate tissue samples: 
A total of 65 breast (primary=35, metastatic=30) and 33 prostate (benign prostate 
hyperplasia (BPH)=15, malignant=18) formalin fixed parafilm embedded (FFPE) tissue 
samples from cancer tissue library were selected and analyzed. The tissue embedded in 
parafilm blocks were cut into 0.5μm sections and subjected to antigen retrieval with tris-
EDTA buffer, endogenous peroxidase blocking and rinsed with tris-buffered saline (TBS) 
containing 0.025% Triton X-100 (Himedia-RM845) (TBS-T). Rabbit polyclonal anti-
Oct4 (Abcam-ab19857), rabbit polyclonal anti-Sox2 (Abcam-ab59776) and rabbit 
polyclonal anti-Nanog (Abcam-ab21624) were used as primary antibodies. After 
incubation with primary antibody at 4° C for overnight, tissue sections were rinsed with 
TBS and incubated at room temperature for 1 h with appropriate HRP conjugated 
secondary antibody (Goat anti-rabbit IgG-HRP, Santa Cruz Biotechnology- sc-2004). All 
specimens were developed with 3, 3′-Diaminobenzidine tetrahydrochloride (DAB, Sigma-
D3939). Immunoreactive Score (IRS) was calculated using ImmunoRatio Software 
wherein the percentage of staining was taken as three different scores: 1: no staining, 2: 
medium staining and 3: high staining.  
3.2.3 Cell culture:  
Human breast carcinoma cell lines MCF7 and MDA-MB-231, human prostate cancer cell 
lines PC3 and DU145 and  immortalized human keratinocytes HaCaT were obtained from 
National Centre for Cell Science (NCCS), Pune. MCF7 was cultured and maintained in 
Minimum Essential Medium (MEM, Himedia-AL047A),  MDA-MB-231 in Leibovitz's 
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medium (L-15, Himedia-AL011S), PC3 was cultured in Nutrient Mixture F-12 Ham 
medium (F-12, Himedia-AL106S)  whereas DU145 and HaCaT in Dulbecco’s Modified 
Eagle’s Medium (DMEM, Himedia-AL007A)  supplemented with 10% (v/v) fetal bovine 
serum (FBS, Himedia-RM1112)  and 100 IU/mL penicillin and 0.1 mg/mL streptomycin 
(Himedia-A002A) in a humified atmosphere of 5% CO2 at 37° C. The cells were 
harvested by trypsinization (Trypsin, Sigma-T4049) and the number of living cells was 
calculated by trypan blue (Himedia-TC193) staining (0.2% v/v) using hemocytometer 
before seeding for future experiments. 
3.2.4 Relative mRNA expression analysis by real-time PCR: 
Total cellular RNA from each of the five cell lines was extracted with TRI Reagent 
(Sigma-T9424) according to the manufacturer’s instructions. cDNA was prepared from   
1 μg of total RNA by using RevertAidTM First Strand cDNA Synthesis Kit (Thermo 
Scientific-K1622) followed by quantitative real-time PCR (RT-PCR) using Maxima 
SYBR Green/ROX qPCR Master Mix (2X, Thermo Scientific-K0221) in the Realplex4 
Eppendorf system according to the manufacturer’s instructions. The mRNA level was 
normalized to house-keeping gene GAPDH used as an endogenous control and 
calculations were done using 2
−ΔΔCt
 method, as described earlier (Schmittgen and Livak, 
2008).  
3.2.5 Western Blotting:  
2 X 10
5 
cells of each cell line were seeded and incubated till 80% confluency. Cells were 
harvested and total cellular protein was extracted using lysis buffer (RIPA Buffer, Sigma-
R01278) supplemented with protease inhibitor cocktail (PIC, Sigma-P8340). Bradford 
method was used to quantify the protein concentration and equal amount of cell lysate 
was loaded and separated in 10% SDS-PAGE and subsequently transferred onto PVDF 
membrane (Millipore, USA-ISEQ00010). Protein containing membranes were blocked in 
3% bovine serum albumin (BSA, Himedia-5RMI05) in PBS containing 0.1% Tween 20 
(Himedia-MB067) (PBST), followed by overnight incubation with primary antibodies -- 
rabbit polyclonal anti-Oct4 (Abcam-ab19857), rabbit polyclonal anti-Sox2 (Abcam-
ab59776) and rabbit polyclonal anti-Nanog (Abcam-ab21624), then incubated with 
appropriate HRP conjugated secondary antibody (Goat anti-rabbit IgG-HRP, Santa Cruz 
Biotechnology, sc-2004) for 2 h at 37° C in dark. The membranes were thoroughly 
washed with PBST buffer and were developed by Supersignal
TM
 West Femto 
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Chemiluminescent substrate kit (ThermoScientific-34095). β-Actin (Primary-Mouse IgG1 
(Monoclonal),Santa Cruz Biotechnology-sc-47778 and Secondary-Goat Anti-Mouse IgG-
HRP, Santa Cruz Biotechnology-sc-2005) protein levels were used as control for equal 
protein loading. Relative protein expression was analyzed from the blots obtained using 
ImageJ quantification software.  
3.3 Results: 
3.3.1 Oct4, Sox2 and Nanog are amplified in breast and prostate cancer 
cell lines: 
Pre-experimental in silico analysis by cBioportal database (http://www.cbioportal.org/) 
linked to Cancer Genome Atlas (TCGA) using a cohort of clinical (patient-derived) tissue 
samples is typically an assessment of the expression profile of a gene set (e.g. Oct4, Sox2 
and Nanog) and its associated functional characterization in different cancer types. 
Copy Number Alteration (CNA) and genomic profiling:  
CNA (amplification, deletion and mutation) and genomic profile (mRNA up-and down-
regulation) of Oct4, Sox2 and Nanog in breast and prostate cancer tissue samples was 
analyzed from generated Oncoprint. In breast cancer, alterations for Oct4 was observed in 
17 (1.8%, amplification in 1.2%) samples, for Sox2 in 37 (3.8%, amplification in 3.6%) 
cases and for Nanog in 30 (3.0%, amplification in 2.7%) cases (Fig. 3.1). In prostate 
cancer, Oct4 and Sox2 were amplified in 0.4% and 1.9% cases, whereas Nanog showed 
allelic deletion in 1.5% cases (Fig. 3.1). From genomic profiling it is evident that mRNA 
up-regulation of Oct4 occurs in both breast (5.54%) and prostate cancer (6.0%) which is 
higher that gene amplification (Fig. 3.1). Similarly, Sox2 shows higher mRNA up-
regulation in prostate cancer (6.6%) than in breast cancer (1.84%) in comparison to gene 
amplification (Fig. 3.1). In case of Nanog, gene amplification is more prevalent that 
mRNA up-regulation in breast cancer, but not in prostate cancer (Fig. 3.1). The above 
results indicate that mRNA up-regulation of Oct4, Sox2 and Nanog play a predominant 
role in over-expression of these factors in breast and prostate cancer.   
Mutual exclusivity and co-occurrence: 
When alterations in any one of the genes in a gene set and same cancer sample (breast or 
prostate cancer), is sufficient to deregulate the entire process and lead to cancer 
progression, the alteration events are considered to be mutually exclusive. On the other 
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hand, if alterations occur in multiple genes in the same cancer sample, then the alteration 
events are considered to be co-occurent. As is evident from table 3.1, in breast 
adenocarcinoma (TCGA, Cell, 2015; n= 974), CNA in gene set - Oct4, Sox2 and Nanog 
is observed in total of 84 (8.6%) samples, however these alterations have a tendency 
towards co-occurrence, with statistically significant occurrence between Oct4 and Nanog. 
In case of prostate cancer (TCGA, Cell, 2015; n= 333), overall alterations (20) have a 
tendency towards mutual exclusivity. The results indicate that while genetic alterations in 
Oct4, Sox2 and Nanog are co-occurent in breast cancer (where gene alterations occur 
simultaneously for cancer progression) and mutually exclusive in prostate cancer (where 
alteration in any of the genes can cause cancer). 
 
Figure 3.1: Oncoprint of Oct4, Sox2 and Nanog in breast and prostate adenocarcinoma 
samples using cBioportal. In breast adenocarcinoma patients (n=974), CNA was detected in 
1.8% samples and mRNA up-regulation in 5.54% for Oct4,  Sox2 showed genetic amplification in 
3.6% and mRNA up-regulation in 1.84% and Nanog showed amplification in 2.7% and mRNA 
up-regulation in 0.2%. In prostate adenocarcinoma patients (n=333), Oct4 and Sox2 showed 
amplification in 1% and 1.8% cases,  while Nanog was delected in 1.5% of cases. mRNA up-
regulation is the more dominant reason of over-expression of Oct4, Sox2 and Nanog in both 
breast and prostate cancer. 
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Table 3.1 Mutual exclusivity and co-occurrence of CNA of Oct4, Sox2 and Nanog 
Breast adenocarcinoma (n= 974)                                            Alterations in  84 (8.6%) cases 
Gene 1 Gene 2 p-value Log odds ratio Association 
Oct4 Nanog <0.001 2.347* Tendency towards co-occurrence 
Oct4 Sox2 0.358 0.278 Tendency towards co-occurrence 
Sox2 Nanog 0.452 -0.630 Tendency towards mutual exclusivity 
Prostate adenocarcinoma (n= 333)                                          Alterations in 20 (6.0%) cases 
Gene 1 Gene 2 p-value Log odds ratio Association 
Oct4 Sox2 0.929 <-3 Tendency towards mutual exclusivity 
Oct4 Nanog 0.970 <-3 Tendency towards mutual exclusivity 
Sox2 Nanog 0.169 1.975 Tendency towards co-occurrence 
 
3.3.2 Analysis of Oct4, Sox2 and Nanog expression in breast and 
prostate cancer tissues: 
In order to establish the expression profile of Oct4, Sox2 and Nanog in breast and prostate 
cancer, protein level expressiion in FFPE tissue samples were analyzed. All the three 
proteins showed higher expression in metastatic stage breast tissue samples in comparison 
to  primary stage tissues, indicating that over-expression of these factors is associated 
with advanced stages of cancer and mediates cancer progression (Fig. 3.2a, Table 3.2). 
The immunoreactive score for Oct4, Sox2 and Nanog staining was found to be in 
case of metastatic samples- 4.56 (Oct4), 4.2 (Sox2) and 3.8 (Nanog) indicating that Oct4 
has the highest expression among the three factors in breast cancer (Fig. 3.2b). 
Table 3.2 Expression of Oct4, Sox2 and Nanog in FFPE breast cancer tissue samples 
Clinical breast cancer tissue samples 
Number 
of 
samples 
Age 
Stage of 
cancer/ 
No. of sample 
Oct4 expression in 
protein level (%) 
P-Presence; 
A-Absence 
Sox2 expression in 
protein level (%) 
P-Presence; 
A-Absence 
Nanog expression in 
protein level (%) 
P-Presence; 
A-Absence 
65 ≤50 
Primary 
stage/35 
P 28 (10 samples) P 25 (9 samples) P 31 (11 samples) 
A 71 (25 samples) A 75 (26 samples) A 69 (24 samples) 
Metastasis 
stage/30 
P 83 (25 samples) P 63(19 samples) P 57 (17 samples) 
A 17 (5 samples) A 37 (11 samples) A 43 (13 samples) 
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Figure 3.2: Immunohistochemistry of breast cancer tissue samples for analyzing Oct4, Sox2 
and Nanog protein expression.  [a] Representative immunostained specimens showing Oct4, 
Sox2 and Nanog expression in primary (n= 35) and metastatic (n=30) FFPE tissue samples. 
Metastatic tissues show higher expression of all three proteins in comparison to primary stage 
tissues. Scale Bar = 100 μm, [b] Bar plot shows immunoreactivity score (IRS) for Oct4, Sox2 and 
Nanog staining in tissues. Oct4 has the highest expression in breast cancer tissue samples. Error 
bars indicate SD (P < 0.05). 
Similarly, for prostate cancer, Oct4, Sox2 and Nanog were highly expressed in 
malignant tissues in comparison to benign hyperplasic samples, which is again indicative 
of the fact that expression of these pluripotency inducing factors is tissue-stage specific 
and is involved in progression of cancer stages and mediating aggressive cancer 
phenotype (Fig. 3.3a, Table 3.3). On computing IRS for Oct4, Sox2 and Nanog, it was 
seen that Oct4 has 8.45, Sox2 of 11.2 and Nanog of 5.9 in malignant tissues in 
comparison to BPH where Oct4, Sox2 and Nanog expression is very low (Fig. 3.3b). 
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Table 3.3 Expression of Oct4, Sox2 and Nanog in FFPE prostate cancer tissue samples 
Clinical prostate cancer tissue samples 
Number  
of  
samples 
Age 
Stage of  
cancer/  
No. of sample 
Oct4 expression in  
protein level (%) 
P-Presence;  
A-Absence 
Sox2 expression in  
protein level (%) 
P-Presence;  
A-Absence 
Nanog expression in 
protein level (%) 
P-Presence; 
A-Absence 
33 ≤55 
BPH/15 
P 20 (3 samples) P 40 (6 samples) P 35 (5 samples) 
A 80 (12 samples) A 60 (9 samples) A 65 (10 samples) 
Malignant/18 
P 72.2(13 samples) P 83.3 (15 samples) P 68 (12 samples) 
A 27.8 (5 samples) A 16.7 (3 samples) A 31 (6 samples) 
 
Figure 3.3: Immunohistochemistry of prostate cancer tissue samples for analyzing Oct4, 
Sox2 and Nanog protein expression.  [a] Representative immunostained specimens showing 
Oct4, Sox2 and Nanog expression in benign prostate hyperplasia (BPH; n= 15) and malignant 
(n=18) FFPE tissue samples. Metastatic tissues show higher expression of all three proteins in 
comparison to BPH tissues. Scale Bar = 100 μm, [b] Bar plot shows immunoreactivity score (IRS) 
for Oct4, Sox2 and Nanog staining in tissues. Sox2 has the highest expression in prostate cancer 
tissue samples. Error bars indicate SD (P < 0.05). 
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3.3.3 Detection of Oct4, Sox2 and Nanog in breast and prostate cancer 
cell lines by RT-PCR: 
RT-PCR was done to analyze the relative mRNA expression of Oct4, Sox2 and Nanog in 
breast and prostate cancer cell lines in comparison to house-keeping gene GAPDH. Oct4 
showed higher expression in MDA-MB-231 (4.3 folds) than in MCF7 (3.3 folds) , Sox2 
expression was higher in MCF7 (2.8 folds) and MDA-MBA-231 (2.1 folds), Nanog 
showed almost equal expression in both cell lines (2.4 in MCF7 and 2.7 folds in MDA-
MB-231) in comparison to HaCaT which was considered as non-tumorigenic phenotype 
and its expression normalized to 1 (Fig. 3.4). 
 
Figure 3.4: Relative mRNA expression level of Oct4, Sox2 and Nanog in breast cancer cell 
lines MCF7 and MDA-MB-231. The level of Oct4, Sox2 and Nanog in HaCaT cell line was 
normalized to 1(n=3, mean±S.D, P < 0.05). In comparison to HaCaT, Oct4 mRNA expression was 
highest in MDA-MB-231, Sox2 in MCF7 and Nanog showed almost equalized expression in both 
the cell lines.  
 Similarly for prostate cancer, Oct4 and Sox2 expression was higher in PC3 than in 
DU145, with Sox2 showing highest expression in prostate cancer cells. Nanog expression 
was more or less uniform in both the cell lines (Fig. 3.5). 
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Figure 3.5: Relative mRNA expression level of Oct4, Sox2 and Nanog in prostate cancer cell 
lines DU145 and PC3. The level of Oct4, Sox2 and Nanog in HaCaT cell line was normalized to 
1(n=3, mean±S.D, P < 0.05). In comparison to HaCaT, mRNA expression of Oct4, Sox2 and 
Nanog was higher in PC3 cell line than DU145. 
3.3.4 Protein expression corroborated mRNA expression of Oct4, Sox2 
and Nanog in breast and prostate cancer cell lines: 
Western blotting was done to analyze the protein expression of Oct4, Sox2 and Nanog in 
breast and prostate cancer cell lines. Oct4 showed highest protein expression in MDA-
MB-231 cells consistent with higher mRNA expression in the same cell line. Sox2 
expression was uniformly high in both MCF7 and MDA-MB-231 and Nanog was 
comparatively less in comparison to Oct4 and Sox2 (Fig. 3.6a, 3.6b).  
 
 
Figure 3.6: Western blot analysis of Oct4, Sox2 and Nanog protein expression in HaCaT, 
MCF7 and MDA-MB-231 cell lines. [a] HaCaT cells were used as a positive control, and β-
Actin served as the loading control. [b] Graphical representation of protein expression after 
quantification using ImageJ software (n=3, mean±S.D, P < 0.05). 
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Similarly, for prostate cancer, Oct4 expression was highest in DU145 cells, Sox2 
expression was higher in PC3 and Nanog showed uniform protein expression in all the 
three cell lines (Fig. 3.7a, 3.7b). 
 
 
Figure 3.7: Western blot analysis of Oct4, Sox2 and Nanog protein expression in HaCaT, 
DU145 and PC3 cell lines. [a] HaCaT cells were used as a positive control, and β-Actin served as 
the loading control. [b] Graphical representation of protein expression after quantification using 
ImageJ software (n=3, mean±S.D, P < 0.05).  
3.4 Discussion: 
In recent years, striking similarities between embryogenesis and oncogenesis is being 
increasingly recognized. ESCs, cancer cells and more recently, CSCs arise from the 
progenitor pool and share numerous key biological properties. All of them are capable of 
extensive proliferation and can give rise to differentiated cells. Another interesting 
similarity is the functional and transcriptional role of pluripotency inducing factors like 
Oct4, Sox2 and Nanog in mediating both the above processes (Visvader and Lindeman, 
2008). Transcription factors are critical molecular controllers regulating ESC fate as well 
as in reprogramming cancer cells. Three pluripotency inducing transcription factors Oct 4, 
Nanog and Sox2 form the core regulatory network that coordinates to determine the self-
renewal and differentiation of ESCs. Hence, it is important to investigate the 
pluripotency-related genes associated with embryogenesis and tumorigenesis. The 
aberrant expression of Oct4, Sox2 and Nanog has been shown in numerous types of 
tumors and might be responsible for encouraging oncogenic progress (Chang et al., 2004). 
The present work was carried out to investigate the expression profile of pluripotency-
associated markers in human breast and prostate cancer tissues and cell lines in order to 
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establish the link between expression and functional significance of Oct4, Sox2 and 
Nanog in cancer.  
 Oct4 is an embryonic transcription factor belonging to the POU domain 
containing transcription factor family and is highly expressed in ESCs, carcinoma cells 
and oocytes. It is regarded as essential maternal factor for speciation of female germ line 
and establishment of pluripotency during pre-implantation embryonic stages. It has been 
previously proposed that Oct4 acts as a multifunctional factor in cancer biology as it 
increases the malignant potential of ESCs in a dose-dependent manner (Pan et al., 2002). 
The over-expression of Oct4 has also been documented in some tumors and is thought to 
play a role in tumorigenic aggression (Matin et al., 2004). The current study sought to 
examine the expression of Oct4 at the mRNA and protein levels in human breast and 
prostate cancer tissues and cancer cell lines. The results revealed that Oct4 was expressed 
in all four human cancer cell lines, although differential expression patterns were noted in 
comparison to immortalized HaCaT cell line taken as control. Oct4 was detected in breast 
cancer and prostate cancer tissues, with higher expression evident in metastatic stages 
suggesting that Oct4 promotes breast and prostate cancer (Fig. 3.2 and 3.3). Furthermore, 
Oct4 expression levels were significantly up-regulated in MDA-MB-231 and MCF7 cells 
as well as in PC3 and DU145 in comparison to HaCaT at both mRNA and protein levels 
(Fig. 3.4, 3.5, 3.6 and 3.7). Oct4 expression was highest in case of MDA-MB-231 cell 
line at both mRNA and protein level. MDA-MB-231, MCF7, PC3 and DU145 are all 
adenocarcinoma cell lines derived from metastatic sites, implying that over-expression of 
Oct4 contribute towards advanced tumor phenotypes. Nanog is a recently identified 
transcription factor crucial as a negative regulator of differentiation programs. The 
constitutive expression of Nanog during development maintains the pluripotent nature of 
stem cells and allows them to continuously replenish the stem cell compartment while 
simultaneously suppressing differentiation into lineages (Darr et al., 2006; Zaehres et al., 
2005). Studies in tumors have suggested the tumorigenic potential of Nanog and its role 
in regulation of tumor development (Siu et al., 2008; Wang et al., 2009). The current 
study demonstrated that Nanog was detected to be over-expressed at both the mRNA and 
protein levels in the breast and prostate cancer cell lines and tissues respectively in 
comparison to HaCaT; however, the expression is not as significantly high as in case of 
Oct4 and Sox2 (Fig. 3.4, 3.5, 3.6 and 3.7). The data is in support of the fact that over-
expression of Nanog in breast and prostate cancer cell lines and tissues may correlate with 
the tumorigenesis of breast and prostate cancer. 
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 Sox2 is essential for the maintenance of stem cell proliferation and has prolific 
differentiation capabilities as it can give rise to multiple cell lineages. A number of 
studies have implicated the involvement of transcription factor Sox2 in human cancers 
(Wilbertz et al., 2011). Sox2 is known to be oncogenic and participates in embryonal 
carcinoma, teratoma, lung, pancreatic and gastric adenocarcinoma (Dong et al., 2004; 
Santagata et al., 2007). The present study demonstrated that Sox2 was expressed in all 
breast and prostate cell lines tested. MCF7, MDA-MB-231, PC3 and DU145 cells 
expressed significantly higher levels of Sox2 compared to HaCaT cells, thus indicating 
that Sox2 may be a possible driver of the basal-like phenotype and play an early role in 
breast and prostate carcinogenesis (Fig. 3.4, 3.5, 3.6 and 3.7). In conclusion, the present 
study confirms the over-expression of pluripotency-inducing transcription factors Oct4, 
Sox2 and Nanog in breast and prostate cancer tissues and cell lines. Further experiments 
are required to explore the complex role of Oct4, Nanog and Sox2 in mediating 
tumorigenic progression in human breast and prostate cancer. 
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Chapter 4 
To evaluate the role of pluripotency 
inducing TFs in promoting tumorigenicity 
in breast and prostate cancer 
4.1 Introduction:  
Pluripotency inducing TFs Oct4, Sox2 and Nanog are considered as the functional and 
mechanistic link between embryonic stem-cell state and oncogenic self-renewal potential.  
Over-expression of Oct4, Sox2 and Nanog has been documented in human cancers and 
evidences have vindicated them in promoting inherent tumorigenicity. The up-regulation 
of Oct4 is characteristic of several types of human cancers where it is known to promote 
pro-tumorigenic properties. As a pluripotency determinant essential for maintaining 
ESCs, Oct4 recapitulates its function in tumor cells and assists in acquisition of CSC 
properties by boosting de-differentiation. Some of the enhancing abilities conferred by 
Oct4 on tumor cells include increased metastatic ability and development of drug 
resistance. (Zbinden et al., 2010; Choi et al., 2012). Particularly in breast and prostate 
cancer, Oct4 has been known to sustain the survival of CSCs and support conversion of 
primary tumors to invasive neoplasia by EMT.  
 Sox2 amplification and functional over-expression is a characteristic feature of 
many cancer types where it positively influences tumor initiation, maintenance and 
evolution into more aggressive types (Weina and Utikal, 2014). Sox2 is known to 
increase CSC proliferation and augment their growth, support metastatic behavior by 
improving EMT capacity, develop resistance to therapeutic drugs and finally interact with 
number of oncogenic signaling pathways such as HH, Wnt and Notch to promote stem-
cell like properties (Bourguignon et al., 2012).  In fact, Sox2 is considered to be one of 
the most significant oncogenic transcription factors mediating tumorigenic conversion in 
many instances. In cancers, over-expression of Nanog mediates increased tumor cell 
proliferation and growth. Nanog interacts with members of cell cycle machinery 
transcriptionally activates them to accelerate proliferation of neoplastic cells by over-
riding cell cycle checkpoints (Golubovskaya et al., 2013; Siu et al., 2013). Nanog
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enhances tumor metastasis and invasive potential of tumor cells, and provides resistance 
against apoptosis and chemotherapeutic drugs. It also improves tolerance of tumor cells to 
immune attack and surveillance and interacts with oncogenic pathways to encourage 
malignant growth. Hence, the following study was undertaken to investigate the role of 
these pluripotency transcription factors in promoting inherent tumorigenicity in breast and 
prostate cancer by gene knockdown using si-RNAs against Oct4, Sox2 and Nanog. A 
number of pro-tumorigenic properties such as cell proliferation, chromatin condensation, 
metastatic behavior, colony forming ability and cell cycle distribution were analyzed after 
ectopic silencing of Oct4, Sox2 and Nanog.  
4.2 Materials and Methods: 
4.2.1 Cell culture: 
Human breast carcinoma cell lines MCF7 and MDA-MB-231 and human prostate cancer 
cell lines PC3 and DU145 were obtained from National Centre for Cell Science (NCCS), 
Pune. MCF7 was cultured and maintained in Minimum Essential Medium (MEM, 
Himedia-AL047A), MDA-MB-231 in Leibovitz's medium (L-15, Himedia-AL011S), 
PC3 was cultured in Nutrient Mixture F-12 Ham medium (F-12, Himedia-AL106S) 
whereas DU145 and HaCaT in Dulbecco’s Modified Eagle’s Medium (DMEM, Himedia-
AL007A) supplemented with 10% (v/v) fetal bovine serum (FBS, Himedia-RM1112) and 
100 IU/mL penicillin and 0.1 mg/mL streptomycin (Himedia-A002A) in a humified 
atmosphere of 5% CO2 at 37° C. The cells were harvested by trypsinization (Trypsin, 
Sigma-T4049) and the number of living cells was calculated by trypan blue (Himedia-
TC193) staining (0.2% v/v) using hemocytometer before seeding for future experiments. 
4.2.2 si-RNA transfection: 
si-RNA against Oct4 (Oct-3/4 si-RNA (h), sc-36123), Sox2 (Sox2 si-RNA (h), sc-38408), 
Nanog (Nanog si-RNA (h), sc-43958) and control si-RNA (control si-RNA-A, sc-37007) 
were purchased from Santa Cruz Biotechnology, USA. For determining the optimum 
concentration of si-RNA that completely abolished gene and protein expression, 5 X 10
5
 
cells of each of the four cell lines were seeded and after 24 h incubation, were treated with 
three different concentrations (10, 20, 30 nM) of different si-RNAs using Lipofectamine 
2000 (Invitrogen-11668019) and serum free opti-mem (Gibco-31985-070) according to 
manufacturer’s instructions. Six hours after transfection, opti-mem was replaced by 
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respective cell culture media and cells were left to incubate for next 24 hours. 30 nM of 
si-RNA efficiently blocked the expression of Oct4, Sox2 and Nanog protein in all the four 
cell lines. Control si-RNA was also used at the same concentration.  
4.2.3 Cell proliferation analysis by colometric MTT assay: 
For assaying cellular proliferation after treatment with si-RNAs, 2 X 10
3
 cells were 
seeded in 35mm plates and treated with desired concentrations of si-RNAs. After 24, 48, 
72 and 96 h incubation, 100 μL of 3-(4, 5-Dimethylthiazol-2-yl)-2, 5-Diphenyltetrazolium 
Bromide (MTT, Himedia-TC191) solution was added to each well and left in the 
incubator at 37° C for 4 h in dark. Subsequently, 100 μL of di-methyl sulphoxide (DMSO, 
Himedia-TC185) was added and optical absorbance was measured at 570 nm. Number of 
extra cells present in comparison to the number of cells seeded earlier i.e. cell number 
(plotted in the graph) = Number of cells after 24/48/72/96 h – number of cells originally 
seeded (Santini et al., 2014). 
4.2.4 Chromatin condensation assay: 
2 X 10
4
 cells per well of each cell line were seeded in 6 well plates separately, and then 
treated with desired concentrations of si-RNAs for 24 h and drugs for 72 h. Cells were 
then stained with Hoechst 33342 (1 μg/mL, Invitrogen- H1399) dissolved in serum-free 
media followed by incubation for 10 min at 37° C. Finally, images were taken under UV 
filter using Epi-fluorescent Microscope (Olympus IX71, excitation wavelength of 355 to 
366 nm, emission wavelength of 465 to 480 nm) at 20X magnification. Nuclei with 
condensed chromatin were counted amongst total number of nuclei in the field, and the 
percentage of condensed nuclei was calculated and plotted graphically. 
4.2.5 Wound healing or scratch assay: 
2 X 10
5
 cells per well were seeded in 6-well plate and incubated at 37° C until a fully 
confluent and adherent monolayer is formed. Scratch is then made using sterile 200 μL 
micropipette tip. Cells were washed thoroughly with PBS to remove the debris and 
smoothen the edge of the scratch. Treatment with the desired concentrations of si-RNAs 
for 24 h and drugs for 72 h was done. Images were taken using phase contrast microscope 
at 0 h (immediately after treatment) and 72 h. 
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4.2.6 Clonogenic assay: 
Briefly, 1000 cells were seeded in six-well plates. After 6 h, cells were treated with 
different si-RNAs with above mentioned concentrations. After 7 days, colonies were 
stained with mixture of 6.0% glutaraldehyde (Himedia-RM5927) and 0.5% crystal violet 
(Himedia-S012) in water. After 30 min staining and cell fixation, colonies were washed 
with water. Air dried colonies were calculated.  
4.2.7 Cell cycle analysis by FACS: 
MCF7, MDA-MB-231, DU145 and PC3 cells after treatment with desired concentrations 
of si-RNAs for 24 h and drugs for 72 h were incubated in their respective media with 5% 
FBS for 24 h. The cells were then trypsinized, collected by centrifugation (500 × g for 5 
min at 4° C), washed twice with PBS and then fixed in 90% ice-cold methanol (Himedia- 
AS058). After incubation at -20° C for 1 h, cells were centrifuged and resuspended in 
PBS followed by treatment with RNaseA (500 IU/mL, Fermentas -EN0531) to digest 
residual RNAs and stained with propidium iodide (PI, 10 μg/mL, Sigma-81845). Samples 
were incubated for 30 min at 4° C and cell cycle analysis was performed with a Becton-
Dickinson fluorescence-activated cell sorter (FACS). The percentage of apoptotic cells 
was graphically represented.  
4.3 Results: 
4.3.1 Silencing of Oct4, Sox2 and Nanog inhibits cell growth and reduces 
rate of cell proliferation in breast and prostate cancer cell lines: 
After knockdown of Oct4, Sox2 and Nanog genes, the rate of cell proliferation was 
examined by MTT assay. It was observed that cells treated with control si-RNA remain 
unaffected and proliferated vigorously, however, rate of proliferation declined in cells 
transfected with si-Oct4, si-Sox2 and si-Nanog (Fig. 4.1). In breast cancer cell lines, Oct4, 
Sox2 and Nanog silencing resulted in slow proliferation with lesser growth in metastatic 
cell line MDA-MB-231, implying that Oct4, Sox2 and Nanog might be involved in 
boosting proliferative potential in metastatic cancers (Fig. 4.1a, 4.1b).  In prostate cancer 
also, similar results were obtained in case of PC3 cells. It was observed that silencing of 
Oct4 and Sox2 have almost identical effect on the rate of proliferation; however, Nanog 
has significantly lesser effect (Fig. 4.1c, 4.1d).  It might imply that initially, Oct4 and 
Sox2 act concomitantly to regulate cell cycle and survival machinery with Nanog acting 
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as an accomplish in the later stages of cancer proliferation. However, it is very clear that 
both breast and prostate cancer cells grow slower after silencing of Oct4, Sox2 and Nanog 
which proves that these pluripotency factors influence the tumorigenic growth and 
proliferation potential during oncogenic transformation. 
     
Figure 4.1: Analysis of cell proliferation after si-RNA knockdown of Oct4, Sox2 and Nanog. 
30 nM of si-RNA against Oct4, Sox2, Nanog were used for 24 h. Graphical representation of 
number of proliferated cells in [a] MCF7, [b] MDA-MB-231, [c] DU145 and [d] PC3 after 
treatment with si-RNA against Oct4, Sox2 and Nanog  and control si-RNA (n=3, mean ± S.D, P < 
0.05). 
4.3.2 Silencing of Oct4, Sox2 and Nanog induces chromatin condensation 
and DNA damage in both breast and prostate cancer cell lines: 
Chromatin condensation analysis was done to assess the role of pluripotency factors in 
inducing DNA damage and chromatin compaction. It was observed that in comparison to 
si-control treated cells, Oct4, Sox2 and Nanog silenced cells exhibited higher number of 
condensed chromatin indicating greater DNA damage upon silencing of these factors. In 
breast cancer cell lines, the percentage of condensed nuclei in MCF7 for si-control, si-
Oct4, si-Sox2 and si-Nanog treated cells was 21%, 34.5%, 28.34%, 31.75% and in MDA-
MB-231 was 26.43%, 39.63%, 32.13% and 27.45% respectively  The above data indicate 
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that chromatin condensation was higher in metastatic cell lines in comparison to primary 
cell lines (Fig. 4.2a, 4.2b). 
 
Figure 4.2: Chromatin condensation analysis in breast cancer cell lines after treatment with 
si-Oct4, si-Sox2 and si-Nanog. 30 nM of si-RNA against Oct4, Sox2, Nanog were used for 24 h. 
[a] Representative images of Hoechst 33342 stained nuclei in breast cancer cell lines (MCF7 and 
MDA-MB-231) after treatment with si-RNA against Oct4, Sox2 and Nanog and control si-RNA. 
Magnification 20X, Scale bar 20 μm. [b] Graphical representation of the percentage of condensed 
nuclei per field (n=3, mean ± S.D, P < 0.05). 
 Similarly, in prostate cancer cell lines, the percentage of condensed nuclei per 
field was found to be 19.68%, 28.21%, 34.67%, 23.84% in DU145 cell line and 31%, 
42.54%, 51.65%, 37.89% in PC3 cells after treatment with si-contol, si-Oct4, si-Sox2 and 
si-Nanog respectively (Fig. 4.3a, 4.3b). The results are in agreement with those found in 
breast cancer wherein knockdown of Oct4, Sox2 and Nanog increased chromatin 
compaction and apoptotic DNA damage. In both breast and prostate cancer, silencing of 
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Sox2 resulted in the highest number of condensed chromatin. The percentage of 
condensed chromatin is higher in advanced stages of both the cancers implying that Oct4, 
Sox2 and Nanog might participate during metastatic conversion of primary tumors and 
that they support this behaviour by reducing apoptotic DNA damage and protecting cells 
from being subjected to cellular processes of death. 
                           
Figure 4.3: Chromatin condensation analysis in prostate cancer cell lines after treatment 
with si-Oct4, si-Sox2 and si-Nanog. 30 nM of si-RNA against Oct4, Sox2, Nanog were used for 
24 h. [a] Representative images of Hoechst 33342 stained nuclei in prostate cancer cell lines 
(DU145 and PC3) after treatment with si-RNA against Oct4, Sox2 and Nanog and control si-
RNA. Magnification 20X, Scale bar 20 μm. [b] Graphical representation of percentage of 
condensed nuclei per field (n=3, mean ± S.D, P < 0.05). 
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4.3.3 Silencing of Oct4, Sox2 and Nanog diminishes the rate of cell 
migration in both breast and prostate cancer cell lines: 
The ability of cancer cells to migrate from one site to another site and result in 
tumorigenic growth is considered one of the most detrimental effects of cancer. In order 
to investigate how Oct4, Sox2 and Nanog influence the migratory behavior in breast and 
prostate cancer cells, wound healing assay was done. After treatment with the respective 
si-RNAs, it was observed that upon silencing of oct4, Sox2 and Nanog, there is decrease 
in number of migrating cells in comparison to si-control treated cells in both breast and 
prostate cancer. In breast cancer cell lines, the percentage of invaded cells after treatment 
in MCF7 was 29.64%, 8.915%, 11.56% and 17.86% and in MDA-MB-231 was 33.45%, 
13.56%. 12.45% and 23.51% for si-control, si-Oct4, si-Sox2 and si-Nanog treated cells 
respectively (Fig. 4.4a, 4.4b). In case of prostate cancer cell lines, the percentage of 
invaded cells were 31.45%, 18.94%, 14.67% and 23% in DU145 and 45.67%, 15.34%, 
17% and 27.89% in PC3 cells after treatment with si-control, si-Oct4, si-Sox2 and si-
Nanog treated cells respectively (Fig. 4.5a, 4.5b). In case of breast cancer, Oct4 
knockdown resulted in lowest migration while Sox2 was more effective in prostate 
cancer. Nanog showed comparatively lesser effect on cell migration potential in 
comparison to Oct4 and Sox2. Thus, these pluripotency factors help to mediate migration 
and invasion of cancer cells most probably by encouraging epithelial to mesenchymal 
transition. 
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Figure 4.4: Wound healing assay in breast cancer cell lines after knockdown of Oct4, Sox2 
and Nanog. 30 nM of si-RNA against Oct4, Sox2, Nanog were used for 24 h. [a] Representative 
images of migrating cells in breast cancer cell lines (MCF7 and MDA-MB-231) after traetment 
with si-RNA against Oct4, Sox2 and Nanog and control si-RNA. Magnification 20X, Scale bar 20 
μm. [b] Graphical representation of percentage of invaded cells per field (n=3, mean ± S.D, P < 
0.05). 
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Figure 4.5: Wound healing assay in prostate cancer cell lines after knockdown of Oct4, Sox2 
and Nanog. 30 nM of si-RNA against Oct4, Sox2, Nanog were used for 24 h. [a] Representative 
images of migrating cells in prostate cancer cell lines (DU145 and PC3) after treatment with si-
RNA against Oct4, Sox2 and Nanog and control si-RNA. Magnification 20X, Scale bar 20 μm. 
[b] Graphical representation of percentage of invaded cells per field (n=3, mean ± S.D, P < 0.05). 
4.3.4 Silencing of Oct4, Sox2 and Nanog inhibits cell growth and colony 
forming ability in both breast and prostate cancer cell lines: 
Colony forming or clonogenic assay was conducted to examine the ability of cancer cells 
to grow and produce colonies. Oct4, Sox2 and Nanog are known to support self-renewal 
in embryonic and pluripotent cells. Also, in malignant phenotype they are known to 
induce clonal growth, self-renewal and proliferation of cancer stem cells. In order to 
assess whether Oct4, Sox2 and Nanog affect clonal growth in cancer cells, treatment with 
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si-RNA directed against Oct4, Sox2 and Nanog was done and it was observed that 
number of colonies formed drastically reduced in comparison to si-control cells. The 
number of surviving colonies after treatment with si-Oct4, si-Sox2 and si-Nanog in case 
of MCF7 cells were 39.48%, 19.86% and 45.55% and in case of MDA-MB-231 cells 
were 27.46%, 36.57% and 59.12% respectively in comparison to 85.31% and 93.12% 
control si-RNA treated cells (Fig. 4.6a, 4.6b). While Oct4 and Sox2 down-regulation 
greatly reduced colony forming ability, in comparison when Nanog is silenced, cells 
showed less effect.  
 
 
Figure 4.6: Clonogenic assay in breast cancer cell lines after treatment with si-RNA against 
Oct4, Sox2 and Nanog. 30 nM of si-RNA against Oct4, Sox2, Nanog were used for 24 h. [a] 
Representive images of colonies formed after treatment with si-RNA directed against Oct4, Sox2 
and Nanog in breast cancer cell lines (MCF7 and MDA-MB-231).   [b] Graphical representation 
of number of colonies formed (n=3, mean ± S.D, P < 0.05). 
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Figure 4.7: Clonogenic assay in prostate cancer cell lines after treatment with si-RNA 
against Oct4, Sox2 and Nanog. 30 nM of si-RNA against Oct4, Sox2, Nanog were used for 24 h. 
[a] Representive images of colonies formed after treatment with si-RNA directed against Oct4, 
Sox2 and Nanog in breast cancer cell lines (DU145 and PC3). [b] Graphical representation of 
number of colonies formed (n=3, mean ± S.D, P < 0.05). 
 In prostate cancer cell lines, number of surviving colonies drastically 
reduced in case of cells transfected with si-RNAs. The number of surviving colonies after 
treatment with si-Oct4, si-Sox2 and si-Nanog in case of DU145 cells were 21.36%, 
19.56% and 35.26% and in case of PC3 cells were 32.56%, 35.46% and 48.97% 
respectively in comparison to 75.32% and 85.23% control si-RNA treated cells (Fig. 4.7a, 
4.7b). The above results indicate that in both breast and prostate cancer cell lines, 
silencing of Oct4, Sox2 and Nanog resulted in decrease in percentage of surviving 
colonies indicating a decrease in the cell survival ability of breast and prostate cancer 
cells. The number of colonies in case of primary cell lines like MCF7 and DU145 is lesser 
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in comparison to metastatic cells implying that these factors might promote cell survival 
in early stage cancer. 
4.3.5 Silencing of Oct4, Sox2 and Nanog causes cell cycle arrest and 
promotes apoptotic cell death in both breast and prostate cancer 
cell lines:  
Cell cycle analysis was performed in order to assess the role of Oct4, Sox2 and Nanog in 
cell cycle distribution. In general, upon silencing of these factors, cell cycle was arrested 
at G0/G1 phase indicating that Oct4, Sox2 and Nanog affected cell cycle machinery and 
promoted unchecked cell division in cancer. In breast cancer cell lines, the distribution of 
G0/G1 in MCF7 cell line after treatment with si-Oct4, si-Sox2 and si-Nanog were 66.78%, 
59.56%, 54.21% respectively in comparison to 52.67% in si-control treated cells. 
Similarly, for MDA-MB-231 cells, percentage of G0/G1 phase population was 56.78%, 
49.13%, 52.29% respectively for si-Oct4, si-Sox2 and si-Nanog with respect to si-control 
(32.31%) (Fig. 4.8). The drastic increase in G0/G1 cells indicated that Oct4, Sox2 and 
Nanog are instrumental in dysregulating cell cycle and allowing unchecked cell division.  
 
Figure 4.8: Cell cycle analysis in breast cancer cell lines after treatment with si-RNA against 
Oct4, Sox2 and Nanog. 30 nM of si-RNA against Oct4, Sox2, Nanog were used for 24 h. 
Representative FACS images showing distribution of different cell populations after treatment 
with si-RNA against Oct4, Sox2 and Nanog.  
 In prostate cancer cell lines also, there is increase in G0/G1 arrested cells, but it is 
observed that Oct4 and Sox2 are more effective in inhibiting cell cycle than Nanog as 
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percentage of G0/G1 cells is 52.28% and 56.15% for Oct4 and Sox2 and 46.69 for Nanog 
knockdown cells in DU145. In PC3, percentage of G0/G1 cells after knockdown of Oct4, 
Sox2 and Nanog is 68.53%, 64.72% and 51.83% respectively (Fig. 4.9). 
Figure 4.9: Cell cycle analysis in prostate cancer cell lines after treatment with si-RNA 
against Oct4, Sox2 and Nanog. 30 nM of si-RNA against Oct4, Sox2, Nanog were used for 24 h. 
Representative FACS images showing distribution of different cell populations after treatment 
with si-RNA against Oct4, Sox2 and Nanog.  
 The apoptotic cell population was examined and  it was found that in comparison 
to control si-RNA treated cells, Oct4 and Sox2 silencing increased the apoptotic cell 
population in breast and prostate cancer cell lines indicating that Oct4, Sox2 and Nanog 
affect apoptotis (Fig. 4.10a, 4.10b). 
 
 
Figure 4.10: Analysis of apoptotic cell death in breast and prostate cancer cell lines. 
Graphical representation of percentage of apoptotic cell population in [a] breast cancer cell lines 
(MCF7 and MDA-MB-231) and [b] prostate cancer cell lines (DU145 and PC3) after traetment 
with si-RNA against Oct4, Sox2 and Nanog and control si-RNA (n=3, mean ± S.D, P < 0.05). 
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4.4 Discussion: 
As is evident from the first objective, Oct4, Sox2 and Nanog are over-expressed in both 
breast and prostate cancer. Therefore, the role of these oncogenic transcription factors in 
promoting inherent tumorigenicity in breast and prostate cancer was evaluated using si-
RNAs directed against them. Although, Oct4, Sox2 and Nanog have always been 
accredited for contributing towards maintenance of CSC population and promoting stem 
cell phenotype, we have established that in addition to their role in maintenance of stem 
cell population, Oct4, Sox2 and Nanog are functionally relevant in tumor bulk in breast 
and prostate cancer cells. 
 Colorimetric MTT assay was performed for assessing the rate of proliferation after 
silencing of Oct4, Sox2 and Nanog  in breast and prostate cancer cell lines. It was 
observed that cell proliferation in Oct4, Sox2 and Nanog silenced cells were lower in 
comparison to cells transfected with control si-RNA in both breast and prostate cancer.  In 
case of breast cancer, silencing of Nanog resulted in slowest proliferation of cells whereas 
in case prostate cancer, Oct4 knockdown drastically reduced cell proliferation with much 
greater effect on PC3 cells (Fig. 4.1). Chromatin condensation analysis using Hoechst 
stain was performed to study the cytotoxic effect of knockdown of Oct4, Sox2 and 
Nanog. The blue-fluorescent DNA-binding Hoechst 33342 dye can detect DNA damage 
such as condensed nuclei induced by apoptosis. It brightly stains the highly condensed, 
dense chromatin of apoptotic cells in comparison to the chromatin of non-apoptotic cells. 
Therefore, increased number of condensed nuclei indicates higher DNA damage and 
apoptotic rate. Upon knockdown of Oct4, Sox2 and Nanog, percentage of condensed 
chromatin in both breast and prostate cancer cell lines dramatically increased indicating 
that these oncogenic factors have anti-apoptotic activity in tumor niche. In breast cancer, 
percentage of condensed nuclei was highest for Sox2 knockdown MDA-MB-231 cells 
whereas in prostate cancer, cells transfected with si-Nanog showed highest apoptotic 
nuclei in comparison to cells transfected with control si-RNA (Fig. 4.2, 4.3).  
 EMT is considered to be a pro-oncogenic process in which primary cancer cells 
become detached from their site of origin and travel to distant sites to promote oncogenic 
differentiation of other organs and tissues. Cancer metastasis is one of characteristic 
hallmarks of malignant progress, and is considered to be influenced by stemness 
promoting factors that recapitulate embryonic potential in neoplastic cells (Tsai et al., 
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2014; Han et al., 2013). Scratch or wound-healing assay was conducted to study the role 
of Oct4, Sox2 and Nanog in promoting cell migration and motility. For the first time, we 
have shown that Oct4, Sox2 and Nanog can also support metastatic behavior in non-stem 
cancer cells. It was observed that after treatment with respective si-RNAs, the percentage 
of invading or migrating cells significantly decreased in both breast and prostate cell lines 
indicating that Oct4, Sox2 and Nanog encourage metastatic and invasive behaviour in 
tumor cells and help in acquiring more aggressive phenotype (Fig. 4.4, 4.5). Clonogenic 
assay was performed to examine the impact of knockdown of Oct4, Sox2 and Nanog on 
colony forming ability in breast and prostate cancer cells. It was observed that after gene 
knockdown, number of colonies formed in comparison to si-control treated cells is 
significantly lower. In case of breast cancer, si-Sox2 treated cells exhibited the least 
number of colonies whereas for prostate cancer, knockdown of Oct4 severely decreased 
the growth of prostate cancer cells (Fig. 4.6, 4.7). 
 Finally, the impact of Oct4, Sox2 and Nanog over-expression over cell cycle 
progression and apoptosis was deliberated by performing FACS analysis. Cells 
transfected with si-RNAs against Oct4, Sox2 and Nanog displayed G1 phase growth arrest 
and increase in apoptotic cell population implying that these transcription factors mediate 
cell cycle progression from G1 to S phase and help in tumorigenic progression. In case of 
breast cancer, highest percentage of apoptotic population was observed in Sox2 silenced 
cells whereas knockdown of Oct4 in prostate cancer cell lines greatly increased apoptotic 
death (Fig. 4.8, 4.9, 4.10).  It has already been evidently proven that Oct4, Sox2 and 
Nanog influence CSCs properties by confering advantageous properties like increased 
cellular proliferation and tumor growth, evasion of apoptotic death and improved 
metastatic and invasive potential. The above-mentioned findings however strengthen our 
hypothesis that Oct4, Sox2 and Nanog are equally responsible for facilitating oncogenic 
properties in bulk of breast and prostate cancer cells. In other words, over-expression of 
oncogenic transcription factors Oct4, Sox2 and Nanog enhance the inherent 
tumorigenicity in breast and prostate cancer by increasing metastatic behavior, improving 
survival and proliferation capacity, as well as deregulating cell cycle machinery.
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Chapter 5 
To elucidate the epigenetic modifications 
regulating pluripotency inducing TFs in 
breast and prostate cancer 
5.1 Introduction: 
The molecular signatures underlying neoplastic transformation are now regarded to be of 
epigenetic origin with the notion that aberrant alterations in the epigenomic organization 
are mostly responsible for cancer initiation, maintenance and progression (Hadjimichael 
et al., 2015). With the epigenetic progenitor model of cancer taking center-stage in the 
field of oncology, it is generally acknowledged that abnormal epigenetic gene silencing 
events are superior surrogates to mutational inactivation/silencing during tumorigenic 
conversion. Early epigenetic variations in the stem/progenitor cell population disrupt the 
fine balance between cell proliferation and cell division, thus pre-disposing them towards 
genetic mutations (Klimczak, 2015). As mutational instability affects the phenotypic 
characteristics, enhancing genetic and epigenetic plasticity and heterogeneity in tumor 
cell enables them to acquire stemness properties such as invasion, metastasis and drug 
resistance (Feinberg et al., 2006; Feinberg et al., 2016). This deregulation is possible due 
to disruption of pluripotency related transcriptional network in stem cells during early 
cancer development. We hypothesize that the pluripotency transcriptome maintained by 
nuclear transcription factors Oct4, Sox2 and Nanog is epigenetically regulated during 
embryonic pluripotency and differentiation. Hence, it is imperative that alterations in the 
stem cell pluripotency circuitry via epigenetic aberrations are functionally responsible for 
augmenting the evolution of tumor into potentially aggressive phenotype. 
 The major players involved in epigenetic deregulation during cancer are DNA 
methylation and histone modifications. Global loss of methylation was the first epigenetic 
change to be characterized in human cancers and is one of the major mechanisms 
responsible for genomic instability (Eden et al., 2003). Epigenetic gene silencing 
mediated by promoter DNA hypermethylation is another important contributor to 
malignant transformation. Silencing of crucial tumor suppressor genes, cell cycle
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regulatory and DNA repair genes, genes involved in detoxification of carcinogen induced 
cytotoxicity as well as important signaling molecule results in inhibition of cellular 
response against carcinogenic insults and paves the way for neoplastic distress (Scaffidi 
and Misteli, 2010; Kanwal and Gupta, 2012) Similarly, histone modifications mediate 
tumorigenic potential by providing accessible chromatin environment that facilitates 
transcriptional activation of oncogenes. These changes affect the overall epigenomic 
landscape around the pluripotency maintaining transcriptome which in turn allows for 
transcriptional plasticity responsible for acquisition of stem cell features (Muller et al., 
2016). In fact, epigenetic reprogramming of pluripotency inducing transcription factors is 
now considered as a potential mechanism of tumorigenic adaption of cancer cells. 
 It has already been discussed how epigenetic regulation modulates the expression 
and activity of Oct4, Sox2 and Nanog during embryonic development (Christophersen 
and Helin, 2010). Oct4 gene locus is generally maintained in an active state by the help of 
activating histone marks such as H3K9Ac, H3K14Ac and H3K4me2/me3; however 
during differentiation, Oct4 is silenced transiently by repressive histone marks such as 
H3K9me3 followed by DNA methylation mediated permanent silencing (Deshpande et 
al., 2009; Athanasiadou et al., 2010). Similarly, Sox2 and Nanog expression during 
maintainenance of pluripotency and initiation of lineage-speciation and commitment is 
subjected to extensive epigenetic modifications. The promoter of Nanog is activated by 
histone acetyltransferases and methyltransferases such as WDR5 and repressed by EZH2 
through enrichment of H3K27me3 marks (Baltus et al., 2009; Li et al., 2012). Although 
epigenetic regulation of Oct4, Sox2 and Nanog is relatively known and established during 
embryonic development, similar regulatory mechanism(s) responsible for Oct4, Sox2 and 
Nanog expression in cancer remains poorly understood. As the importance of Oct4, Sox2 
and Nanog was acknowledged during generation of induced pluripotency, it was 
discovered that ESC-like signature mediated by Oct4, Sox2 and Nanog is also prevalent 
in cancer. Hence, it was assumed that an epigenetic regulatory system is functionally 
responsible for over-expression of Oct4, Sox2 and Nanog in human cancers and that this 
system affects the overall activity of these TFs in mediating tumorigenesis (Savarese et 
al., 2009).  
 In this light, the present objective has been designed to investigate various 
epigenetic modifications regulating Oct4, Sox2 and Nanog expression and function in 
breast and prostate cancer. The role of epigenetic modifications were studied by 
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employing epigenetic modulators/inhibitors against prominent epigenetic modifying 
enzymes, for example 5-aza-2'-deoxycytidine (AZA) against DNMTs, Trichostatin A 
(TSA) against HDACs and 3-Deazaneplanocin A (DZNeP) against EZH2. The effect of 
ectopic inhibition of the following epigenetic enzymes on the promoter methylation and 
histone mark enrichment was analyzed via MS-PCR and ChIP assays so as to obtain a 
clear picture regarding the methylation status and histone marks enrichment that arbitrates 
aberrant expression of Oct4, Sox2 and Nanog in breast and prostate cancer.    
5.2 Materials and Methods: 
5.2.1 Cell culture:  
Human breast carcinoma cell lines MCF7 and MDA-MB-231 and human prostate cancer 
cell lines PC3 and DU145 were obtained from National Centre for Cell Science (NCCS), 
Pune.  MCF7 was cultured and maintained in Minimum Essential Medium (MEM, 
Himedia-AL047A), MDA-MB-231 in Leibovitz's medium (L-15, Himedia-AL011S), 
PC3 was cultured in Nutrient Mixture F-12 Ham medium (F-12, Himedia-AL106S) 
whereas DU145 in Dulbecco’s Modified Eagle’s Medium (DMEM, Himedia-AL007A) 
supplemented with 10% (v/v) fetal bovine serum (FBS, Himedia-RM1112) and 100 
IU/mL penicillin and 0.1 mg/mL streptomycin (Himedia-A002A) in a humified 
atmosphere of 5% CO2 at 37° C. The cells were harvested by trypsinization (Trypsin, 
Sigma-T4049) and the number of living cells was calculated by trypan blue (Himedia-
TC193) staining (0.2% v/v) using hemocytometer before seeding for future experiments. 
5.2.3 In vitro treatment of epigenetic modulators: 
In order to determine IC30 concentration of AZA (Sigma-A3656), TSA (Sigma-T8552) 
and DZNeP (Santa Cruz Biotechnology-sc-397045), 5 X 10
3
 cells per well were seeded in 
96-well microtiter plates. After reaching 70% confluency, growth medium was replaced 
with respective experimental media containing epigenetic modulators at different 
concentrations supplemented with 5% FBS. AZA and DZNeP treatment was done with 1, 
5, 10, 15, 20, 25 μM concentrations whereas for TSA, 10, 50, 100, 150, 200, 250 nM 
concentrations were used in all four cell lines. Control cells were treated with di-methyl 
sulphoxide (DMSO, Himedia-TC185) only.  
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5.2.4 Cell viability assay by colometric MTT assay: 
The effect of the epigenetic modulators on cell viability was assessed by 3-(4, 5-
Dimethylthiazol-2-yl)-2, 5-Diphenyltetrazolium Bromide (MTT, Himedia-TC191) assay, 
using our standard protocol (Kar et al., 2014). Cells were incubated for 24 and 72 h after 
treatment with TSA, AZA and DZNeP respectively. Drug-treated cells were trypsinized 
and washed twice with phosphate buffered saline (PBS) prior to use. Working 
concentration of 0.8 mg/mL MTT solution was prepared from stock (5 mg/mL PBS, pH 
7.2). To each well, 100 μL working MTT solution was added. After incubation in dark for 
4 h at 37° C, 100 μL of DMSO was added to each well to dissolve the formazan crystals. 
The absorbance was measured at 570 nm and results were expressed as the mean of three 
replicates as a percentage of control (taken as 100%). The extent of cytotoxicity was 
defined as the relative reduction in optical density (OD) of treated cells in comparison to 
control cells, which indicated the amount of viable cells in relation to control (100%). The 
cell viability was graphically represented and IC30 value of drugs was calculated 
accordingly to decide the optimum dosage for further studies.  
5.2.5 Relative mRNA expression analysis by real-time PCR after 
treatment with epigenetic modulators: 
After treatment with sub-lethal dosages of drugs for effective time period, total cellular 
RNA from each of the four cell lines was extracted with TRI Reagent (Sigma- T9424) 
according to the manufacturer’s instructions. cDNA was prepared from 1 μg of total RNA 
by using RevertAid
TM
 First Strand cDNA Synthesis Kit (Thermo Scientific-K1622) 
followed by quantitative real-time PCR (RT-PCR) using Maxima SYBR Green/ROX 
qPCR Master Mix (2X, Thermo Scientific-K0221). The mRNA level was normalized to 
house-keeping gene GAPDH used as an endogenous control and calculations were done 
using 2
−ΔΔCt
 method, as described earlier (Schmittgen and Livak, 2008). The primer 
sequences are provided in Table 5.1. 
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Table 5.1: List of sequence and product length of PCR primers used 
Gene Primer Sequence Product Length (bp) 
Real-Time Primers 
Oct4 
F 5’- AGCAAAACCCGGAGGAGT-3’ 
114 
R 5’- CCACATCGGCCTGTGTATATC-3’ 
Sox2 
F 5’- GGAAATGGAGGGGTGCAAAAGAGG-3’ 
150 
R 5’- TTGCGTGAGTGTGGATGGGATTGGTG-3’ 
Nanog 
F 5’- TCCTCCTCTTCCTCTATACTAAC-3’ 
112 
R 5’- CCCACAATCACAGGCATAG-3’ 
GAPDH 
F 5’- TGTTGCCATCAATGACCCCTTC -3’ 
204 
R 5’- CTCCACGACGTACTCAGCGC-3’ 
Methyl-Specific PCR Primers 
Oct4 
M 
F 5’-CGGGATATTTGGTTTCGGATTTC-3’ 
209 
R 5’-CCCACAAAACTCATACGACGA-3’ 
U 
F 5’-TGGGATATTTGGTTTTGGATTTT-3’ 
210 
R 5’-CCCCACAAAACTCATACAACAAA-3’ 
Sox2 
M 
F 5’-TTTTTTTTATGTAAAATTCGGTAGC-3’ 
122 
R 5’-AATAAACAACCATCCATATAACGAA-3’ 
U 
F 5’-TTTTTTATGTAAAATTTGGTAGTGA-3’ 
122 
R 5’-AATAAACAACCATCCATATAACAAA-3’ 
ChIP PCR Primers 
Oct4 
F 5’- CTTCCACAGACACCATTGCC-3’ 
240 
R 5’- GAGAAGGCGAAATCCGAAGC-3’ 
Sox2 
F 5’- CAAAGGTTTCTCAGTGGCTGG-3’ 
190 
R 5’-GGGTTTCTAGCGACCAATCAG-3’ 
5.2.6 Western Blotting: 
2 X 10
5 
cells of each cell line were seeded and incubated till 80% confluency. Cells were 
harvested and total cellular protein was extracted using lysis buffer (RIPA Buffer, Sigma- 
R01278) supplemented with protease inhibitor cocktail (PIC, Sigma-P8340). Bradford 
method was used to quantify the protein concentration and equal amount of cell lysate 
was loaded and separated in 10% SDS-PAGE and subsequently transferred onto PVDF 
membrane (Millipore,USA-ISEQ00010). Protein containing membranes were blocked in 
3% bovine serum albumin (BSA, Himedia-5RMI05)  in PBS containing 0.1% Tween 20 
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(Himedia-MB067; PBST), followed by overnight incubation with primary antibodies such 
as rabbit polyclonal anti-Oct4 (Abcam-ab19857), rabbit polyclonal anti-Sox2 (Abcam- 
ab59776) and rabbit polyclonal anti-Nanog (Abcam-ab21624), then incubated with 
appropriate HRP conjugated secondary antibody (Goat anti-rabbit IgG-HRP, Santa Cruz 
Biotechnology-sc-2004) for 2 h at 37° C in dark. The membranes were thoroughly 
washed with PBST buffer and were developed by Supersignal
TM
 West Femto 
Chemiluminescent substrate (ThermoScientific-34095). β-Actin (Primary-Mouse IgG1 
(Monoclonal),Santa Cruz Biotechnology-sc-47778 and Secondary-Goat Anti-Mouse IgG-
HRP, Santa Cruz Biotechnology-sc-2005) protein levels were used as control for equal 
protein loading. Relative protein expression was analyzed from the blots obtained using 
ImageJ quantification software.  
5.2.7 Immunocytochemistry: 
Immunocytochemistry was performed as per our previous protocol with some 
modifications. In brief, MCF-7, MDA-MB-231, PC3 and DU145 cells were grown on 
glass coverslips and treated with AZA (10 μM), TSA (150nm, 100 nM) and DZNeP (10 
μM) for 24 and 72 h respectively.  The treated cells were fixed by ice cold methanol 
(Himedia-AS058) and permeabilized by 0.25% triton X-100 (Himedia-RM845) in PBS. 
Cells were incubated with 1% BSA in PBST for 30 mins to block nonspecific binding of 
the antibodies. The endogenous peroxidase activity was blocked by incubating in 5% 
hydrogen peroxide (H2O2-Himedia) in methanol for 20 mins followed by incubation in 
primary antibodies for Oct4 (Abcam-ab19857), Sox2 (Abcam-ab59776) and Nanog 
(Abcam-ab21624) overnight at 4° C. The cells were then washed in PBS and incubated 
with HRP-conjugated anti-rabbit secondary antibody (Santa Cruz Biotechnology-sc-2004) 
for 1 h followed by another wash. Finally, reactions were visualized by incubation with 3, 
3′-Diaminobenzidine tetrahydrochloride (DAB, substrate and chromogen, Sigma-D3939) 
and counterstained with Mayer's hematoxylin (Thermo Scientific-38803). For negative 
control, cells were incubated overnight with dilution buffer (no primary antibody). 
5.2.8 Bi-sulphite conversion and MS-PCR: 
Promoter region of Oct4 and Sox2 were retrieved by http://www.genomatix.de/ software. 
Retrieved promoters were analyzed by UCSC genome browser. ChIP specific primers 
were designed by Perl primer software. Meth-primers and bisulfite primers were designed 
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using meth-primer designing tool (http://www.urogene.org/methprimer/). Genomic DNA 
was isolated from treated cells by phenol-chloroform method. 2μg of genomic DNA was 
converted by bisulfite treatment using EpiTect
®
 Bisulfite Kit (Qiagen-59104) according to 
the manufacturer’s instructions. Bisulfite-treated DNA was then used as template in PCR 
reactions for PCR analysis. Promoter regions of Oct4 and Sox2 were analyzed by bisulfite 
genomic DNA sequencing with specific primers.  
5.2.9 Chromatin immunoprecipitation analysis: 
ChIP assay was performed using primary antibodies – Rabbit anti-H3K4me3 (Invitrogen- 
49-1005), Rabbit anti-H3K9me3 (Invitrogen-49-1008), Rabbit anti-H3K9acS10p 
(Invitrogen-49-1011) and rabbit anti-H3K27me3 antibody (Abcam-mAbcam6002) by 
employing Imprint
®
 Chromatin Immunoprecipitation Kit (Sigma-CHP1) according to the 
manufacturer’s instructions. Conventional and real-time PCR techniques were used to 
analyze ChIP DNA. For RT-PCR (Realplex4 Eppendorf) analysis, Maxima SYBR 
Green/ROX qPCR Master Mix (2X, Thermo Scientific-K0221) was used.  2μL of 
sonicated DNA was used for PCR analysis with the following PCR conditions ; 95° C for 
2 min, followed by 40 cycles of 95° C for 20s alternating with 55° C for 30s annealing 
and 72° C extension for 30s. Anti-mouse IgG precipitated DNA was used as template for 
negative control. Nonspecific antibody (mouse IgG) precipitated DNA was used for 
normalization. Default input fraction is 1% which is a dilution factor of 100 or 6.644 
cycles (i.e. log2 of 100). % Input is calculated as 2 
(-ΔCt [normalized ChIP])
 where ΔCt 
[normalized ChIP] = (Ct [ChIP] - (Ct [Input] - Log2 (Input Dilution Factor))). Fold of 
enrichment is calculated as 2 
(-ΔΔCt ChIP)
. 
5.3 Results: 
5.3.1 Epigenetic modulators affect cell viability and hinder growth in 
breast and prostate cancer cell lines in a dose-dependent manner: 
The effect of three different epigenetic modulators (AZA, TSA and DZNeP) on cell 
viability after treatment for 24h (TSA) and 72h (AZA, DZNeP) was assessed by 
colorimetric MTT assay in both breast and prostate cancer cell lines. It is observed that 
cell viability of treated cells gradually decreased with increase in concentration of 
modulators in comparison to untreated control cells indicating dose-dependent behaviour 
(Fig. 4.1). The IC30 concentration (concentration of drug at which 70% of cells remain 
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viable) of each drug were almost similar; IC30 value of AZA for MCF7, MDA-MB-231, 
DU145, PC3 was 10 μM, IC30 value of TSA was found to be 150 nM for MCF7 and 
MDA-MB-231 and 100 nM for DU145 and whereas IC30 value of DZNeP was observed 
to be 10 μM for all the four cell lines (Fig. 4.1). The IC30 value was considered as the 
effective drug concentration for further experiments. The inhibitory effect of epigenetic 
modulators on cancer cell growth is suggestive of the fact that epigenetic changes induced 
by treatment with AZA, TSA and DZNeP affect growth and proliferation by regulating 
Oct4, Sox2 and Nanog expression. 
 
 
Figure 5.1: Cell viability assay to determine IC30 concentration after treatment with 
epigenetic modulators.  [a] AZA, [b] TSA and [c] DZNeP treatment in breast (MCF7 and MDA-
MB-231) and prostate (DU145 and PC3) cell lines, [d)] IC30 value corresponding to different cell 
lines for different drugs (n=3, mean±S.D; P < 0.05). 
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5.3.2 Expression profiling of Oct4, Sox2 and Nanog gene expression 
after treatment with epigenetic drugs AZA, TSA and DZNeP:  
Expression of Oct4 after treatment with AZA, TSA and DZNeP: 
All the four cell lines were treated with AZA, TSA and DZNeP to observe the changes in 
Oct4 expression level and attempts were made to correlate Oct4 expression with effect of 
epigenetic modulators. After AZA treatment, Oct4 mRNA expression increased by 1.67 
folds and 3.85 folds, in MCF7 and MDA-MB-231 cells (Fig. 5.2) and by 2.36 and 2.57 
folds in DU145 and PC3 respectively (Fig. 5.3). Increased Oct4 expression was observed 
after TSA treatment individually in all four cell lines. Folds of increase in Oct4 mRNA 
level were 4.03 in MCF7 and 11.3 in MDA-MB-231 (Fig. 5.2), 12.2 folds in DU145 and 
24.35 folds in PC3 respectively (Fig. 5.3). After DZNeP treatment, Oct4 expression 
increased by1.39 folds in MCF7 and 2.54 folds in MDA-MB-231 (Fig. 5.2), 3.21 folds in 
DU145 and 3.45 folds in PC3 respectively (Fig. 5.3). 
 
Figure 5.2: RT-PCR analysis of Oct4 expression in MCF7 and MDA-MB-231. AZA, TSA 
and DZNeP treatment increased Oct4 mRNA level in both cell lines. Oct4 mRNA level was 
measured by reverse transcription–PCR. The Oct4 level in DMSO treated cells for AZA, TSA and 
DZNeP treated cells was normalized to 1 (n=3, mean±S.D., P < 0.05). 
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Figure 5.3: RT-PCR analysis of Oct4 expression in DU145 and PC3. AZA, TSA and DZNeP 
treatment increased Oct4 mRNA level in both cell lines. Oct4 mRNA level was measured by 
reverse transcription–PCR. The Oct4 level in DMSO treated cells for AZA, TSA and DZNeP 
treated cells was normalized to 1 (n=3, mean±S.D., P < 0.05). 
Expression of Sox2 after treatment with AZA, TSA and DZNeP: 
After AZA treatment, Sox2 mRNA level increased by 2.34 folds in MCF7, 3.5 folds in 
MDA-MB-231 (Fig. 5.4), 6.7 folds in DU145 and 5.78 folds in PC3 (Fig. 5.5).  In case of 
treatment with TSA, there was 4.8 folds increase for MCF7 and 3.9 folds increase in case 
of  MDA-MB-231 (Fig. 5.4), 5.4 folds for DU145 and 4.65 folds for PC3 (Fig. 5.5). After 
DZNeP treatment, the increase in Sox2 expression for MCF7, MDA-MB-231, DU145 and 
PC3 are 7.8, 6.9, 6.5 and 5.8 folds respectively (Fig. 5.4, 5.5). 
 
Figure 5.4: RT-PCR analysis of Sox2 expression in MCF7 and MDA-MB-231. AZA, TSA 
and DZNeP treatment increased Sox2 mRNA level in both cell lines. Sox2 mRNA level was 
measured by reverse transcription–PCR. The Sox2 level in DMSO treated cells for AZA, TSA 
and DZNeP treated cells was normalized to 1 (n=3, mean±S.D., P < 0.05). 
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Figure 5.5: RT-PCR analysis of Sox2 expression in DU145 and PC3. AZA, TSA and DZNeP 
treatment increased Sox2 mRNA level in both cell lines. Sox2 mRNA level was measured by 
reverse transcription–PCR. The Sox2 level in DMSO treated cells for AZA, TSA and DZNeP 
treated cells was normalized to 1 (n=3, mean±S.D., P < 0.05). 
Expression of Nanog after treatment with AZA, TSA and DZNeP: 
Similar to Oct4 and Sox2, there is increase in expression of Nanog but the increase is not 
as significant as in case of Oct4 and Sox2 for all the epigenetic modulators (Fig. 5.6, 5.7). 
The effect of all the above drugs on the transcript level expression shows that epigenetic 
regulation works at transcriptional level of gene regulation. 
 
Figure 5.6: RT-PCR analysis of Nanog expression in MCF7 and MDA-MB-231. AZA, TSA 
and DZNeP treatment increased Sox2 mRNA level in both cell lines. Sox2 mRNA level was 
measured by reverse transcription–PCR. The Sox2 level in DMSO treated cells for AZA, TSA 
and DZNeP treated cells was normalized to 1 (n=3, mean±S.D., P < 0.05). 
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Figure 5.7: RT-PCR analysis of Nanog expression in DU145 and PC3. AZA, TSA and DZNeP 
treatment increased Nanog mRNA level in both cell lines. Nanog mRNA level was measured by 
reverse transcription–PCR. The Nanog level in DMSO treated cells for AZA, TSA and DZNeP 
treated cells was normalized to 1 (n=3, mean±S.D., P < 0.05). 
5.3.3  Expression profiling of Oct4 and Sox2 protein expression after 
treatment with epigenetic modulators AZA, TSA and DZNeP: 
Similar to mRNA expression, protein expression of Oct4 and Sox2 was found to be 
highest in breast and prostate cancer respectively. In breast cancer cell lines MCF7 and 
MDA-MB-231, Oct4 expression was analyzed as it showed the highest expression at the 
transcript level. In MCF7 cells, Oct4 expression was highest after DZNeP tretament, but 
in MDA-MB-231 cells, Oct4 expression was highest after TSA treatment (Fig. 5.8a). In 
case of prostate cancer cell lines, Oct4 expression was highest after TSA treatment in both 
DU145 and PC3 cell lines (Fig. 5.8b). The expression at protein level corraborated with 
mRNA level indicating that histone modifications play an important role in regulating the 
expression of pluripotency inducing transcription factors. 
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Figure 5.8: Western blot analysis of Oct4 expression in breast and prostate cancer cell lines. 
Protein expression and quantification was measured by western blot in [a] breast (MCF7 and 
MDA-MB-231) and [b] prostate (DU145 and PC3) cell lines with antibody specific for Oct4 after 
treatment with epigenetic modulators. Graphical representation of relative expression level of 
Oct4 protein in [c] breast and [d] prostate cancer cell lines after treatment with epigenetic 
modulators.  
  Similarly, Sox2 was found to be expressed higher than Oct4 and Nanog; 
hence, Sox2 protein expression was analyzed after treatment with AZA, TSA and 
DZNeP. There is increase in protein expression of Sox2 in each of the four cell lines (Fig. 
5.9a, 5.9b). However, DZNeP treated cells showed highest expression (Fig. 5.9c, 5.9d). 
The findings are suggestive of the fact that epigenetic inhibitors can affect the 
corresponding epigenetic enzyme and therefore affect its regulatory function over 
pluripotency inducing transcription factors and other important genes which might have 
role to play in cancer. 
 
[a] 
[c] 
[b] 
[d] 
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Figure 5.9: Western blot analysis of Sox2 expression in breast and prostate cancer cell lines. 
Protein expression and quantification was measured by western blot in (a) breast (MCF7 and 
MDA-MB-231) and (b) prostate (DU145 and PC3) cell lines with antibody specific for Sox2 after 
treatment with epigenetic modulators. Graphical representation of relative expression level of 
Sox2 protein in (c) breast and (d) prostate cancer cell lines after treatment with epigenetic 
modulators.  
5.3.4 Analysis of promoter DNA methylation of Oct4 and Sox2 in breast 
and prostate cancer cell lines: 
In order to understand the effect of promoter DNA methylation of Oct4 and Sox2 
expression, in silico analysis of methylation in Oct4 and Sox2 promoters was conducted. 
Promoter regions of Oct4 and Sox2 were retrieved using http://www.genomatix.de 
software followed by analysis in the UCSC genome browser (Fig. 5.10a, 5.11a).  
[b] [a] 
[c] [d] 
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Figure 5.10: Promoter DNA methylation analysis of Oct4 promoter in breast cancer cell 
lines MCF7 and MDA-MB-231 [a] UCSC genome browser view of Oct4 chromosomal location, 
[b] The CpG island promoter distribution of Oct4, [c] Analysis of co-relation between promoter 
DNA methylation and mRNA expression of Oct4 in breast cancer, [d] Methylation-specific PCR 
of Oct4 promoter in MCF7 and MDA-MB-231. U, results with primers specific for unmethylated 
sequence. M, results with primers specific for methylated sequence. 
It was observed that while Oct4 promoter has no CpG islands (Fig. 5.10b), Sox2 
promoter contains CpG island composed of around 270 bps (Chr3: 181,711,970-
181,713,540; 1571 bp) with 70% CG percentage (Fig. 5.11b). In order to analyze the 
influence of promoter methylation on expression of Oct4 and Sox2, relative co-relation 
between these two parameters was analyzed by methHC software. In both cases, promoter 
methylation was negatively co-related with mRNA expression indicating that over-
expression of Oct4 and Sox2 in breast and prostate cancer is independent of promoter 
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DNA methylation (Fig. 5.10c, 5.11c). In order to validate the above findings 
experimentally, methyl specific PCR was done to establish the methylation pattern in 
Sox2 promoter region in prostate cancer. No significant changes in methylation pattern 
was detected after treatment with epigenetic inhibitors indicating that promoter DNA 
methylation doesn’t affect the over-expression of Oct4 and Sox2 in breast and prostate 
cancer respectively (Fig. 5.10d, 5.11d). 
 
Figure 5.11: Promoter DNA methylation analysis of Sox2 promoter in prostate cancer cell 
lines DU145 and PC3. [a] UCSC genome browser view of Sox2 chromosomal location. [b] The 
CpG island promoter distribution of Sox2. [c] Analysis of co-relation between promoter DNA 
methylation and mRNA expression of Sox2 in prostate cancer. [d] Methylation-specific PCR in 
DU145 and PC3. U, results with primers specific for unmethylated sequence. M, results with 
primers specific for methylated sequence. 
5.3.5 Analysis of gene specific histone modifications of Oct4 and Sox2 
promoters in breast and prostate cancer cell lines: 
Detection of H3K4me3, H3K9me3, H3K27me3, H3K9AcS10p level in Oct4 promoter 
in breast cancer cell lines:  
After methylation analysis, it has been observed that DNA methylation has no significant 
effect on Oct4 expression in breast cancer cell lines. So epigenetic marks other than 
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promoter DNA methylation must be responsible for regulating Oct4 expression. To 
investigate whether histone modifications are involved in the regulation of Oct4 
expression, PCR analysis was performed in breast cancer cell lines MCF7 and MDA-MB-
231 to identify the enrichment of H3K4me3 and H3K9acS10p (active histone marks) as 
well as H3K9me3 and H3K27me3 (repressive histone marks) in the Oct4 promoter 
region. The region amplified by ChIP-primers was similar to the amplified region which 
was analyzed by bisulphite sequencing. The presence of H3K4me3, H3K9me3, 
H3K27me3 and H3K9acS10p in the CGI promoter region of Oct4 is evident from PCR 
analysis (Fig. 5.12a). This was followed by RT-PCR analysis which revealed that 
promoter region of Oct4 gene has high levels of H3K4me3, H3K9acS10p and low levels 
of H3K9me3 and H3K27me3. In MCF7, H3K4me3, H3K9acS10p, H3K9me3, 
H3K27me3 occupancy was 1.67, 0.59, 0.36 and 0.18 and in MDA-MB-231, occupancy 
was 5.23, 1.93, 0.67 and 0.34 respectively. Fold of H3K4me3 and H3K9acS10p 
enrichment were higher in MDA-MB-231 than in MCF7 (Fig. 5.12b).  
 
 
[a] 
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Figure 5.12: H3K4me3, H3K9me3, H3K27me3 and H3K9acS10p occupancy in Oct4 
promoter in breast cancer cell lines MCF7 and MDA-MB-231. Histone post-translational 
modifications in CGI promoter region of Oct4 [a] PCR analysis Oct4 promoter H3K4me3 
enrichment and mouse IgG precipitated DNA used as negative control, [b] Graphical 
representation of RT-PCR analysis of H3K4me3, H3K27me3, H3K9acS10p and H3K9me3 
occupancy in Oct4 promoter in MCF7 and MDA-MB-231. The Oct4 level in input was 
normalized to 1 (n=3, mean± S.D., P < 0.05). 
Detection of H3K4me3, H3K9me3, H3K27me3, H3K9acS10p level in Sox2 promoter 
in prostate cancer cell lines:  
Since there was no significant change in promoter DNA methylation for regulation of 
Sox2 gene expression, it was assumed that histone modulations might be involved. 
Accordingly, ChIP was performed for visualizing histone tail modifications. ChIP of 
Sox2 gene promoter was executed in PC3 and DU145 to identify the abundance of 
H3K4me3, H3K9me3, H3K27me3 and H3K9acS10p in the Sox2 promoter. From PCR 
analysis, presence of higher amount of H3K4me3 in the promoter region of Sox2 was 
evident (Fig. 5.13a). This was followed by RT-PCR analysis of ChIP-precipitated DNA 
which revealed that promoter of Sox2 gene has high level of H3K4me3 enrichment in 
both the cell lines. Relative presence of H3K4me3 was 1.67 and 1.92 folds in DU145 and 
PC3, respectively. But level of H3K27me3, H3K9me3 and H3K9acS10p occupancy was 
0.60, 0.61, 0.89 folds in DU145 and 0.43, 0.64, 0.45 folds in PC3 cells, very much lower 
than H3K4me3 in both cell lines. The apparent levels of H3K4me3 and H3K9acS10p 
enrichment in the Sox2 promoter region of untreated cells indicates that perhaps 
H3K4me3 enrichment is the cause of relatively very high Sox2 expression in prostate 
cancer cell lines.  
[b] 
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Figure 5.13: H3K4me3, H3K9me3, H3K27me3 and H3K9acS10p occupancy in Sox2 
promoter in prostate cancer cell lines DU145 and PC3. Histone post-translational 
modifications in promoter region of Sox2 [a] qPCR analysis Sox2 promoter H3K4me3 
enrichment and mouse IgG precipitated DNA used as negative control. [b] Graphical 
representation of RT-PCR analysis of H3K4me3, H3K27me3, H3K9acS10p and H3K9me3 
occupancy in Sox2 promoter in DU145 and PC3 cells. The Sox2 level in input was normalized to 
1 (n=3, mean± S.D, P < 0.05). 
[a] 
[b] 
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5.4 Discussion: 
In this study, we attempted to investigate the epigenetic regulatory mechanisms 
controlling Oct4, Sox2 and Nanog expression in breast and prostate cancer. Our 
investigations on post-operated and FFPE breast and prostate cancer tissues had 
confirmed over-expression of Oct4, Sox2 and Nanog in metastasis tissue samples in 
comparison to that in primary cancer tissues. The findings further indicated that enhanced 
Oct4, Sox2 and Nanog expression during metastasis stage facilitates cancer progression 
by encouraging pro-tumorigenic attributes and enhancing the inherent tumorigenicity in 
breast and prostate cancer. Therefore, we attempted to decipher the regulatory 
mechanisms behind over-expression of these TFs in breast and prostate cancer. Ectopic 
modulation by epigenetic inhibitors such as AZA, TSA and DZNeP were conducted so as 
to assess the impact of epigenetic enzymes on the gene and protein level expression of 
Oct4, Sox2 and Nanog. 
After treatment with AZA, TSA and DZNeP, cell viability was seen to decrease in a dose-
dependent manner implying that the epigenetic inhibitors affect the cell growth and 
survival by affecting in turn the epigenetic enzymes (Fig. 5.1). Next, the transcript level 
expression of Oct4, Sox2 and Nanog was analyzed after treatment which showed that the 
expression level of Oct4 and Sox2 were differentially up-regulated in the respective breast 
and prostate cancer cell lines. A sharp rise in expression at mRNA level of Oct4 and Sox2 
gene after treatment with AZA, TSA and DZNeP with respect to untreated samples 
clearly depicts that Oct4 and Sox2 are directly controlled by epigenetic modifications 
with histone modifications playing a more significant impact on expression level (Fig. 
5.2, 5.3, 5.4, 5.5, 5.6, 5.7). To validate whether, gene expression is exemplified at the 
protein level, Western Blotting analysis and immunofluorescence was performed. A 
concordant elevation in protein expression of Oct4 and Sox2 was observed in both breast 
and prostate cancer cell lines corresponding to their transcript level expression (Fig. 5. 8, 
5.9). 
The differential pattern of over-expression of Oct4 and Sox2 after treatment with 
AZA, TSA and DZNeP made us ponder regarding the effector modification controlling 
their expression. Therefore, analysis of promoter DNA methylation in Oct4 and Sox2 was 
conducted by means of in silico and in vitro investigations. The promoter regions of Oct4 
and Sox2 were obtained using Genomatix software and analyzed by UCSC genome 
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browser. The Oct4 chromosomal location and promoter size was determined to be Chr 6: 
31,164,337-31,170,693; 6357 bp). However, analysis of promoter sequence revealed no 
significant CpG island in the sequence (Fig. 5.10). Further, negative co-relation between 
DNA methylation and mRNA expression of Oct4 was observed in methHC analysis. MS-
PCR also revealed that promoter DNA methylation is not affecting the mRNA expression 
of Oct4. Similar analysis was performed for Sox2 and it was found that Sox2 promoter 
contained CpG island made up around 270 bps (Chr3: 181,711,970-181,713,540; 1571 
bp) with high (70%) CG percentage (Fig. 5.11). However, promoter DNA methylation 
was again found to be negatively co-related with mRNA expression of Sox2, implying 
that in case of both Oct4 and Sox2, promoter DNA methylation is ineffective and doesn’t 
influence Oct4 and Sox2 over-expression in cancer. 
Finally, histone modifications present in the promoters of Oct4 and Sox2 were 
analyzed by chromatin immunoprecipitation (ChIP) assay. In case of Oct4 promoter, 
enrichment of H3K4me3, H3K9acS10p enrichment and low level of H3K9me3 and 
H3K27me3 was observed in breast cancer cell lines. Fold of H3K4me3 and H3K9acS10p 
enrichment were higher in MDA-MB-231 than in MCF7 implying that over-expression of 
Oct4 in metastatic advanced stage breast cancer is facilitated by active histone marks (Fig. 
5.12). Similar results were also obtained in case of Sox2 promoter analysis in prostate 
cancer with high levels of H3K4me3 and H3K9acS10p alongside low levels of 
H3K27me3 and H3K9me3 occupancy in both the cell lines (Fig. 5.13). Thus, it is 
confirmed that over-expression of Sox2 and Oct4 in breast and prostate cancer is mostly 
regulated by active histone methylation and acetylation marks such as H3K4me3 and 
H3K9acS10p in absence of promoter DNA methylation. 
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Chapter 6 
To explore the connection between 
oncogenic Hedgehog signaling pathway 
and pluripotency inducing TFs in breast 
and prostate cancer 
6.1 Introduction: 
Phenotypic and functional identity of cells during the course of development is an 
integrated function of extrinsic signaling cues translated by the intrinsic pluripotency 
inducing transcription factors into diverse cellular features and physiological behavior. In 
contrast, unrestrained signaling circuits disrupt the homeostatic balance between cell 
growth and cell death resulting in physiological disorders, degenerative diseases and in 
many instances, leading to the development of aggressive and metastatic cancers (Patra et 
al., 2011). Pluripotency inducing factors in concert with developmental signaling 
pathways are now envisioned as the common instructive cues influencing ESCs identity 
as well as facilitating CSC phenotype. In case of ESCs, they function as differentiation 
repressors and guide ESCs into their respective cell fates, whereas in case of CSCs, 
aberrant expression of transcriptional regulators in concert with constitutive activation of 
oncogenic signaling pathways encourages malignant transformation (Ben-Porath et al., 
2008; Patra et al., 2008; Liu et al., 2013). Henceforth, understanding the delicate 
functional relationship between pluripotency inducing TFs and cellular signaling 
pathways is of paramount importance in order to clearly elaborate the molecular 
mechanisms behind carcinogenesis.  In this chapter, the co-operative interaction between 
developmentally inclined HH signaling and core pluripotency inducing TF, Sox2 in 
prostate cancer is thoroughly investigated in order to throw light on the nexus between 
these two developmental manipulators.   
 Sox2 is a high-mobility group DNA-binding transcription factor which contributes 
critically towards maintenance of clonogenicity, pluripotency and self-renewal properties 
of undifferentiated ESCs, regulating cellular identity of adult tissue progenitor cells 
during developmental transition as well as in adult tissue homeostasis and regeneration
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(Liu et al., 2013; Sarkar and Hochedlinger, 2013; Kamachi and Kondoh, 2013). Sox2 is 
also one of key transcription factors whose ectopic introduction can revert back 
differentiated somatic cells into ESC like condition known as iPSCs (Takahashi and 
Yamanaka, 2006). In recent years, it has been increasingly acknowledged that Sox2 is 
amplified and functionally relevant in various cancer types including glioblastoma, 
osteosarcoma, lung, esophagus, oral, breast, ovarian, pancreatic and gastric where it 
promotes oncogenic phenotype via cellular proliferation, contributes towards cancer 
maintenance by evading apoptotic signals and encourages acquisition of more aggressive 
tumor properties such as metastasis and lymph node invasion (Chou et al., 2013; Dai et 
al., 2014; Hutz et al., 2014; Santini et al., 2014).  Not surprisingly, Sox2 is also vindicated 
for causing tumorigenic changes in the prostate; higher expression of Sox2 is observed in 
prostate cancer tissues with advanced histologic grade in comparison to normal prostate 
or benign prostate hyperplasias ascertaining the claim that Sox2 encourages more “stem-
cell like” tumor phenotype that increases the chemo-resistant property of prostate cancer 
cells resulting in tumor recurrence. Studies have shown that Sox2 is associated with 
increased cancer aggressiveness by promoting EMT and stimulating castration-resistance 
by decreasing the dependence of prostate cancer cells on androgen receptor (AR) 
signaling for their growth and survival (Lin et al., 2012; Kregel et al., 2013; Russo et al., 
2016). 
  The HH signaling pathway is a central coordinator in embryonic developmental 
scheme participating in cell proliferation, cell fate determination, patterning and 
differentiation. It plays a crucial role during organogenesis in many adult tissues by 
facilitating epithelial-to-mesenchymal transitions, tissue repair and regeneration as well as 
stem cell maintenance (Barakat et al., 2010; Kar et al., 2012). Given the strategic 
importance of this HH signaling as a developmental morphogen, it is imperative that 
inactivation of the pathway results in developmental defects such as holoprosencephaly, 
spinal cord anomalies and hyper-activation of this pathway is responsible for neoplastic 
transformation. HH signaling pathway can mediate initiation, maintenance and 
progression of many different types of cancers through constitutive activation of the 
pathway via up-regulation of HH ligands and pathway components or by genetic and 
epigenetic modifications in the pathway (Teglund and Toftgard, 2010; Yang et al., 2010). 
Deregulation in the pathway promotes tumorigenic potential such as increased metastatic 
behavior, improved survival capability via up-regulation of anti-apoptotic agents, 
enhanced proliferative capacity through modulation of the cell cycle machinery and 
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elevation of tumor invasiveness (Clement et al., 2007; Kasper et al., 2009). With regards 
to prostate cancer, it is widely known that HH signaling is actively present in the 
urogenital epithelium from where the prostate derives, mainly promoting ductal budding 
and extension. HH signaling is relatively quiescent in adult prostate, but is still present 
and important for regeneration, maintenance and repair of prostate epithelium. 
Consequently, deregulated HH signaling is implicated in development and progression of 
prostate cancer to more aggressive and even therapy-resistant state in an autocrine fashion 
(Datta and Datta, 2006; Chen et al., 2011 (a); Chen et al., 2011 (b); Gonnissen et al., 
2013).  
 A growing body of evidence shows that Sox2 is associated with oncogenic 
signaling pathways controlling tumor cell physiology by affecting cell fate determination, 
proliferation, and apoptosis in cancer cells (Weina and Utikal, 2014).  It has been already 
reported that Sox2 endows proliferation and survival advantages on adult lung 
stem/progenitor cells by enhancing EGFR pathway mediated oncogenic phenotypes 
(Chou et al., 2013).  Similarly, it was also established that Sox2 expression  is 
functionally responsible for sustaining the proliferation of melanoma cells and inducing 
self-renewal of melanoma initiating cells (MIC) by supporting HH signaling (Santini et 
al., 2014). Thus, targeting Sox2 and its associated oncogenic signaling partner i.e HH 
pathway is a novel approach for inhibiting neoplastic growth and turning of the tumor 
“switch” in prostate cancer. In this note, the present study has been carried out to 
elucidate in details the connection between oncogenic pluripotency inducing transcription 
factor Sox2 and HH signaling pathway in androgen independent prostate cancer. We have 
thoroughly investigated the role of Sox2 and its interaction with HH signaling in prostate 
cancer cell proliferation and tumorigenicity in two prostate cancer cell lines DU145 and 
PC3 as well as in human immortalized cell line HaCaT considered as the normal 
phenotypic counterpart to prostate cancer cell lines. We have shown that silencing of 
Sox2 leads to a remarkable growth suppression and apoptosis in prostate cancer cells. 
Similarly, HH signaling pathway is also shown to contribute significantly towards 
prostate cancer progression. Most importantly, simultaneous Sox2 abrogation and HH 
impairing greatly reduces the ability of prostate cancer cells to proliferate, migrate and 
progress towards a more aggressive state, thus providing a novel therapeutic approach for 
treatment of chemotherapy resistant aggressive prostate cancer. 
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6.2 Materials and Methods: 
6.2.1 In silico analysis of Sox2 expression from publicly available 
databases: 
Pre-experimental in silico analyses of expression of Sox2 and HH pathway components 
was done by employing publicly available online bioinformatics tools cBioPortal having 
links to TGCA database (Cerami et al., 2012; Gao et al., 2013). From patient samples 
available in this database, cross-cancer histogram for copy number alteration (CNA), 
oncoprint analysis (indicating amplification, deletion and mutations) and genomic profiles 
(indicating mRNA up-regulation and down-regulation) of Sox2, SHH, SMO, PTCH and 
GLI1 were examined for all cancer types and separately for prostate cancer. Further, 
mutually exclusive relationship between Sox2 and HH pathway components in prostate 
cancer was also computed. The survival analysis plot individually for Sox2 and together 
for HH components in prostate cancer was also plotted. 
6.2.2 Cell culture:  
Human prostate cancer cell lines PC3 and DU145 and immortalized human keratinocytes 
HaCaT were obtained from National Centre for Cell Science (NCCS), Pune. PC3 was 
cultured and maintained in Nutrient Mixture F-12 Ham medium (F-12, Himedia-AL106S) 
whereas DU145 and HaCaT in Dulbecco’s Modified Eagle’s Medium (DMEM, Himedia-
AL007A) supplemented with 10% (v/v) Fetal Bovine Serum (FBS, Himedia-RM1112) 
and 100 IU/mL Penicillin and 0.1 mg/mL streptomycin (Himedia-A002A) in a humified 
atmosphere of 5% CO2 at 37° C. The cells were harvested by trypsinization (Trypsin, 
Sigma-T4049) and the number of living cells was calculated by Trypan blue (Himedia-
TC193) staining (0.2% v/v) using hemocytometer before seeding for future experiments. 
6.2.3 In vitro drug treatment and transfection: 
si-RNA against Sox2 (Sox2 si-RNA (h), sc-38408) and control si-RNA (control si-RNA-
A, sc-37007) were purchased from Santa Cruz Biotechnology. For determining the 
optimum concentration of si-RNA that completely abolished gene and protein expression, 
5 X 10
5 
cells of each of the three cell lines were seeded and after 24 h incubation, were 
treated with three different concentrations (10, 20, 30 nM) of si-RNA using 
Lipofectamine 2000 (Invitrogen-11668019) and serum free opti-mem (Gibco-31985-070) 
according to manufacturer’s instructions. Six hours after transfection, opti-mem was 
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replaced by the respective cell culture mediums and cells were left to incubate for next 24 
hours. 30 nM of si-RNA efficiently blocked the expression of Sox2 protein in all the three 
cell lines. Control si-RNA was also used at the same concentration.  
 Similarly, for determining the IC30 concentration of Oct4-activating compound 1 
(OAC1, Santa Cruz Biotechnology-sc-397046) and cyclopamine (Santa Cruz 
Biotechnology-sc-200929), 5 X 10
3
 cells per well were seeded in 96-well microtiter plates 
and treated with drugs at different concentrations (5, 10, 15, 20, 25, 30 μM) mixed in 
respective medias supplemented with 10% FBS after reaching 70% confluency. Control 
cells were treated with di-methyl sulphoxide (DMSO, Himedia-TC185) only. For 
simultaneous transfection with si-Sox2 and treatment with cyclopamine, first transfection 
was carried out and after 6 h, cyclopamine at the IC30 concentration was administered 
dissolved in complete media and cells were then incubated for 72 h. 
6.2.4 Cell viability and proliferation analysis by colorimetric MTT assay: 
The effect of the drugs on cell viability was assessed by 3-(4, 5-Dimethylthiazol-2-yl)-2, 
5-Diphenyltetrazolium Bromide (MTT, Himedia-TC191) assay, using standard protocol  
(Kar et al., 2014). Briefly, drug-treated cells after incubation for 72 h were washed twice 
with phosphate buffered saline (PBS). Working concentartion of 0.8 mg/mL MTT 
solution was prepared from stock (5 mg/mL PBS, pH 7.2). To each well, 100 μL working 
MTT solution was added. After incubation in dark for 4 h at 37° C, 100 μL of DMSO was 
added to each well to dissolve the formazan crystals. The absorbance was measured at 
570 nm and results were expressed as the mean of three replicates as a percentage of 
control (taken as 100%). The extent of cytotoxicity was defined as the relative reduction 
in optical density (OD) of treated cells in comparison to control cells, which indicated the 
amount of viable cells in relation to control (100%). The cell viability was graphically 
represented and IC30 value of drugs was calculated accordingly to decide the optimum 
dosage for further studies.  
 For assaying cellular proliferation after treatment with si-RNAs, the above 
described procedure was followed but with slight variations. Briefly, 2 X 10
3
 cells were 
seeded in 35mm plates and treated with desired concentrations of si-RNAs. After 24, 48, 
72 and 96 h incubation, 100 μL MTT solution was added to each well and left in the 
incubator at 37° C for 4 h in dark. Subsequently, 100 μL of DMSO was added and optical 
absorbance was measured at 570 nm. Number of extra cells present in comparison to the 
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number of cells seeded earlier i.e. cell number (plotted in the graph) = Number of cells 
after 24/48/72/96 h – number of cells originally seeded (Santini et al., 2014). 
6.2.5 Relative mRNA expression analysis by real-time PCR: 
After treatment with the desired concentrations of si-RNAs for 24 h and drugs for 72 h, 
total cellular RNA from each of the three cell lines was extracted with TRI Reagent 
(Sigma-T9429) according to the manufacturer’s instructions. cDNA prepared from 1 μg 
of total RNA prepared using RevertAid
TM
 First Strand cDNA Synthesis Kit (Thermo 
Scientific-K1622) followed by quantitative RT-PCR using Maxima SYBR Green/ROX 
qPCR Master Mix (2X, Thermo Scientific-K0221) in the Realplex4 Eppendorf system. 
The mRNA level was normalized to house-keeping gene GAPDH used as an endogenous 
control and calculations were done using 2
−ΔΔCt
 method, as described earlier (Schmittgen 
and Livak, 2008).  
6.2.6 Western Blotting: 
2 X 10
5
 cells of each cell line were seeded, incubated till 80% confluency and treated with 
desired concentrations of si-RNAs for 24 h and drugs for 72 h. Cells were harvested and 
total cellular protein was extracted using lysis buffer (RIPA Buffer, Sigma-R01278) 
supplemented with protease inhibitor cocktail (PIC, Sigma, P8340). Bradford method was 
used to quantify the protein concentration and equal amount of cell lysate was loaded and 
separated in 10% SDS-PAGE and subsequently transferred onto PVDF membrane 
(Millipore, USA-ISEQ00010). Protein containing membranes were blocked in 3% bovine 
serum albumin (BSA, Himedia-5RMI05) in PBS containing 0.1% Tween 20 (Himedia-
MB067) (PBST), followed by overnight incubation with primary antibodies for anti-Sox2 
(Abcam-ab59776) and β-Actin (Santa Cruz Biotechnology-sc-47778) then incubated with 
appropriate HRP conjugated secondary antibody (Goat anti-rabbit IgG-HRP, Santa Cruz 
Biotechnology, sc-2004, Goat anti-mouse IgG-HRP, Santa Cruz Biotechnology, sc-2005) 
for 2 h at 37° C in dark. The membranes were thoroughly washed with PBST buffer and 
were developed by Supersignal
TM
 West Femto Chemiluminescent substrate kit (Thermo 
Scientific-34095). β-Actin protein levels were used as control for equal protein loading. 
Relative protein expression was analyzed from the blots obtained using ImageJ 
quantification software.  
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6.2.7 Immunohistochemistry: 
A total of 33 prostate ( BPH=15, malignant=18) FFPE tissue samples from cancer tissue 
library were selected and analyzed. The tissue embedded in parafilm blocks were cut into 
0.5μm sections and subjected to antigen retrieval with tris-EDTA buffer, endogenous 
peroxidase blocking and rinsed with tris-buffered saline (TBS) containing 0.025% Triton 
X-100 (TBS-T). After incubation with primary antibody -- rabbit polyclonal anti-Sox2 
(Abcam-ab59776) at 4° C for overnight, tissue sections were rinsed with TBS and 
incubated at room temperature for 1 h with secondary antibody (Goat anti-rabbit IgG-
HRP, Santa Cruz Biotechnology, sc-2004). All specimens were developed with 3, 3′-
Diaminobenzidine tetrahydrochloride (DAB, Sigma-D3939). 
6.2.8 Immunocytochemistry:  
Immunocytochemistry was performed as per our previous protocol with some 
modifications (Patra et al., 2001; Patra et al., 2002; Patra et al., 2009; Patra et al., 2011). 
In brief, HaCaT, DU145 and PC3 cells were grown on glass coverslips and treated with 
desired concentrations of si-RNAs for 24 h and drugs for 72 h. The treated cells were 
fixed in ice cold methanol (Himedia, AS058) and permeabilized by 0.25% triton X-100 
(Himedia-RM845) in PBS. Cells were incubated with 1% BSA in PBST for 30 min to 
block non-specific binding of antibodies. The endogenous peroxidase activity was 
blocked by incubating in 5% hydrogen peroxide (H2O2, Himedia) in methanol for 20 min 
followed by overnight incubation in primary antibodies for Sox2 (Abcam, ab59776) and 
β-Actin (Santa Cruz Biotechnology-sc-47778) at 4° C. The cells were then washed in 
PBS and incubated with HRP-conjugated secondary antibodies (Santa Cruz 
Biotechnology-sc-2004, sc-2005) for 1 h followed by another PBST wash. Finally, cells 
were visualized by incubation with 3, 3-Diaminobenzidine tetrahydrochloride (DAB, 
substrate and chromogen, Sigma-D3939) and counterstained with Mayer’s hematoxylin 
(Sigma-38803). For negative control, cells were incubated overnight with dilution buffer 
(no primary antibody). 
6.2.9 Chromatin condensation analysis: 
2 X 10
4
 cells per well of each cell line were seeded in 6-well plates separately, and then 
treated with desired concentrations of si-RNAs for 24 h and drugs for 72 h. Cells were 
then stained with Hoechst 3342 (1 μg/mL, Invitrogen-H1399) dissolved in serum-free 
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media followed by incubation for 10 min at 37° C. Finally, images were taken under UV 
filter using Epi-fluorescent Microscope (Olympus IX71, excitation wavelength of 355 to 
366 nm, emission wavelength of 465 to 480 nm) at 20X magnification. Nuclei with 
condensed chromatin were counted amongst total number of nuclei in the field, and the 
percentage of condensed nuclei was calculated and plotted graphically (Kar et al., 2014). 
6.2.10 Wound healing or scratch assay:  
2 X 10
5 
cells per well were seeded in 6-well plate and incubated at 37° C until a fully 
confluent and adherent monolayer is formed. Scratch is then made using sterile 200 μL 
micropipette tip. Cells were washed thoroughly with PBS to remove the debris and 
smoothen the edge of the scratch. Treatment with the desired concentrations of si-RNAs 
for 24 h and drugs for 72 h was done. Images were taken using phase contrast microscopy 
at 0 h (immediately after treatment) and 72 h. 
6.2.11 Cell cycle analysis by FACS: 
HaCaT, DU145 and PC3 cells after treatment with desired concentrations of si-RNAs for 
24 h and drugs for 72 h were incubated in their respective media with 10% FBS for 24 h. 
The cells were then trypsinized, collected by centrifugation (500 × g for 5 min at 4° C), 
washed twice with PBS and then fixed in 90% ice-cold methanol. After incubation at -20° 
C for 1 h, cells were centrifuged and resuspended in PBS followed by treatment with 
RNaseA (500 U/mL, Fermentas-EN0531) to digest residual RNAs and stained with 
propidium iodide (PI, 10 μg/mL, Sigma-81845). Samples were incubated for 30 min at 4° 
C and cell cycle analysis was performed with a Becton-Dickinson fluorescence-activated 
cell sorter (FACS). The percentage of apoptotic cells was graphically represented. 
6.2.12 Statistical analysis:  
 Three independent experiments were done to calculate the P value and validate the 
results. All data are presented as means ± standard deviation (SD). Statistical analysis was 
performed using the Student’s t-test. Values of P <0.05 were considered as significant 
values. 
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6.3 Results: 
6.3.1 Sox2 is highly amplified in cancer and this amplification is co-
related to its biological function: 
Pre-experimental in silico analyses were undertaken to have a comprehensive overview of 
Sox2, SHH, PTCH, SMO and GLI1 expression and function in all cancer types, 
particularly in prostate cancer. Using the publicly available cBioportal database, we 
observed the copy number alteration including amplification, deletion and mutations in 
almost all major types of cancer. All the five genes were subjected to wide-spread 
alterations with highest amplification for Sox2 in lung cancer (55%), for SHH in ovarian 
cancer (11%), for PTCH in sarcoma (2.5%), for SMO in ovarian cancer (6.4%) and for 
GLI in case of glioblastoma (8.4%) (Fig. 6.1a). Next, copy number alteration of all the 
five genes was done in prostate cancer which showed that Sox2 is amplified in 8%, SHH 
in 6%, PTCH in 7%, SMO in 10% and GLI in 5% of all prostate cancer patients with 
simultaneous mRNA up-regulation for all genes (Fig. 6.1b). Next, mutual exclusivity 
between Sox2 and all the components of HH pathway were computed and it was found 
that the alterations are mutually exclusive, however alterations in Sox2 and GLI1 were 
found to be co-current (p-value: 0.199, Log odds ratio 1.748). Survival (both with disease 
and disease-free) study for cases with alterations in Sox2 did not yield any significant 
result (Fig. 6.1c, 6.1d). However, survival analysis for cases with alterations in SHH, 
PTCH, SMO and GLI when done together showed significant values of 0.00158 (Fig. 
6.1e). All the above results agree that both Sox2 and components of HH pathway are 
over-expressed and actively participate in mediating prostate cancer. 
Table 6.1: Mutual exclusivity and Co-occurrence in prostate adenocarcinoma patients 
Prostate adenocarcinoma (n= 333)                               Alterations in 20 (6.0%) cases 
Gene 1 Gene 2 p-value Log odds ratio Association 
Sox2 GLI1 0.199 1.748 Tendency towards co-occurrence 
Sox2 PTCH 0.801 <-3 Tendency towards mutual exclusivity 
Sox2 SMO 0.863 <-3 Tendency towards mutual exclusivity 
Sox2 SHH 0.929 <-3 Tendency towards mutual exclusivity 
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Figure 6.1: Pre-experimental in silico analysis of Sox2, SHH, PTCH, SMO and GLI1 using 
cBioportal. [a] Histogram showing cross-cancer summary of copy number alterations for Sox2, 
SHH, PTCH, SMO and GLI1 (28 studies/5 genes) depicted wide-spread alterations in all the 5 
genes in almost all cancer types. [b] Oncoprint analysis in prostate cancer showed that Sox2 was 
amplified in 8%, SHH in 6%, PTCH in 7%, SMO in 10% and GLI in 5% of all patient tissue 
samples. [c] Survival plot with disease in case of alteration in Sox2 depicted no significant 
difference. [d] Survival plot for disease-free state with alteration in Sox2 was not significant. [e] 
Survival plot with disease in case of alteration in all the HH components showed significant value 
(P= 0.00158). 
6.3.2 Sox2 expression in prostate cancer cells is indicative of its role in 
prostate tumorigenesis: 
As is evident from the above mentioned in silico data analysis, Sox2 as well as SHH, 
PTCH, SMO, GLI were found to be amplified and showed up-regulation at the mRNA 
level in prostate cancer in prostate cancer. To validate the above data in cell lines, we 
employed qRT-PCR to examine the expression of all the 5 genes in two human prostate 
cancer cell lines-DU145 and PC3 taking human immortalized cell line HaCaT as the 
control. Our results agree with the databases and showed that in comparison to HaCaT 
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cells, Sox2, SHH, PTCH, SMO and GLI are over-expressed in both androgen independent 
prostate cancer cell lines, with PC3 showing a relatively higher level of expression of all 
the 5 genes (Fig. 6.2a). Protein expression of Sox2 further augmented the data obtained 
from RT-PCR with PC3 cells exhibiting higher Sox2 protein expression in comparison to 
HaCaT and DU145 cells (Fig. 6.2b, 6.2c). Immunohistochemistry done from a cohort of 
33 prostate tissues comprising both benign and malignant samples showed that higher 
expression of Sox2 protein is observed in malignant prostate tissues, further strengthening 
our hypothesis that expression of Sox2 is tissue-stage specific and is involved in 
progression of cancer stages and mediating aggressive cancer phenotype (Fig. 6.2d). 
Immunocytochemical detection provided evidence for higher Sox2 expression in prostate 
cancer cells in comparison to HaCaT cells and also highlighted the nuclear localization of 
Sox2 (Fig. 6.2e).  
 
Figure 6.2: Sox2 is over-expressed in both the androgen independent prostate cancer cell 
lines. [a] qRT-PCR analysis for relative expression of Sox2, SHH, PTCH, SMO and GLI1 at the 
transcript level in DU145 and PC3 cells showed that all 5 genes are over-expressed in prostate 
cancer cell lines in comparison to HaCaT cells. [b] Western blot analysis showed that Sox2 
protein expression is highest in case of PC3 cells in comparison to HaCaT and DU145. [c] 
Graphical representation of Sox2 protein expression after quantification using ImageJ software 
showed highest expression in case of PC3 cells. [d] Immunocytochemical staining of Sox2 protein 
in three cell lines showed nuclear localization of Sox2. Error bars indicate SD (n=3, mean± S.D, P 
< 0.05). 
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6.3.3 Silencing of Sox2 hinders cell proliferation and induces apoptotic 
cell death: 
To assess the functional impact of Sox2 in prostate cancer, HaCaT, DU145 and PC3 cell 
lines were stably transfected with 30 nm of Sox2 si-RNA. As shown, all the three cell 
lines showed lower levels of Sox2 protein expression in comparison to cells treated with 
control si-RNA (Fig. 6.3a). From colorimetric MTT assay for assessing the rate of 
proliferation after silencing of Sox2, it was observed that cell proliferation in Sox2 
silenced HaCaT, DU145 and PC3 cells was lower in comparison to cells transfected with 
control si-RNA with PC3 cells showing the slowest rate of cell proliferation (Fig. 6.3b). 
To evaluate the effect of Sox2 knockdown on cell cycle distribution, flow cytometric 
analysis was done. In case of treatment with si-control, percentage of apoptotic cells was 
found to be 18% for HaCaT, 21% in DU145 and 16% in PC3 cells. But after treatment 
with si-Sox2, the percentage of apoptotic cells increased to 24% in HaCaT, 25% in 
DU145 and 27% for PC3 cells in comparison to control cells (Fig. 6.3c). Chromatin 
condensation analysis using Hoechst stain was performed to study the cytotoxic effect of 
Sox2 knockdown. The morphological changes induced by apoptosis such as 
packaged/condensed nuclei can be detected by blue-fluorescent Hoechst 33342 dye which 
brightly stains the highly condensed, dense chromatin of apoptotic cells in comparison to 
the chromatin of non-apoptotic cells. Sox2 knockdown cells show higher chromatin 
condensation as is evident from 34%, 28% and 42% condensed cells in HaCaT, DU145 
and PC3 respectively with respect to 21%, 13% and 24% condensed cells in control si-
RNA transfected cells (Fig. 6.3d, 6.3e).  Scratch assay was performed to evaluate the 
wound healing capacity of the Sox2 silenced cells and it was observed that after Sox2 si-
RNA treatment, migration of cells drastically reduced. While cells transfected with 
control si-RNA had 31%, 29% and 45% migrated cells respectively for HaCaT, DU145, 
and PC3 cells, Sox2 silenced cells had lower migration as 22%, 11% and 31% 
respectively (Fig. 6.3f, 6.3g).  Altogether, these results indicate that interference with 
Sox2 function impedes cell and metastatic growth by reducing cell proliferation, 
stimulating apoptosis and constraining invasive ability of prostate cancer cells. 
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Figure 6.3: Silencing of Sox2 affects tumorigenic properties of prostate cancer. [a] Western 
blot analysis showed that Sox2 protein expression was completely abolished after treatment with 
30 nM si-RNA against Sox2. [b] Graphical representation of cell proliferation in HaCaT, DU145 
and PC3 after treatment with si-RNA against Sox2 and control si-RNA for 96 h showed that PC3 
cells were highly restricted in proliferating ability. [c] Graphical representation of percentage of 
apoptotic cell population showed increase in apoptotic cells for si-Sox2 treated cells w.r.t control 
si-RNA treated cells. [d] Chromatin condensation analysis after treatment with si-RNA against 
Sox2 and control si-RNA. Magnification 20X. [e] Graphical representation of percentage of 
condensed nuclei per field showing increase in number of condensed nuclei. [f] Scratch assay 
after treatment with si-RNA against Sox2 and control si-RNA showed decrease in number of 
migrating cells. Magnification 20X. [g] Graphical representation of percentage of invaded cells 
per field. Error bars indicate SD (n=3, mean± S.D, P < 0.05). 
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6.3.4 Over-expression of Sox2 boosts cell proliferation and facilitates 
apoptotic escape: 
In our study, for the first time, over-expression of Sox2 was achieved via use of a 
chemical activator called Oct4-activating compound 1 (OAC1). OAC1 is known to 
increase transcription of Oct4-Nanog-Sox2 triad, enhance and accelerate efficiency of 
iPSC reprogramming methods. Through MTT assay, IC30 concentration of OAC1 was 
determined to be 15 μM for DU145, PC3 and 10 μM for HaCaT cells and henceforth used 
for future experiments (Fig. 6.4a). The relative mRNA expression of all the three core 
transcription factors Oct4, Sox2 and Nanog was evaluated by real time PCR and results 
indicated over-expression of all the three factors in comparison to the housekeeping genes 
GAPDH (Fig. 6.4b). The protein expression of Sox2 was studied by Western Blotting in 
all three cell lines after treatment with OAC1 which showed elevated expression in 
comparison to control untreated cells, with PC3 again exhibiting higher protein 
expression in comparison to the other cell lines (Fig. 6.4c). The percentage of apoptotic 
cells in control cells were 14.4%, 13% and 18.5% and after OAC1 treatment were 11%, 
10% and 12% for HaCaT, DU145, PC3 respectively. This decrease is accompanied by 
increase in S and G2 phase population, implying that higher expression of Sox2 could 
promote G1 to S phase transition of the cell cycle and evasion of apoptosis (Fig. 6.4d). 
The number of condensed chromatin was not significantly high as was the case after si-
Sox2 treatment, which may further prove that over-expression of Sox2, facilitates 
apoptotic escape (Fig. 6.4e, 6.4f). Even the migration properties of prostate cancer cells 
were boosted after treatment with OAC1 showing 12%, 19% and 31% for HaCaT, 
DU145, PC3 respectively (Fig. 6.4g, 6.4h). All the above results implicate Sox2 as a 
mediator of malignant transformation and validate Sox2 as an essential player during 
acquisition of stem cell properties. 
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Figure 6.4: Over-expression of Sox2 induced by chemical activator OAC1. [a] Colorimetric 
MTT assay determined the IC30 concentration of OAC1 to be 15 μM for DU145, PC3 and 10 μM 
for HaCaT cells. [b] Relative gene expression of pluripotency inducing transcription factors-Oct4, 
Sox2 and Nanog after treatment with OAC1 showed elevated expression in all the three cell lines. 
[c] Western blot analysis showed that after OAC1 treatment, Sox2 protein expression increased in 
all cell lines with PC3 showing highest expression. [d] Graphical representation of percentage of 
apoptotic cell population showed decrease in apoptotic cells for OAC1 treated DU145 and PC3 
cells. [e] Chromatin condensation analysis after treatment with OAC1 showed no significant 
condensed nuclei. Magnification 20X. [f] Graphical representation of percentage of condensed 
chromatin after treatment with OAC1. [g] Scratch assay in HaCaT, DU145, PC3 after treatment 
with OAC1 showed increase in cell migration. Magnifications 20X. [h] Graphical representation 
of percentage of invaded cells per field after treatment with OAC1. Error bars indicate SD (n=3, 
mean± S.D, P < 0.05). 
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6.3.5 Consequences of inactivating HH signaling pathway in prostate 
cancer: 
Constitutively active HH signaling pathway is known to promote malignant growth in 
prostate tissues; hence the role of HH signaling pathway was investigated by down-
regulating SMO using cyclopamine and subsequently inhibiting the pathway. MTT assay 
was performed to decide the optimum concentration of drug to be used and IC30 value of 
15 μM for 72 h was determined as the ideal concentration for subsequent treatments (Fig. 
6.5a). From the cBioportal, it was evident that alterations in Sox2 and GLI1 pathway were 
co-occurent, hence in order to the gene expression of HH pathway components – SHH, 
PTCH, SMO and GLI was examined along with Sox2 after cyclopamine treatment. It was 
seen that transcript level expression of all the HH pathway components in cyclopamine 
treated DU145 and PC3 cells was reduced in comparison to their expression in HaCaT 
cells observed earlier (Fig. 6.5b). In agreement with the above results, Sox2 protein 
expression was also greatly reduced in all the three cell lines further highlighting the 
connection between Sox2 and HH pathway (Fig. 6.5c). After FACS analysis, we observed 
that percentage of apoptotic cells is higher for drug treated HaCaT, DU145 and PC3 cells 
with 17%, 23% and 29% apoptotic cells in comparison to untreated cells with 8.3%, 
15.2% and 19% apoptotic cells (Fig. 6.5d). Upon treatment with cyclopamine, it was 
observed that chromatin condensation increases considerably. Percentage of condensed 
chromatin was 26% in case of HaCaT, 32% for DU145 and 36% for PC3 cells; with 
highest percentage in case of PC3 in comparison to control untreated cells with 18%, 23% 
and 19% condensed nuclei for HaCaT, DU145 and PC3 respectively (Fig. 6.5e, 6.5f). 
Similarly, scratch assay provided concomitant results showing that cyclopamine reduced 
the invasive potential of the cell lines with PC3 cells showing least invasion (Fig. 6.5g, 
6.5h). Thus, inactivating HH signaling pathway in prostate cancer cells by using 
cyclopamine can be considered to be possible mechanism of targeting aggressiveness in 
advanced prostate cancer cells. 
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Figure 6.5: Inhibition of HH pathway receptor SMO by using cyclopamine. [a] MTT assay 
determined the IC30 concentration of cyclopamine to be 15 μM for 72 h for all three cell lines. [b] 
Relative expression analysis showed decrease in gene expression for Sox2, SHH, PTCH, SMO 
and GLI in all three cell lines. [c] Protein expression of Sox2 after treatment with cyclopamine 
showed decrease in protein expression with PC3 showing almost complete absence of protein. [d] 
Graphical representation of percentage of apoptotic cell population after treatment with 
cyclopamine showed increase in apoptosis. [e] Chromatin condensation analysis after treatment 
with cyclopamine. Magnification 20X. [f] Graphical representation of percentage of condensed 
chromatin after treatment with cyclopamine showed DNA damage in all cell lines. [g] Scratch 
assay after treatment with cyclopamine. Magnification 20X. [h] Graphical representation of 
percentage of invaded cells per field after treatment with cyclopamine showed decrease in 
migration and invasion potential. Error bars indicate SD (n=3, mean± S.D, P < 0.05). 
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6.3.6 HH signaling pathway and Sox2 can be targeted concomitantly in 
prostate cancer: 
In order to evaluate the effect of simultaneous inhibition of both Sox2 and HH pathway, 
we used si-RNA against Sox2 as well as HH pathway inhibitor cyclopamine 
simultaneously in HaCaT, DU145 and PC3 cell lines. At the transcript level, Sox2 
expression was drastically reduced in DU145 and PC3 cells in comparison to HaCaT. 
After treatment with both cyclopamine and si-Sox2, expression level of Sox2 in HaCaT 
was 2.4, in DU145 were 3.2 folds, in PC3 were 1.9 folds as compared to 4.5, 5.1 and 3.9 
folds change in HaCaT, DU145, and PC3 respectively when treated with si-Sox2 alone 
(Fig. 6.6a). In all the three cell lines, number of viable cells drastically reduced as 
compared to that observed when only Sox2 was silenced. PC3 showed the lowest cell 
proliferation capacity among all the three lines (Fig. 6.6b). These results support the 
hypothesis that endogenous Sox2 might associate with HH pathway in regulating prostate 
cancer cell proliferation. Next we investigated the impact of parallel inhibition of Sox2 
and HH pathway on prostate cancer properties. From FACS analysis we observed that 
percentage of apoptotic cells in HaCaT, DU145 and PC3 were 31.4%, 29%, 34.2% after 
co-treatment which is comparatively higher in comparison to controls—RNA and si-Sox2 
treatment done earlier (Fig. 6.6c). Chromatin condensation was also significantly higher 
with HaCaT, DU145 and PC3 showing 22%, 26% and 49% of condensed chromatin (Fig. 
6.6d). Identically, invasive ability of the cells was also greatly reduced when subjected to 
simultaneous treatment with both the agents (Fig. 6.6e). Results obtained from FACS, 
chromatin condensation and scratch assays further strengthened the hypothesis that Sox2 
and HH pathway work together in promoting tumorigenic nature. In order to understand 
how Sox2 and HH work at the molecular level, we analyzed the gene expression of EMT 
gene such as E-cadherin and apoptotic markers like Bcl-2 and Bax. At the transcript level, 
E-cadherin gene expression was significantly down-regulated in comparison to only si-
Sox2 treated cells. Change in expression of E-cadherin in HaCaT was 2.8 folds, 3.5 folds 
in DU145 and 1.9 folds in PC3 which were in agreement with the reduction in percentage 
of migrating cells shown earlier (Fig. 6.6f). Similarly the expression of pro-apoptotic 
agent Bax was enhanced, while anti-apoptotic marker Bcl-2 in both DU145 and PC3 was 
relatively down-regulated in comparison to HaCaT (Fig. 6.6g). In case of Bax, the change 
in expression was 4.4 folds, 3.6 folds and 5.1 folds for HaCaT, DU145 and PC3 
respectively and for Bcl-2; expression was changed by 2.4, 1.7 and 2.3 folds for HaCaT, 
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DU145 and PC3 with respect to house-keeping gene GAPDH (Fig. 6.6h). This data 
further substantiates our claim that both Sox2 and HH pathway integrate at the molecular 
level to promote cancer aggressiveness. Also, targeting Sox2 and HH pathway 
simultaneously will be more beneficial as a therapeutic option in comparison to 
differential treatment using HH inhibitors or gene knock-down of Sox2 individually. 
 
Figure 6.6: Co-treatment using si-RNA against Sox2 and cyclopamine against HH receptor. 
[a] Relative gene expression of Sox2 after si-control, si-Sox2 and si-Sox2+Cyclopamine treatment 
showed down-regulation of Sox2 gene expression. Error bars indicate SD (n=3). [b] Cell 
proliferation in HaCaT, DU145 and PC3 after treatment with si-RNA against Sox2 and 
cyclopamine showed drastic decrease in cell number in PC3. [c] Graphical representation of 
percentage of apoptotic cells showed huge increase after co-treatment. [d] Graphical 
representation of percentage of condensed chromatin showed increase in chromatin condensation. 
[e] Graphical representation of percentage of invaded cells per field showed reduction in 
migration potential in all three cell lines. [f] Relative gene expression of E-cadherin was decreased 
in PC3 and DU145 in comparison to HaCaT. [g] Relative gene expression of Bcl-2 also showed 
down-regulation. (h) Relative gene expression of Bax showed increase in expression w.r.t house-
keeping gene GAPDH. Error bars indicate SD (n=3, mean± S.D, P < 0.05). 
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6.4 Discussion: 
Prostate cancer is a widespread malignancy considered to be second major cause of 
cancer-related deaths in men. Tumor heterogeneity in prostate cancer is profound; during 
early neoplastic changes, tumor growth is dependent upon AR signaling; however, at the 
advanced stages, cancer cells become androgen independent and consequently become 
resistant to chemo-therapy. Androgen deprivation therapy however effective in the initial 
prognosis, fails to prevent post-therapeutic recurrence. Lack of proper insight into the 
molecular mechanisms behind advanced prostate cancer largely impinges on the 
therapeutic strategies currently employed. As more and more studies are emphasizing on 
the role of pluripotency factors and signaling pathways in facilitating aggressive tumor 
phenotype, addressing the issue of prostate cancer therapy in light of the above factors 
could serve as an effective treatment policy. In this study, we have described for the first 
time an important connection between pluripotency inducing transcription factors and 
cellular signaling pathways in prostate cancer. Pluripotency transcription factors have 
always been accredited for contributing towards maintenance of CSC population and 
promoting stem cell phenotype. However, the major finding of our investigation 
establishes that in addition to its role in maintenance of stem cell population, Sox2 is 
functionally relevant in non-stem prostate cancer cells. We have shown that depletion of 
Sox2 reduces cellular proliferation, progressively restricts metastatic ability, leading to 
significant increase in apoptotic death. Our study strongly suggests that in prostate cancer, 
Sox2 is essential for tumorigenic properties and that targeting this transcription factor is a 
viable therapeutic option. Furthermore, we provide evidence that Sox2 is functionally 
affiliated to HH signaling in controlling prostate cancer characteristics. Both Sox2 and 
HH pathway components are amplified in prostate cancer and their co-expression is 
significantly co-related to aggressive properties of advanced prostate cancer. Down-
regulating both Sox2 and HH pathway concomitantly results in significant decrease in 
metastatic behavior, reduced survival capacity and cell proliferation, reduction in 
migration and invasiveness as well as greater degree of apoptotic death in androgen 
independent prostate cancer cells, thus affecting all the major hallmarks of aggressive 
tumor phenotype. In line with other studies, our findings suggest that HH-Sox2 axis is as 
much crucial for maintenance and survival of tumor bulk as it is for CSC population in 
prostate cancer. 
Chapter 6                                                                                                                                        Objective 4                                                                                                                          
 
 
108 
Sox2, an important pluripotency inducing transcription factor, is known to be 
over-expressed in almost all human cancer types, including prostate cancer. In the current 
study, we demonstrated that Sox2 mRNA and protein were expressed in both of the 
androgen independent prostate cancer cell lines, with PC3 showing a relatively higher 
endogenous Sox2 expression (Fig. 6.2). This finding agrees with the previous studies 
where it was shown that androgen independent cell lines DU145 and PC3 have higher 
Sox2 expression than androgen dependent LnCaP cell line. This fact signifies that Sox2 
might play a vital role during evolution of prostate cancer from androgen dependent to 
androgen independent mode. Upon silencing Sox2, we observed lower cell proliferation 
indicating that Sox2 is responsible for encouraging oncogenic growth and proliferation in 
prostate cancer. Our data also indicated that silencing of Sox2 resulted in apoptotic death 
and DNA damage in prostate cancer cells (Fig. 6.3). However, the detailed molecular 
mechanisms by which Sox2 knockdown directs apoptotic induction must be investigated 
further in order to discern downstream transcriptional targets of Sox2 in apoptotic 
pathways. DU145 cells were reported to have lower Sox2 gene and protein expression in 
comparison to PC3. Given the fact that DU145 is moderately and PC3 is highly 
metastatic, the above-mentioned expression pattern might indicate towards possible 
contribution of Sox2 during prostate cancer cell invasion. Sox2 knockdown greatly 
reduced the wound healing ability of prostate cancer cells especially PC3, demonstrating 
that Sox2 is an important contributor to EMT and encourages metastastic behaviour in 
prostate cancer cells. We also observed that knockdown of Sox2 expression lead to cell 
cycle arrest in G1 phase resulting in more apoptotic population. In contrast, upon chemical 
activation by OAC1, gene and protein expression of Sox2 greatly increased along with 
concurrent decrease in apoptotic cell population, reduction in condensed nuclei and 
increase in percentage of invading cells. In comparison to HaCaT, the above-mentioned 
changes were more profound in DU145 and PC3 cells indicating that Sox2 over-
expression favors tumorigenic properties. All the above data substantiate our claim that 
silencing of Sox2 is equally effective in diminishing the oncogenic properties in prostate 
cancer cells as it is in case of prostate cancer stem cells (Fig. 6.4).  
 Aberrantly active HH signaling plays crucial role during tumorigenic progression 
and metastasis of prostate cancer and prostate cancer stem cells. We have used the natural 
antagonist cyclopamine to inhibit SMO receptor and effectively downregulate HH 
pathway. After cyclopamine treatment, there is marked reduction in the number of 
condensed nuclei as well as increase in the apoptotic cell populations. Moreover, data 
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from the scratch assay also agrees with the above findings implying that HH pathway 
plays an important role during prostate cancer metastasis and progression (Fig. 6.5). We 
further provide strength to the claim that HH signaling and Sox2 work together to 
promote prostate cancer progression by targeting them simultaneously. Gene expression 
of Sox2 was greatly reduced after co-treatment signifying that Sox2 is a downstream 
target of HH in prostate cells. Our findings are in sync with other studies; for example, 
Sox2 is an important contributor in Sonic Hedgehog-associated medulloblastoma. 
Further, in melanoma initiating cells via chromatin immunoprecipitation (ChIP) assays, it 
was reported that putative GLI-binding sites are present at about 300 bp upstream to Sox2 
transcription start site (TSS), within the core proximal promoter region of Sox2 (−528 and 
+238 from the TSS). Thus, Sox2 expression at transcriptional level is influenced by HH 
signaling by the binding of GLI1 and GLI2 to Sox2 promoter. Moreover, HH-GLI and 
epidermal growth factor receptor (EGFR) signaling synergistically interact to initiate 
Sox2 and Sox9 expression in basal cell carcinoma and tumor-initiating pancreatic cancer 
cells. As previously mentioned, Sox2 knock-down resulted in reduction of cell migration, 
so we decided to investigate the connection between EMT gene and HH-Sox2 axis. The 
transcript level expression of E-cadherin was greatly reduced in all three cell lines, but 
most prominently in PC3 indicating that metastatic ability of PC3 cells can be targeted by 
the above method. It is generally known that HH pathway regulates components of both 
cell-intrinsic and cell-extrinsic pathways of apoptosis including Bcl-2 and Bax. We have 
shown that upon treatment with cyclopamine and si-Sox2, the transcript level expression 
of Bcl-2 was decreased and that of Bax increased, along with an increase in apoptotic cell 
population. Therefore, HH-Sox2 can be considered as better therapeutic target for 
addressing androgen-independent aggressive prostate cancer (Fig. 6.6).  
 Although the probability of selectively targeting Sox2 or other oncogenic 
transcription factors for tissue-specific treatment options for cancer is challenging and 
debatable; recently, studies have focused on developing new strategies to inhibit Sox2. In 
this line, we have for the first time adopted the method of downregulating both Sox2 by 
gene knockdown and HH pathway via inhibiting its receptor molecule using cyclopamine. 
Our study firmly establishes Sox2 as a potential therapeutic target in prostate cancer by 
providing rational evidences of its involvement in prostate cancer. First, we showed that 
silencing of Sox2 reduces proliferation and induces apoptosis in non-cancer stem cell 
population of androgen independent prostate cancer cells. Secondly, we demonstrated that 
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HH signaling pathway knockdown greatly hampers the tumorigenicity of prostate cancer 
cells. Finally, we have established that HH-Sox2 axis is a better therapeutic target with 
much higher reduction in cell proliferation, complete inhibition of migration and elevated 
chromatin condensation than individual treatment policies (Fig. 6.7). Although, this 
strategy needs to be further validated in vivo before it can be safely and effectively 
applied to patients; co-targeting both transcription factor and oncogenic signaling 
pathway can be adopted as a novel therapeutic approach for treatment of prostate cancer. 
As contemporary research in the field of cancer biology is turning towards more 
unconventional methods for treatment of cancer, co-targeting Sox2 and HH signaling 
pathway might just be the right arsenal against therapeutically resistant prostate cancer. 
 
Figure 6.7: Sox2 and HH signaling Pathway can be targeted together for prostate cancer 
therapy. Sox2 and HH pathway both work synergistically to promote aggressive tumor 
phenotype in prostate cancer by increasing metastasic behaviour, improving survival and 
proliferation capacity, as well as deregulating cell cycle machinery. However, by targeting both 
the factors, tumorigenic potential in androgen independent prostate cancer can reduced to a great 
extent thus presenting a novel therapeutic approach. 
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Chapter 7 
General Discussion and Conclusions 
Efficient gene transcription programs and coordinated regulation of the basal 
transcriptional machinery underlies smooth homeostatic functioning of cells in any 
biological system. This system of regulation is jointly undertaken by three important 
enforcers which are cellular signaling cascades, epigenetic modifiers and chromatin 
remodeling agents and finally, core group of nuclear transcription factors. These agents 
synergistically co-operate with each other to form the cornerstone of cellular 
specialization and functional potential. Given the strategic significance of these factors in 
maintaining cellular structure, any deregulation or aberrant behavior by any one of the 
factors can disrupt the delicate molecular stability inside a cell and cause widespread 
mayhem leading to pathophysiological conditions and disorders. Cancer is one such 
disorder which gradually destabilizes the entirety of molecular organization and breaks 
down barriers against de-differentiation. In other words, malignant transformation 
symbolizes the onset of cellular anarchy exemplified by the aberrant activity of 
pluripotency transcription factors, epigenetic modifiers and developmentally inclined 
signaling pathways, all of which work to destroy developmental capacity of a cell. 
 In recent years, epigenetic definition of neoplasm explains that early, initiating 
abnormal epigenetic events predispose a group of progenitor cells towards acquiring of 
oncogenic mutations and plasticity that favors malignant growth. In the abnormally 
changed progenitor population of pre-malignant cells, signaling pathways which are 
normally engaged in translating developmental and differentiation specific cues to 
functional specialization, become constitutively active and provide signals for deregulated 
growth, proliferation and survival. These signaling pathways with the help of epigenetic 
modifiers activate inappropriate transcriptional programs that provide crucial advantages 
to the growing population of neoplasia ready cells. The nuclear transcription factors 
involved in this act are effectively regulated to trigger expression of genes crucial to 
maintaining self-renewal, proliferation and survival of cancer cells. Thus, pluripotency 
inducing transcription factors that generally maintain embryonic and stem cell identity 
become rogue and facilitate oncogenic reprogramming. The most notable transcription 
factors involved in this scheme include Oct4, Sox2 and Nanog which together form the
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“Holy Trinity” of transcription factors. These three factors are now considered as tumor 
progenitor genes and thought to mediate tumorigenic reprogramming and evolution from 
normal cellular state. In the light of above rationale, this work was designed to understand 
in details the role of pluripotency transcription factors in mediating inherent tumorigenic 
potential under the influence of epigenetic modifications and signaling pathways. The aim 
of the project was to establish whether Oct4, Sox2 and Nanog are oncogenic in nature and 
elucidate the epigenetic effectors that guide them in their role. Firstly, the expression 
profile of Oct4, Sox2 and Nanog in breast and prostate cancer was established. Secondly, 
by gene knockdown experiments, the direct involvement of Oct4, Sox2 and Nanog in pro-
tumorigenic characters such as cell proliferation, EMT and metastatic invasion, anti-
apoptotic nature was examined. Next, epigenetic modifications especially DNA 
methylation and histone modifications regulating the expression and function of these 
factors were investigated. Finally, the interaction of HH signaling and pluripotency 
inducing transcription factors was studied in order to fully visualize the upstream 
regulatory control over these factors.  
 In the first step, expression of Oct4, Sox2 and Nanog in different stages of clinical 
breast and prostate tissue samples was studied. With the help of publicly available 
database cBioportal which is linked to TCGA database, we learnt that Oct4, Sox2 and 
Nanog are amplified in breast and prostate adenocarcinomas. In order to validate in silico 
data, we examined protein expression of Oct4, Sox2 and Nanog in FFPE tissues and 
found that all the three factors are over-expressed in stage-specific manner, as metastatic 
samples exhibited higher protein expression in comparison to primary stage tissues. To 
further confirm this result, we analyzed relative mRNA and protein expression of Oct4, 
Sox2 and Nanog in breast and prostate cancer cell lines. It was observed that Oct4, Sox2 
and Nanog were over-expressed in both breast and prostate cancer cell lines in 
comparison to non-tumorigenic control used. The results clearly established that Oct4, 
Sox2 and Nanog are over-expressed in breast and prostate cancer and can be considered 
as oncogenic markers that can facilitate malignant transformation by facilitating inherent 
tumorigenic properties in breast and prostate tumor cells. 
 Next, we analyzed the involvement of Oct4, Sox2 and Nanog by conducting a 
series of gene knockdown experiments using si-RNA against Oct4, Sox2 and Nanog. 
Tumorigenic properties such as cell proliferation, colony formation, migration and 
invasion as well as cell cycle deregulation were examined after gene silencing. It was 
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observed that cell proliferation was drastically reduced in cells treated with si-Oct4, si-
Sox2 and si-Nanog with respect to control si-RNA cells indicating that Oct4, Sox2 and 
Nanog promote cancer cell proliferation and that by preventing their expression, tumor 
growth can be checked. Secondly, chromatin condensation analysis revealed that after 
gene silencing of Oct4, Sox2 and Nanog, percentage of condensed nuclei drastically 
increased and apoptotic DNA damage was greatly enhanced. This suggests that Oct4, 
Sox2 and Nanog helped in protecting cells against apoptotic death and that down-
regulating these factors can reset cellular death in tumor cells. Next, migration and colony 
forming ability of breast and prostate cancer cells were investigated and results indicated 
that Oct4, Sox2 and Nanog are responsible for promoting metastatic behavior in tumor 
cells. Finally cell cycle analysis was done after si-RNA treatment and it was observed that 
upon inhibition of Oct4, Sox2 and Nanog, G0/G1 arrest is induced and apoptotic cell 
population greatly increased. All of the above findings substantiated the claim that over-
expression of Oct4, Sox2 and Nanog in breast and prostate cancer enhanced tumorigenic 
characteristics such as increased cellular proliferation and cell survival, augmented 
apoptotic cell population and enhanced metastatic invasive properties. This is for the first 
time that the role of Oct4, Sox2 and Nanog in maintenance and survival of tumor bulk as 
opposed to CSC population was investigated. The results further emphasized another 
fundamental finding that Oct4, Sox2 and Nanog are as actively involved in mediating 
oncogenic features in non-stem cancer cells as they are known to do in cancer stem cells 
and tumor-initiating cells. 
 After establishing that Oct4, Sox2 and Nanog are over-expressed and facilitate 
malignancy in breast and prostate cancer, we investigated the various epigenetic 
mechanisms responsible for controlling their behavior. Breast and prostate cancer cells 
were treated with well-known epigenetic inhibitors AZA (which acts against DNMT1), 
TSA (which act against HDACs) and DZNeP (which acts against EZH2) and transcript 
and protein level expression of Oct4, Sox2 and Nanog was analyzed. After treatment with 
these modulators, mRNA and protein levels of Oct4, Sox2 and Nanog were found to be 
up-regulated in comparison to untreated cells which suggested that epigenetic 
modifications play a crucial role in regulating these factors. Promoter DNA methylation 
was analyzed by bisulphite conversion followed by methyl specific PCR. The promoter of 
Sox2 was found to be unmethylated and hence DNA methylation induced silencing was 
found to be lacking. Next, histone enrichment profile containing H3K4me3, H3K9me3 
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H3K27me3 and H3K9AcS10p in the promoter of Sox2 and Oct4 was analyzed. It was 
observed that both the promoters were enriched with active histone marks H3K4me3 and 
H3K9AcS10p and repressive marks like H3K9me3 and H3K27me3 were very low. This 
proved that the over-expression of Oct4 and Sox2 in breast and prostate cancer was 
facilitated by active histone modifications like H3K4me3 and H3K9AcS10p in the 
absence of promoter DNA methylation. 
 Finally, to investigate the interaction between signaling pathways and 
pluripotency factors we performed experiments to understand the link between Sox2 and 
HH pathway in prostate cancer. We provide strong evidence implying that Sox2 is 
functionally associated with HH signaling in controlling prostate cancer characteristics. 
Both Sox2 and HH pathway components are over-expressed in prostate cancer and their 
co-expression is significantly co-related to aggressive properties of advanced prostate 
cancer. Down-regulating both Sox2 and HH pathway concomitantly results in significant 
decrease in metastatic behavior, reduced survival capacity and cell proliferation, reduction 
in migration and invasiveness as well as greater degree of apoptotic death in androgen 
independent prostate cancer cells, thus affecting all the major hallmarks of aggressive 
tumor phenotype. In line with other studies, our findings suggest that HH-Sox2 axis is as 
much crucial for maintenance and survival of tumor bulk as it is for CSC population in 
prostate cancer. From all the above results and findings, we have clearly explained the 
role of epigenetic modifications and signaling pathways in influencing pluripotency 
transcription factors as they mediate tumorigenic activities in case of breast and prostate 
cancer. In the contemporary field of clinical oncology, novel strategies of targeting cancer 
cells are in demand. Our project provides one such fresh prospective on therapeutic 
targeting of malignancy by simultaneously acting against all the three enforcers of 
malignant phenotype i.e. transcription factors, epigenetic agents and signaling pathways. 
Based on our findings from the above mentioned objectives, we have tried to formulate a 
novel strategy and have proposed the following model wherein co-targeting pluripotency 
inducing TF such as Sox2, epigenetic modifiers and signaling molecules can effectively 
counteract and restrict oncogenic transformation in solid tumors (Fig. 7.1). 
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Figure 7.1: A schematic representation of the mechanism by which HH signaling pathway and epigenetic modifications influence pluripotency 
inducing transcription factors-Oct4, Sox2 and Nanog in breast and prostate cancer. 
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